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Chapter 1 
Introduction 
 2 
Chapter 1 - Introduction 
 
1.1. Cancer 
In developed countries, cancer is the second leading cause of death behind 
cardiovascular disease with an estimated 18.1 million people diagnosed each 
year and 9.6 million cancer related deaths reported in 2018. (1) Despite the 
introduction of new and improved chemotherapies over the past two decades, 
cancer deaths continue to rise due to a growing and aging population. Cancers 
of the lung and breast in both men and women have the highest incidence of new 
cases worldwide each year making up 23.2% of all new cancer cases followed by 
prostate and colorectal cancers. (1)  
 In simplistic terms, cancer can be characterised as a disease which arises 
when normal cell growth in the body is disrupted through alterations in the 
genes which control this process, resulting in the uncontrolled division of cells. 
These cells can subsequently invade surrounding tissues as well as other organs 
in a process known as metastasis. In addition to uncontrolled cell growth, cancers 
are characterised by the downregulation of antiapoptotic proteins which prevent 
programmed cell death. (2) 
Significant progress has been made over the past few decades to identify 
the underlying mechanisms of the disease. These “hallmarks of cancer” were 
elegantly summarized in the seminal review by Hanahan & Weinberg and were 
categorised into ten groups: (i) the sustenance of proliferative signalling,  (ii)  
evasion of growth suppressors through the down regulation of tumour 
suppressor gene expression, (iii) resistance to cell death, (iv) replicative 
immortality, (v) induction of angiogenesis, (vi) induction of invasion and 
metastasis, (vii) genomic instability and mutation, (viii) evasion of immune 
destruction, (ix) tumour inflammation and (x) downregulation of cellular 
energetics. (2) 
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Table 1.1. Treatment strategies for targeting specific cancer hallmarks 
 
Current chemotherapy drugs actively target specific molecular pathways 
involved in many of the hallmarks described above (Table 1.1.). This specific 
targeting of pathways was the cause of much excitement within the field as active 
targeting of a specific pathway meant that off-target side effects would be 
minimised whilst still maintaining a high therapeutic efficacy. However, current 
clinical results to date have demonstrated that due to the heterogeneity of tumour 
cells, sub-fractions of cancer cell populations survive initial treatment and are 
free to continue replicating. This adaptive resistance often leads to localised 
recurrence. Furthermore, resistance to certain treatments may be brought about 
through treatment induced secondary mutations. For example, patients can 
develop an acquired resistance upon exposure to certain endothelial growth 
Hallmark 
Treatment 
strategy Examples Reference 
Sustaining 
proliferative 
signalling EGRF inhibitors Cetuximab, Erlotinib (3), (4) 
Evading growth 
suppressors 
Cyclin-dependent 
kinase inhibitors Palbociclib, Ribociclib (5) 
Avoiding immune 
destruction 
Immune 
activating anti-
CTLA4 mAb 
Ipilimumab, 
Tremelimumab (6) 
Enabling replicative 
immortality  
Telomerase 
inhibitors Fomivirsen, Imetelstat (7), (8) 
Tumour-promoting 
inflammation 
Selective anti-
inflammatory 
drugs Ibuprofen, Celecoxib (9), (10) 
Activating invasion 
& metastasis 
Inhibitors of 
HGF/c-Met Cabozantinib, Crizotinib (11), (12) 
Inducing 
angiogenesis 
Inhibitors of VEGF 
signalling Bevacizumab, Aflibercept (13), (14) 
Genome instability 
& mutation PARP inhibitors Olaparib, Talazoparib (15), (16) 
Resisting cell death 
Proapoptotic BH3 
mimetics Venetoclax, Navitoclax (17), (18) 
Deregulating 
cellular energetics 
Aerobic glycolysis 
inhibitors 
2-deoxy-D-glucose, 3-
Bromopyruvate (19), (20) 
4 
factor receptor (EGFR) inhibitors. (21) Indeed, cancer cells are capable of shifting 
their dependence on a particular hallmark capability, thereby becoming more 
dependent on another. (2) This often leads to a reduced response to targeted 
therapies. For this reason, there is now a growing trend within oncology in using 
combinations of chemotherapies to maximise treatment response.  
1.2. Pancreatic cancer 
1.2.1. Overview 
Pancreatic cancer is one of the most lethal malignant neoplasms worldwide. A 
2012 study estimated deaths from pancreatic cancer to be 331,000 per year, 
making it the seventh leading cause of cancer related deaths worldwide for both 
males and females. (22) Pancreatic ductal adenocarcinoma (PDAC) accounts for 
more than 90% of pancreatic cancer cases. The survival rate for this form of the 
disease is extremely poor with a 1-year survival of less than 18% which drops to 
less than 4% after 5 years. Due to the asymptomatic nature of the disease, early 
detection of pancreatic tumours is often challenging. As a consequence, many 
patients will present with inoperable tumours or distant metastases leading to 
increased rates of mortality.  The 5-year survival rate for pancreatic cancer has 
only increased by 2% since 1975 (23), clearly demonstrating the deadliness of the 
disease and a need for improving the survival rates of those who are diagnosed 
with pancreatic cancer. National Institute for Health and Care Excellence (NICE) 
treatment guidelines for advanced pancreatic cancer recommend combination 
chemotherapy with FOLFRINOX or gemcitabine + Abraxane as the first line 
treatment in patients with an eastern cooperative performance status (ECOG) of 
1 or 2. (24) However, these combination treatments are often poorly tolerated by 
an elderly patient population. Therefore, novel therapeutic alternatives are 
highly sought-after. 
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1.2.2. Anatomy of the Pancreas 
The pancreas has a critical function within the human gastrointestinal tract. It is 
located in the retroperitoneum directly behind the stomach and is generally split 
into four main segments: (i) the head, (ii) neck, (iii) body and (iv) tail. The head 
of the pancreas is surrounded by the neighbouring duodenum while the tail lies 
near the hilium of the spleen. The body of the pancreas lies behind the distal 
portion of the stomach between the tail and neck while the neck of the pancreas 
lies in close proximity to the superior mesenteric artery and vein (Figure 1.1). (25) 
 
Figure 1.1. Illustration of the anatomy of the pancreas. (Taken from (25)) 
The pancreas serves two important functions within the human body. 
First, as an exocrine organ, secreting digestive enzymes such as pancreatic 
proteases, lipases and amylases from the bile duct in the head of the pancreas 
into the neighbouring duodenum. This role accounts for approximately 95% of 
the mass of the pancreas. The second function of the pancreas is as an endocrine 
organ made up of alpha, beta and acinar cells in the pancreatic islets of 
Langerhans. These cells serve to produce and secrete hormones such as insulin, 
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glucagon, somatostatin, and pancreatic polypeptide into the splenic artery. This 
role accounts for a relatively small portion of the mass of the pancreas (1-2%). (25) 
The majority of pancreatic tumours are adenocarcinomas (PDAC) which 
affect the exocrine cells which line the pancreatic duct. Between 60-70 % of 
pancreatic cancers occur in the head of the pancreas, whereas 20-30% occur in the 
body and tail. (26) According to the location of the tumour within the pancreas, 
presentation of symptoms can often vary. Patients with tumours originating in 
the head of the pancreas often present with jaundice and hyperbilirubinemia as 
a result of obstruction of the common bile duct while tumours of the body or tail 
often present with middle-back pain and weight loss. There have been numerous 
studies which have suggested that the anatomical location of tumours within the 
pancreas is a significant prognostic factor for overall survival. (27–29). These 
findings were further corroborated by a recent meta-analysis which found that 
tumours located in the head of the pancreas coincided with a significantly 
improved survival. (30)  
1.2.3. Incidence and mortality 
Pancreatic cancer is the 11th most common cancer in the world with 458,918 new 
cases and 432,242 deaths (4.5% of all cancer deaths) reported in 2018 making it 
the 7th leading cause of cancer related death. (1) The disease is also expected to 
become the 2nd leading cause of cancer related death in the United States by 2030. 
(31) Pancreatic cancer is slightly more common in men than in women. For both
men and women, the likelihood of developing the disease increases with age
with most cases being diagnosed at 70 years old.
1.2.4. Risk factors  
Risk factors for pancreatic cancer can be broadly separated into two categories: 
(i) controllable and (ii) uncontrollable. Uncontrollable risk factors include gender,
race, age and genetic inheritance. As has been mentioned previously, the
incidence of pancreatic cancer is elevated in both the male and elderly
populations. Ethnicity is also a risk factor for pancreatic cancer with the black
population being at higher risk of the disease than Caucasian populations. (32)
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Family history is a significant risk factor in people with first degree relatives 
having had pancreatic cancer, with this group being at significantly higher risk 
of developing the disease when compared to the general population. (33,34) The 
main controllable risk factor for pancreatic cancer is smoking, with smokers 
being twice as likely to develop the disease than non-smokers. (35–37) There is 
also a correlation between body mass index (BMI) and pancreatic cancer, with a 
BMI ³30 indicating people with an increased risk. (38) Other notable controllable 
risk factors include high alcohol consumption, consumption of processed meats, 
and occupational exposure to carcinogens. (39) 
1.2.5. Molecular mechanisms of pancreatic cancer 
The development of pancreatic tumours is as a result of multiple complex 
molecular alterations within pancreatic cells. The formation of tumours from 
precursor lesions (pancreatic intraepithelial neoplasia (PanIN)) through to 
carcinoma is a multistep process. (40) In addition to PanIN, pancreatic cancer can 
also arise as a result of other precursor lesions such as intraductal papillary 
mucinous neoplasms and mucinous cystic neoplasms. (41) Accordingly, most 
early detection and screening studies are aimed at finding these precursor lesions, 
as resection of these lesions at an early stage can halt the development of 
advanced disease. Generally PanIN can be further characterised into grades 1A, 
1B, 2 and 3 which represent incremental increases in cytological atypia. (42) 
Following the progression from PanIN-1 to PanIN-3, many specific genetic 
changes such as loss/gain of tumour promoting/suppressing genes and 
microRNA overexpression, resulting in an invasive phenotype. (43) 
Pancreatic cancer, as with most cancers, arises as a result of mutations in 
proto-oncogenes, tumour-suppressor genes, and genomic maintenance genes. 
Proto-oncogenes have an important role in the regulation of growth factors, 
signal transduction, transcription factor and apoptotic inhibitors. Oncogenes 
arise as a result of mutations in proto-oncogenes resulting in permanent 
overproduction of growth factors as well as permanent apoptotic inhibition, 
resulting in uncontrolled cell proliferation. This process is often likened to a car 
with the accelerator jammed on but with no brake pedal. (42) 
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Table 1.2. List of frequently mutated genes in pancreatic cancer. Reproduced from (42). 
The most commonly mutated gene in PDAC is the KRAS gene. This gene 
plays a key role in mediating downstream signalling by the activation of 
transcription factors, which has been involved in over 90% of pancreatic 
carcinogenesis. (44) Tumour suppressor genes are also commonly mutated in 
pancreatic cancer patients.  The gene, TP53, is mutated in approximately 60% of 
pancreatic cancers. (45) The main function of tumour suppressor genes is to 
control cell proliferation. Mutations in these genes can result in uncontrolled cell 
proliferation.  
1.2.6. Treatments for pancreatic cancer 
Due to both the aggressive and asymptomatic nature of PDAC, approximately 
50% of patients will present with a metastatic form of the cancer, meaning that 
the cancer has spread to other parts of the body (most commonly the liver, lungs 
or peritoneum). (46) Treatment options for this patient group are limited and are 
generally palliative involving chemotherapy regimens such as FOLFRINOX 
(leucovorin, fluorouracil, irinotecan, and oxaliplatin). Approximately 20% of 
patients will present with tumours which are deemed suitable for surgical 
resection. (47) For patients who are eligible for surgery and who obtain an R0 
resection, the overall survival improves considerably with a mean survival of 20 
- 24 months. (48) Approximately 30% of patients will present will locally-
advanced of borderline-resectable tumours. Tumours under this classification
Gene name Mutation frequency 
(%) 
Type Signalling or 
system 
KRAS 70-95 Proto-oncogene Ras/Raf/MAPK 
TP53 20-70 Tumour-
suppressor 
Apoptosis Cell 
cycle control 
CDKN2A 49-98 Tumour-
suppressor 
Cell cycle control 
SMAD4 DPC4 19-50 Tumour-
suppressor 
TNFbeta/SMAD 
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may still be confined to the pancreas but due to their size or anatomical position 
within the pancreas, are deemed unsuitable for R0 resection. Since it is generally 
understood that surgical resection with clear margins (R0) is an indicator for 
improved overall survival, there is a growing interest in the use of neo-adjuvant 
chemotherapy for the treatment of this sub-group.  
 
The overall rationale for neo-adjuvant chemotherapy in PDAC is to: (49) 
1. increase rates of patients eligible for curative R0 resection by reducing 
tumour bulk and involvement of nearby critical structures. 
2. downstage disease. 
3. ensure that all patients receive chemotherapy. 
4. allow emergence of resistant, already present metastatic disease, if such 
exists to better inform future clinical decisions. 
5. treat locally invasive disease before resection, as surgery may alter 
perfusion in the area leading to earlier onset of metastasis. 
6. treat micro-metastatic disease earlier, at the time of diagnosis. 
 
The significant benefit of neoadjuvant chemotherapy for patients with locally 
advanced or borderline-resectable pancreatic cancer was illustrated in a 2010 
systematic metanalysis which revealed that approximately one third of patients 
staged with locally advanced/unresectable disease, could undergo successful 
resection following a regimen of neoadjuvant chemotherapy and could 
consequently achieve a median survival comparable with that of initially 
resectable tumour patients. (Figure 1.2). (48) 
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Figure 1.2. Diagram illustrating the effectiveness of neo-adjuvant chemotherapy compared 
with other treatment strategies. Reproduced from (48). 
1.2.6.1. Chemotherapy 
1.2.6.1.1. FOLFRINOX 
Following the landmark PRODIGE 4/ACCORD 11 trial published in 2011, 
FOLFRINOX has become a gold standard treatment for patients with advanced 
or metastatic pancreatic cancer. FOLFRINOX is a combination infusion of 5-
Flourouricil (5-FU) leucovorin, irinotecan and oxaliplatin. The antimetabolite 5-
FU in combination with oxaliplatin and irinotecan was initially developed for the 
treatment of metastatic colorectal cancer. (50)  
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5-flourouracil (5-FU) is an antimetabolite drug which works by inhibiting 
critical biosynthetic processes within the cell through incorporation into DNA or 
RNA. 5-FU is based on the nucleobase uracil and is intracellularly metabolised 
into numerous active forms: fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate 
(FUTP). (51,52) Lecouvorin or folinic acid is the reduced form of folic acid and 
has been shown to modulate the effect of 5-FU by enhancing the inhibition of 
thymidylate synthetase. (53,54) 
  
Figure 1.3. Chemical structures of a) Lecouvorin and b) 5-Flourouricil (5-FU). 
Irinotecan is a water-soluble derivative of the natural product 
camptothecin. (55) Irinotecan is a prodrug which is metabolised intracellularly to 
7-ethyl-10-hydroxycamptothecin (SN-38), which primarily acts as a 
topoisomerase 1 inhibitor and is approximately 1000 times more potent than 
irinotecan. (56) As well as being a part of FOLFRINOX, a nanoliposomal dosage 
form of irinotecan along with 5-FU is currently used as a second line treatment 
for advanced pancreatic cancer. (57) 
 
Figure 1.4. Chemical structures of a) irinotecan and b) SN-38. 
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Oxaliplatin is a platinum compound similar in structure to cisplatin. It has 
a characteristic bidentate oxalate leaving group which has been attributed in part 
to its activity. (58) The precise cytotoxic mechanisms of action of platinum-based 
drugs is still not fully understood, however these agents are generally thought to 
form crosslinks with DNA, which subsequently disrupts DNA replication, 
leading to apoptosis. (59–61) 
Figure 1.5. Chemical structure of oxaliplatin. 
1.2.6.1.2. Gemcitabine 
Gemcitabine (Gem) is a deoxycytidine nucleoside analogue first patented by Eli 
Lilly in 1983 as an antiviral medication and later approved for human use as an 
antineoplastic drug in 1995. (62) It has since been used clinically for a variety of 
solid tumours including breast, ovarian and lung cancers. (63,64) Structurally, 
Gem is composed of a cytidine ring fused to a di-fluorinated deoxyribose ring 
(Figure 1.6). (65) 
Figure 1.6. Chemical structure of gemcitabine (Gem). 
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Gem is a prodrug which must first be metabolised into the active 
triphosphate form (2’,2’-difluoro-2’-deoxycytidine triphosphate). Once shuttled 
into the cell by nucleoside transporter proteins, Gem is mono-phosphorylated by 
deoxycytidine kinase enzymes. This species is then further phosphorylated by 
uridine monophosphate/cytidine monophosphate kinase (UMP-CMP kinase) to 
2’,2’-difluoro-2’-deoxycytidine diphosphate (dFdCDP) before a final 
phosphorylation step to 2’,2’-difluoro-2’-deoxycytidine triphosphate (dFdCTP). 
(66) The anticancer activity of Gem is mediated by replacement of the nucleoside 
cytidine with the active dFdCTP thereby preventing DNA elongation, 
consequently leading to cell death (Figure 1.7). (67) Additionally, both dFdCDP 
and dFdCTP are involved in direct and indirect inhibition of enzymes 
responsible for metabolising deoxynucleotides thereby improving the chances of 
dFdCTP incorporation within DNA. (68) 
 
Figure 1.7. Diagram illustrating the masked chain termination. DNA polymerase incorporates 
dFdCTP into the DNA sequence during DNA synthesis. This is followed by the incorporation 
of another nucleotide triphosphate (dNTP). This disables the action of DNA polymerase 
resulting in the termination of chain elongation which can lead to apoptotic cell death. Taken 
from (68). 
Despite the multiple mechanisms of action for Gem, there are also 
numerous pathways that generate resistance to this drug. These include 
deficiency of nucleoside transporter proteins, down-regulation of the rate-
limiting enzyme deoxycytidine kinase, and up-regulation of Ribonucleoside 
Reductase M1/M2 (RRM1/RRM2) (responsible for the synthesis of 
deoxyribonucleotides from ribonucleotides), and deactivation to an inactive 
uridine derivative catalysed by cytidine deaminase enzymes. (69–72) Results 
from the ESPAC-3 trial showed that patients with low levels of nucleoside 
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transporter proteins had an overall poorer survival than those with higher levels 
of these proteins. (73) 
Figure 1.8. Scheme illustrating the metabolism and mechanism of action of Gem. Adapted 
from (74). 
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1.2.6.1.2.1. Gemcitabine prodrug development 
As with most modern chemotherapeutics, nucleoside analogues such as Gem, 5-
FU and cytarabine suffer from resistance by cancer cells. Resistance to 
chemotherapy is widely regarded as a key driver for poor survival and as a 
consequence much effort has been invested into developing prodrug strategies 
to overcome both innate and acquired resistance to chemotherapeutics.  As was 
described in Section 1.2.6.1.2, there are three prominent mechanisms which 
underpin the resistance of cancer cells to Gem and other nucleoside analogues. 
These include: (i) reduced intracellular conversion of Gem to the active dFdCDP 
and dFdCTP forms through down-regulation of kinase-type enzymes which are 
responsible for the rate limiting first phosphorylation step (75), (ii) rapid 
conversion of Gem to inactive uridine derivatives through overexpression of 
cytidine deaminase (76), (iii) reduced uptake of Gem resulting from a deficiency 
of nucleoside transporter proteins. (77) 
 Accordingly, many prodrugs of Gem have been developed to improve its 
pharmacokinetic profile (by addition of PEG, valproate, squalene, linear acyl 
groups and phosphoramidate moieties). (78) Gem prodrugs with Gem attached 
to a phospholipid have also been developed to bypass multiple resistance 
pathways. Alexander et al developed a Gem-phospholipid prodrug, with Gem 
conjugated to the phospholipid at the 5’ position. It was found that, in contrast 
to the free drug, the highly lipophilic prodrug did not enter the cell via hENT1 
transporter proteins but through passive diffusion. In addition, it was found that 
the prodrug was not rapidly removed from the cell by efflux pumps and wasn’t 
reliant on activation through kinase mediated phosphorylation. (79) Gem has 
also been conjugated to fatty acids at the N-position with an amide bond. In 
addition to overcoming various resistance mechanisms, the addition of a 
lipophilic moiety to Gem also affords the opportunity to formulate the prodrug 
into a micro/nano-particulate formulation. Wang et al successfully synthesised 
an N-stearoyl derivative of Gem and formulated it into DSPE-PEG micelles. In 
BxPC-3 cells the deamination rate of Gem was significantly reduced. 
Furthermore, Gem-loaded micelles showed a significantly improved circulation 
time and subsequently a 3-fold improvement in intertumoral uptake when 
compared to free Gem in BxPC-3 ectopic xenografts. (80) 
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1.2.6.1.3. Paclitaxel 
Paclitaxel (PTX) is a cytotoxic anticancer drug of the taxane class of compounds. 
It was first isolated from the bark of the pacific yew tree following reports from 
a British official in the Indian subcontinent that parts of the European yew, Taxus 
baccata, were being used in a clarified butter preparation for the treatment of 
cancer. (81) This resulted in a national cancer institute (NCI) lead expedition 
which resulted in the isolation of “taxol” in 1964. Following extensive pre-clinical 
studies, PTX was later approved for clinical use by the FDA in 1992 and has since 
become one of the most profitable anticancer agents on the market. (82) 
Figure 1.9. Chemical structure of paclitaxel (PTX). 
The structure of PTX consists of a complex tetracyclic terpenoid with 
multiple functional sites essential to its activity including the C-13 side chain, C-
2 benzoate functionality and the fused oxetane ring (Figure 1.9). (83–85) PTX 
induces cytotoxicity through the stabilization of tubulin polymers which 
prevents correct spindle formation and leads to inhibition of cell replication at 
the G2/M phase (cytostatic). (86) 
Despite its potent activity in halting the growth of neoplastic cells, PTX 
suffers from extremely poor aqueous solubility (< 0.1 µg/mL) (87) which limits 
effective delivery of the drug. Attempts have been made to improve the solubility 
of PTX through the use of  a formulation containing polyethoxylated castor oil 
and ethanol (Cremophor EL). (88) However, this formulation has been associated 
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with acute allergic reactions through activation of the immune protein - 
complement C3, followed by histamine release as well as severe anaphylaxis, 
hyperlipidemia, abnormal lipoprotein patterns, aggregation of erythrocytes, and 
prolonged, sometimes irreversible sensory neuropathy. (89–91) 
As a result of Cremophor EL-induced toxicities, an effort was made to 
develop Cremophor EL-free delivery strategies. This culminated in the 
development of an albumin-bound PTX nanoparticulate formulation (nabPTX) 
which was developed by American BioScience and approved for human use in 
2005 (Figure 1.10). (92) 
 
Figure 1.10. Schematic representation of albumin bound PTX nanoparticles. Taken from (93) 
Following intravenous injection of nabPTX, the nanoparticles undergo 
dissolution and break down into smaller PTX-albumin complexes with a small 
fraction of unbound PTX. (94) Gardner et al demonstrated in a randomised 
crossover pharmacokinetic study (PK) that albumin-bound PTX accounted for 
~94% of the drug following administration with the unbound fraction being ~6% 
which was significantly higher than the Cremophor EL control group (2.4%, p < 
0.001). (95) 
Following administration, it has been shown that nabPTX shows high 
accumulation within tumours. The enhanced permeation and retention effect 
(EPR) has been proposed as a possible mechanism for tumour accumulation. (94) 
The EPR effect is based on the premise that the vasculature within tumours 
displays a “leaky” architecture which allows particles of a certain size (< 200 nm) 
to escape the circulation through small pores in the vessel walls. (96) In addition, 
as the lymphatic drainage in these vessels is often damaged or compromised, the 
end result is a net accumulation of molecules (i.e. albumin) within the tumour 
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microenvironment. (97,98) However due to the heterogeneous blood supply, 
elevated interstitial fluid pressure (IFP), and large transport distances in the 
tumour interstitium, which hinder drug delivery in human subjects, the overall 
effect of the EPR effect in humans is thought to be limited. (93) 
An alternative proposed mechanism for nabPTX tumour accumulation is 
the prevalence of secreted protein acidic and rich in cysteine (SPARC) proteins. 
These proteins have a high affinity for albumin and are observed in abundance 
within tumour interstitium. Despite the positive correlation between SPARC 
levels and disease progression (99,100), many studies have shown that there is 
also a positive correlation between SPARC levels and treatment efficacy of 
nabPTX. (101–103) 
1.2.6.1.4. Combination chemotherapy with Gem + nabPTX 
The use of combinations of chemotherapy drugs has gained traction in recent 
years as this permits the targeting of two separate biochemical pathways and 
reduces the likelihood of chemoresistance. The combination of Gem and nabPTX 
showed early promise as a combination therapy in preclinical murine models. 
Von Hof et al demonstrated that mice treated with nabPTX display a significantly 
depleted desmoplastic stroma when compared to mice treated with Gem alone. 
In addition, mice treated with nabPTX were also observed to have dilated vessels 
within the tumour milieu. Mice treated with the combination therapy showed a 
marked improved response (55%) when compared to Gem alone (24%) and 
nabPTX alone (36%) which was the authors attributed to a decrease in stromal 
content and improved tumour vascularisation. Furthermore, mice treated with 
the combination therapy showed a 2.8-fold increase in intertumoral Gem 
concentration compared with the Gem only group. (101) Subsequent preclinical 
results from Frese and co-workers described how mice treated with nabPTX in 
combination with Gem, not only increased the ratio of dFdC to dFdU, but also 
increased intratumoural levels of the active dFdCTP suggesting that PTX directly 
affects the metabolism of Gem. Additional work also revealed a decrease in CDA 
protein levels – the primary catabolic enzyme for Gem, in mice treated with the 
nabPTX. (104) 
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 These encouraging preclinical findings were corroborated in human 
clinical studies. The MPACT phase 3 trial evaluated the efficacy of the 
combination in patients with metastatic pancreatic cancer and found a significant 
improvement in overall survival for patients treated with the combination (8.5 
months) compared with Gem alone (6.7 months). (105) Results recently 
published from the LAPACT trial in patients with previously untreated locally 
advanced pancreatic cancer showed a progression free survival of 10.2 months. 
(106) 
 The current clinical evidence available on combination chemotherapy in 
pancreatic cancer has informed the choice of FOLFRINOX and Gem + nabPTX as 
first line treatments for the disease. (105,107) However, in spite of the improved 
efficacy in comparison to traditional monotherapy, combination therapy is 
typically accompanied by significantly enhanced side effects, such as 
neutropenia, febrile neutropenia, thrombocytopenia, diarrhoea, sensory 
neuropathy, alopecia and nausea which ultimately diminishes the quality of life 
for the patient, given the relatively small improvement in overall survival. 
(105,107) 
 
1.3. Breast cancer 
Breast cancer is the second most common form of cancer globally with almost 2.1 
million new cases reported in 2018. (1) It is estimated that 627,000 women died 
from breast cancer in 2018 alone, representing 15% of all cancer deaths among 
women, making breast cancer the deadliest cancer in women. (1) Approximately 
80% of invasive breast cancers arise from the ducts of the breast with the 
remaining cases evolving from the terminal duct-lobular apparatus, which has a 
12-fold increased risk of developing into invasive breast cancer. (108) 
 
1.3.1. Risk factors 
Genetic and inherited risk factors make up only a small fraction of cases (5 - 10%). 
These include a family history of breast and ovarian cancer as well as inheritance 
of mutated gene such as BRCA1 and BRCA2. (1) The main drivers for breast 
cancer incidence are generally non-hereditary. Age has been highlighted as an 
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uncontrollable risk factor with incidences beginning to increase after 20 years of 
age. There has been an association made between breast cancer incidence and the 
age of menarche (inverse) and age of menopause (direct) with a 2012 study 
finding that breast cancer risk increased by a factor of 1.05 and 1.03 for every year 
younger at menarche and every year older at menopause, respectively. (109) 
Exogenous use of hormones has also been linked with increased incidence of the 
disease with a 24% increase risk with hormonal birth control and 40% increased 
risk for menopausal hormone therapy. (110)(111) Other risk factors include 
obesity, height (higher incidence in taller women) and smoking. (112) 
1.3.2. Breast cancer disease classification 
The World Health Organisation (WHO) has listed 21 distinct histological types 
of breast cancer based on morphology, growth and architecture patterns 
highlighting the heterogeneity of the disease. (113) The vast majority of cancers 
in the breast are adenocarcinomas which arise from epithelial tissues in the 
terminal duct lobular units and often spread throughout the extensive 
surrounding stroma. A large subgroup of this group is classified as “invasive 
carcinoma of no special type” or NST. The remaining so called “special” types 
can be further subcategorised into lobular, medullary, mucinous and tubular 
cancers among others. (113) 
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Figure 1.11. Diagram showing the anatomy of the breast and chest wall. Taken from (114). 
Due to the heterogeneity of the NST class of breast tumours, molecular 
classification is essential in discriminating between various subgroups. Breast 
cancers can be classified using immunohistological staining techniques for the 
presence of estrogen and progesterone receptors. The presence or absence of both 
of these receptors are defined as hormone receptor (HR) positive/negative 
respectively. (115) Approximately 70% of breast cancer patients have tumours 
cells which stain positive for estrogen receptor or progesterone receptor proteins 
and these patients respond well to endocrine therapies such as tamoxifen, 
letrozole, anastrozole, or exemestane. (116) Besides ER and PR status, the human 
epidermal growth factor receptor-2 (HER2) is also a promising molecular target. 
Part of the epidermal growth factor receptor family, HER2 is amplified or 
overexpressed in 20 - 30% of breast cancers and is associated with a poor 
prognosis. (117) This subset of tumours are often treated with the monoclonal 
antibody, trastuzumab (Herceptin). (117) 
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1.3.3. Treatments 
The primary objectives for treatment of non-metastatic breast cancer is to remove 
the cancerous tissue from the breast and surrounding lymph nodes. This is often 
achieved firstly through surgical resection of the primary tumour or removal of 
the auxiliary lymph nodes followed by radiotherapy. (116) Systemic therapy may 
be in the form of neo-adjuvant therapy (before surgery) in an effort to reduce 
tumour burden prior to surgery to improve surgical margins, or adjuvant 
therapy which is aimed at removing any cancerous cells which were left behind 
following resection.  
The benefit of neoadjuvant systemic chemotherapy has been 
demonstrated in multiple clinical studies (118–121), and has distinguished a clear 
correlation between complete pathological response / breast conservation and 
improved survival odds. (122,123) As outlined previously, patients with HR+ 
cancers will generally be given a regimen of endocrine therapy and patients with 
HER2+ cancers will be given Herceptin. However, for the subgroup of patients 
whose tumours are negative for both HR and HER2, so called triple negative 
breast cancer, chemotherapy alone is currently the only systemic therapy on offer. 
(116) In the neoadjuvant setting, triple negative breast cancers are often treated
with a combination of an anthracycline drug such as doxorubicin in combination 
with a platinum-containing chemotherapy (see above for oxaliplatin). Systemic 
chemotherapy in the adjuvant setting usually involves anthracyclines in 
combination with other agents. These combinations include Fluorouracil, 
Doxorubicin and Cyclophosphamide (FAC) or Fluorouracil, Epirubicin and 
Cyclophosphamide (FEC). More recently, taxane based chemotherapeutics, such 
as PTX and the structurally similar docetaxel, have been used in combination 
with anthracyclines to reduce the chance of axillary metastases. A meta-analysis 
of 13 randomized clinical studies containing 22,903 patients concluded that the 
addition of a taxane to an anthracycline-based regimen improves the disease-free 
survival (DFS) and overall survival (OS) of high-risk early breast cancer patients. 
(124)
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1.3.3.1. Doxorubicin 
Doxorubicin (Dox) is an anticancer drug of the anthracycline class of compounds 
first extracted from Streptomyces peucetius var. caesius in the 1970’s. (125) 
Figure 1.12. Chemical structure of doxorubicin (Dox). 
Structurally, Dox consists of a tetracyclic quinoid aglycone adriamycinone 
(14-hydroxydaunomycinone) linked to the aminosugar daunosamine. (126) 
There are two primary mechanisms by which Dox kills cancer cells. Firstly, Dox 
is capable of intercalating base pairs within DNA molecules. It also binds to 
topoisomerase l and ll which are essential for DNA damage repair mechanisms. 
Following failure to repair DNA damage and growth inhibition in the G1 and G2 
phases of the cell cycle, the apoptosis pathway is triggered. (127) Additionally, 
Dox can be intracellularly oxidised to Dox-semiquinone which upon reduction 
back to Dox, facilitates generation of reactive oxygen species (ROS) which can 
lead to lipid peroxidation (resulting in membrane damage), DNA damage, 
oxidative stress and apoptosis. (128) 
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Figure 1.13. Illustration of the cellular pharmacodynamic mechanisms of Dox. Taken from 
(125). 
Despite being highly efficient at killing cancer cells, Dox has been shown 
to be particularly cardiotoxic. (129) A 2013 meta-analysis of 18 studies containing 
22,815 patients treated with anthracyclines found that 6% of patients displayed 
overt cardiotoxicity with 18% developing subclinical cardiotoxicity. (130) There 
is yet to be a consensus on the exact mechanism of Dox-induced damage to 
cardiomyocytes. However, it is thought to be as a result of 
modification/depletion of cardiolipin which induces the release of cytochrome 
C into the cytosol leading to apoptosis in addition to activating p38 MAPK. These 
events are triggered by the production of reactive oxygen species (ROS) 
produced during the metabolism of Dox. The enhanced effect to cardiac 
myocytes is likely due to their comparatively high concentration of mitochondria 
and subsequent reliance on oxygen-mediated phosphorylation as a means of 
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energy production in comparison to tumour cells which rely mainly on glycolysis 
for energy production even in aerobic conditions. (131,132) 
 
1.3.4. Locally recurrent breast cancer 
As mentioned in section 1.3.3., surgical resection in the form of a mastectomy is 
the first line treatment for patients with anatomically accessible breast tumours. 
Unfortunately, approximately 10 to 13% of patients who receive breast 
conservation therapy (BCT) develop locoregional recurrence (LRR) within 10 
years of their initial treatment, and 3 to 8% of patients who receive a standard 
mastectomy in combination with adjuvant radiotherapy will also develop LRR, 
which in many cases is an indicator for distant metastatic disease. (133,134) A 
review by Wapnir and co-workers suggested 5-year survival probabilities 
ranging between 45% and 80% after LRR. (135) In addition, full-thickness chest 
wall resection is generally perceived as a high-risk and highly skilled operation 
causing significant disfiguration to the patient along with a poor prognosis. As a 
consequence, the application and utility of surgery is limited in this patient group. 
(136) There are few studies in the published literature which allude to the benefit 
of systemic chemotherapy for patients with LRR. A 2014 randomized controlled 
trial (COLOR) with 85 patients with LRR randomly assigned to receive 
chemotherapy and 77 assigned to receive no chemotherapy, showed that 28% of 
patients who received chemotherapy had disease-free survival events (defined 
as any recurrent disease, second primary tumour, or death from any cause) 
compared with 44% in patients receiving no chemotherapy at follow up (4.9 
years). The study also found that 15% of patients receiving chemotherapy 
suffered from serious adverse events such as neutropenia, febrile neutropenia, 
intestinal infection, abdominal pain, respiratory and pulmonary infection among 
other. (137) This study clearly highlights the potential benefit in the use of 
systemic chemotherapy for the treatment of patients with LRR but also highlights 
an opportunity for the targeted delivery of chemotherapeutics to reduce systemic 
side effects. 
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1.4. Targeted cancer treatments 
Systemic chemotherapy has been a mainstay in cancer treatment and prevention 
for more than 60 years. However, as has been discussed in previous sections, the 
utility of conventional chemotherapy is limited by the, often severe, side effects 
associated with systemic delivery of these agents. Often, large doses of these 
drugs are delivered, with only a very small fraction reaching the target tumour 
site. (138) As a result, substantial quantities of these agents are required to 
establish an adequate therapeutic response. There is therefore a growing need for 
a more targeted approach to the delivery of these drugs which will ultimately 
improve the efficacy of the treatments but also the quality of life for the patient. 
 
1.4.1. Photodynamic therapy 
Photodynamic therapy (PDT) is a targeted cancer treatment that been used 
predominantly for superficial neoplasms. PDT involves the irradiation of a light-
sensitive drug (photosensitiser) in the target tissue with light of an appropriate 
wavelength, triggering the localised release of cytotoxic ROS in the target tissue. 
The use of PDT as a cancer therapy is particularly attractive due to its targeting 
ability with release of cytotoxic ROS controlled by the precise positioning of the 
light source. For this reason, PDT is an attractive alternative to traditional 
systemic chemotherapy.  
PDT requires the combination of three distinct components: (i) sufficient 
concentration of a photosensitiser, (ii) presence of molecular oxygen (O2), and (iii) 
light of appropriate wavelength. The photosensitiser alone has negligible toxicity. 
However, upon radiation with light at an appropriate wavelength, an electron in 
the photosensitiser is excited from its singlet ground state (1PS) to the relatively 
short-lived first excited singlet–state (1PS*). The excited electron can then either 
return to the singlet ground state, emitting a photon of light in the process, 
known as fluorescence emission, or it can flip its spin state and engage in a 
process known as inter-system crossing (ISC), converting to the first excited 
triplet state (3PS*). The triplet state electron can either return to the ground state 
releasing a photon, known as phosphorescence or alternatively transfer the 
excited state energy to a neighbouring molecule such as O2 resulting in the 
production ROS (Figure 1.11).  
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Figure 1.14. Diagram illustrating the electronic transitions underpinning photodynamic 
therapy. 
Two types of photochemical reactions of electrons in the T1 state have been 
postulated (Figure 1.14). The first involves redox reactions between the T1 state 
of the sensitizer and a neighbouring substrate, such as another nearby sensitiser 
molecule, to yield free radicals. These radicals are capable of interacting with O2 
to produce superoxide (O2-) ions and the highly reactive hydroxyl ions (OH-). 
(139) Due to its characteristic triplet ground state, molecular oxygen is able to
interact with the excited triplet sate of the photosensitiser. This interaction yields
singlet oxygen (1O2) which can induce severe oxidative damage to biological
substrates and can eventually lead to cell death. While it is generally accepted
that singlet oxygen resulting from type 2 reactions is the major cause of cell death
in PDT, type 1 reactions are thought to predominate in hypoxic conditions.
(140,141)
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Figure 1.15. Type-I and Type-II photoreactions. Reproduced from (139). 
It is generally understood that photoinduced cell death is primarily as a 
result of oxidative stress causing damage to proteins, fats and other biomolecules 
leading to either apoptosis, necrosis or autophagy - with damage to mitochondria 
resulting in apoptosis, significant damage to cellular membranes resulting in 
necrosis, and damage to lysosomes or endoplasmic reticulum resulting in 
autophagy. (142) In addition, treatment of tumours with PDT has been associated 
with a systemic immune response.  This can manifest in the form of a strong 
inflammatory response with large numbers of monocytes or macrophages, 
neutrophils and dendritic cells infiltrating the treated site to attack damaged 
tumour cells. (143) 
1.3.1.1. Photosensitisers 
Photosensitisers are compounds which are capable of absorbing light at a specific 
wavelength range and converting that energy into cytotoxic ROS.  An ideal 
photosensitiser should be capable of producing ROS in an efficient and 
controlled manner while reducing any potential side effects. An efficient 
photosensitiser should be capable of producing ROS in sufficiently high 
concentrations as a result of a high triplet state quantum yield. (144,145) To date 
several photosensitisers have been clinically approved for the treatment of 
various cancers and these have been summarised in Table 1.3.  
 
 
Light + 1PS 3PS*
3PS* + S
PS- + O2 PS + O2-
3PS* + O2* PS+ + O2-
Type 1
3PS* + 3O2 1PS + 1O2
1O2 + S Sadd
PS-+ S+
Type 2
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Table 1.3. Overview of clinically approved photosensitisers. Adapted from (146) 
 
1.4.1.1.1. Rose Bengal  
Rose Bengal (RB) is a synthetic halide derivative of fluorescein from the xanthene 
class of dyes and is currently clinically approved as a dye for ophthalmic defects. 
(147) Structurally, RB consists of a tetra-iodinated xanthene ring system bonded 
to a tetra-chlorinated benzoic acid moiety (Figure 1.16). RB is sold commercially 
as the disodium salt which dramatically improves its aqueous solubility.  
 
 
 
 
 
 
 
Figure 1.16. Chemical structure of rose bengal.  
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RB absorbs visible light efficiently at around 550 nm and has a resultant 
singlet oxygen quantum yield of 0.76 (MeOH) (148,149) The quantity of singlet 
oxygen generated by a photosensitizer is a function of the efficiency of a spin-
forbidden electronic transition from a singlet to a triplet state (ISC). The 
introduction of “heavy atoms” into a molecule is known to have an influence 
over the rate of ISC. (150) The near 8-fold higher singlet oxygen quantum yield 
of RB in comparison to its parent compound fluorescein (φ∆ = 0.1), is an example 
of such an effect and is the result of the iodine atoms present on the molecule. 
(148) In addition, RB has a relatively broad excitation band in the green region of 
visible region of the spectrum (480-550 nm) and possesses a high extinction co-
efficient (εmax = 99,800 M−1 cm−1 at 532 nm). (151) RB has also been shown in in 
vivo models to undergo rapid clearance from the systemic circulation. 
Accordingly, RB is regarded as a highly efficient photosensitiser and has been 
used as model drug for various applications such as anti-microbial and anti-
cancer therapies which will be discussed in more detail in later sections. (152,153) 
  
1.4.1.2. Limitations of PDT 
In spite of the excellent anti-cancer effects of PDT, the utility of this approach in 
oncology has so far been limited to superficial lesions such as cancers of the skin. 
This is as a result of three important shortcomings of PDT: (i) PDT induced cell 
damage is hindered by heterogeneous distribution of the photosensitiser within 
the tumour, (ii) even photons with a wavelength in the near infrared region of 
the spectrum can only penetrate through skin to a depth of less than 1 cm which 
means that during the treatment of deeper-seated tumours, invasive positioning 
of the light source is required to get maximum benefit from the treatment, (154) 
(iii) the efficacy of PDT is severely limited in the hypoxic cores of deeply seated 
tumours as there is less available oxygen present for the excited triplet state of 
the sensitiser to interact with. 
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1.4.2. Sonodynamic therapy  
Sonodynamic therapy (SDT) is in principle very similar to PDT with the 
exception that light is replaced by low intensity ultrasound (US). SDT has been 
proposed to overcome the limitation of light penetration through human tissue. 
Much like PDT, SDT relies on three key components: (i) a sensitiser 
(sonosensitiser), (ii) molecular oxygen (O2) and (iii) a source of US (Figure 1.17). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17. Schematic of sonodynamic therapy in a stylized cancer cell. Taken from (155) 
 
The main advantage of SDT over PDT is increased tissue penetration 
depth as effective doses of ultrasound can be delivered tens of centimetres 
through soft tissue and bone. US is a safe, clinically approved imaging modality 
which has been used for many years in the detection of tumours, blood flow 
analysis, and obstetrics. (156–158) 
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1.4.2.1. Physical principles of US 
Sound is a wave which propagates through a medium transferring its mechanical 
energy. The sound wave is made up of high (compression) and low (rarefaction) 
pressure regions (Figure 1.18). Ultrasound is the term applied to sound waves 
with frequencies greater than 20 kHz and is undetectable by the human ear. 
Instruments used for diagnostic US employ frequencies in the range of 5 – 10 
MHz. (159) US attenuation is the reduction in energy of the US wave as it 
propagates through tissue. This loss in energy is amplified as the frequency of 
the wave increases. In tissue, attenuation increases almost linearly with 
frequency (Table 1.4). 
 
 
 
 
 
 
 
 
 
 
Figure 1.18. Illustration of a longitudinal sound wave (top) and a transverse sound wave 
(bottom). (PPP - peak positive pressure, PNP - peak negative pressure, P2P - peak to peak 
pressure).  
US frequencies typically adopted for use in SDT range from between 0.4 
and 3 MHz which makes it ideally suited for treating deeply seated tumours due 
to the inverse relationship between US frequency and attenuation in tissue. (160)  
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Table 1.4. Attenuation coefficients of various tissues. Adapted from (159). 
Tissue Attenuation (dB/MHz-cm) Reference 
Aqueous humor (human) 0.10 (161) 
Blood (human, 
heparinized) 
0.22 (162) 
Bone (human, femur) 25.6 (162) 
Breast (human) 0.28–0.63 (162) 
Breast (human) 1.7 (163) 
Choroidal melanoma 
(human) 
0.90 (162) 
Fat (human, subcutaneous, 
ex vivo) 
0.64 (162) 
Liver (human, ex vivo) 0.64 (162) 
Ocular lens (human) 2.0 (161) 
Uterus (human) 0.22–0.44 (162) 
Vitreous humor (human) 0.10 (161) 
 
 US power density or intensity is a measure of the power applied to a 
defined area (W/cm2). The loss of energy of the US wave though attenuation is 
converted to heat energy which increases the temperature of the treated tissue 
(Table 1.4). This effect has been used as an advantage by clinicians involved with 
high intensity focused ultrasound (HIFU), where thermal ablation is used to 
selectively increase the temperature of tumour tissue (56 – 100oC) resulting in 
rapid cell necrosis within the focal region. (164,165) Using the US parameters 
typically adapted for diagnostic applications, thermal effects are an undesirable 
side effect. The extent of temperature increases within the focal volume can be 
tempered through the use of pulsed wave US (PW) as opposed to continuous 
wave (CW) (Figure 1.16). The PW application of US is characterised by the term 
- duty cycle, which is defined as the pulse duration over a given pulse repetition 
period. (158) 
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Figure 1.19. Diagram of a) a continuous wave (CW) and b) a pulsed wave (PW). Adapted from 
(159). 
a)
b)
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1.4.2.2. Proposed mechanisms of SDT 
While the underlying mechanisms of PDT are extremely well understood, no 
consensus currently exists regarding the precise mechanism for SDT. As 
mentioned previously, SDT relies on activation by a sound wave propagating 
through tissue. Under the correct parameters, this process can lead to the 
formation of nucleation sites whereby dissolved gasses in tissue come out of 
solution forming small gas filled bubbles. These bubbles can oscillate in an US 
wave, and under the correct conditions, can collapse. (166) As a result of the rapid 
compression of the bubble during this collapsing event, extremely high 
temperatures and pressures can be generated. This event is known as inertial 
cavitation and is widely regarded to be the source of US-induced activation of 
sonosensitisers through two primary mechanisms: (i) pyrolysis and (ii) 
sonoluminescence. (167–169) 
1.4.2.2.1. Pyrolysis 
Following the collapse of a cavitating bubble, a significant increase in localised 
temperature and pressure may occur which can reach up to 10,000 K and 81 MPa. 
As the heat generated by the collapsing bubble is highly focussed and cannot be 
efficiently dispersed through thermal diffusion, this leads to localised hot spots. 
Assuming that these localised areas of high temperature are in close proximity to 
a sensitiser molecule, this can lead to the break-down of the sensitiser into 
radicals which can induce a cytotoxic effect in cells. (167) It has also been 
proposed that through the direct pyrolysis of water vapour, the short-lived H 
and OH radicals may interact with the sensitiser to produce longer lived radicals. 
(170) It should be noted that investigations into pyrolysis as a potential
mechanism for US-induced cytotoxicity, adopted US frequencies far below that
used for SDT (1-3 MHz). There is therefore little evidence to support this theory
in the context of the US frequencies used in SDT.
1.4.2.2.2. Sonoluminescence 
Sonoluminescence is a theory first reported in 1933 by Marinesco and Trillat is 
the generation of light following US irradiation of a solution. (171) Like before, 
this is as a result of the extreme localised temperatures and pressure produced 
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as a result of inertial cavitation. While there has been no consensus on the precise 
mechanism of this light production, it is thought to result from black-body 
radiation, bremsstrahlung radiation or a combination thereof. (172) However, the 
precise mechanism is believed to be of thermal origin resulting from the 
compression phase of bubble collapse. (173) Studies conducted by Umemura et 
al found that light could be generated from air saturated saline solutions 
insonated with US at frequencies relevant to SDT (1.93 MHz) in the wavelength 
range of 250 – 650 nm with a peak intensity at 400 – 450 nm. Under these 
conditions the investigators found that the sensitiser, hematoporphyrin, was 
capable of absorbing the emissions produced in this spectral region. Provided 
that the sonosensitiser is in close proximity to the cavitating bubble, these finding 
provide an explanation for the generation of singlet oxygen as the light generated 
from sonoluminescence could activate the sensitiser via the same mechanisms 
described above for PDT. (160,168) A 2019 study by Beguin et al provided further 
support towards the theory of sonoluminescence. Using sophisticated photo-
acoustic instrumentation, they demonstrated for the first time that upon 
insonation of RB in the presence of gas filled microbubbles, significant quantities 
of photons could be generated. Indeed, the light produced was in the wavelength 
range required to activate RB. (174) 
 
1.4.2.3. Sonodynamic therapy for the treatment of cancer 
The first application of SDT to treat cancer was studied by Yumita and Umemura. 
In these studies, the sensitiser hematoporphyrin was used to treat the rat 
hepatoma cell line - AH-130, and the mouse sarcoma - sarcoma 180, derived from 
the ascites fluid of rats and mice respectively. The cells were suspended in air 
saturated aqueous medium and insonated at a frequency of 1.92 MHz. In all cases, 
cells treated with the sensitiser alone showed no signs of cell damage. However, 
when insonated with US, significant cell lysis was observed. Interestingly, cells 
treated with US alone also showed signs of cell damage which may have been a 
result of cavitation effects within the air saturated medium. (175,176) Later, in 
vivo studies conducted by the same group in an ectopic colon adenocarcinoma 
murine model treated with an intravenous injection the gallium-porphyrin 
complex (ATX-70) followed by US treatment (2 MHz, 3 W/cm2) showed a 50% 
decrease in tumour volume after 3 days. (177) A later study by Yumita and co-
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workers investigated the use of ATX-70 to treat breast tumours. Mammary 
tumours were induced following gavage of the potent carcinogen 7,12-
dimethylanthracene (DMBA). Rats were then treated with ATX-70 at 2.5 mg/Kg 
and US at 3 W/cm2. The results showed a marked synergistic effect between 
ATX-70 and US treatment with significant reductions in tumour volumes and no 
regrowth occurring following treatment. (177)  
The studies discussed thus far utilised US intensities between 1 and 3 
W/cm2. Studies have also been undertaken using much higher US intensities. For 
example, Ohmura and co-workers found that treatment of rat intracranial glioma 
using 5-aminolevulinic acid (5-ALA) and US at 10 W/cm2 showed significant 
reduction in tumour volume with no damage to surrounding brain tissue. 
However significant necrotic lesions were observed upon increasing the intensity 
above 20 W/cm2. (178) In addition to the studies discussed in this section, the 
utility of SDT for anticancer application has been extensively studied in 
numerous in vitro and in vivo models and has been the subject of multiple 
comprehensive reviews. (160,179,180) 
1.4.2.4. Limitations of sonodynamic therapy 
As has been discussed throughout this section, the main advantage of SDT over 
PDT is the enhanced tissue penetration capabilities enabling the activation of the 
sensitiser in deep seated tumours like those of the breast or the pancreas. 
However, despite this, SDT also suffers from some of the same shortcomings as 
PDT. The first shortcoming is the inherent hypoxic nature of many solid tumours. 
While the average oxygen partial pressure in normal tissue is approximately 30–
50 mmHg (181) this drops to approximately 28 mmHg for breast tumours (182) 
and further to approximately 2 mmHg for PDAC. (183,184) This severely limits 
the effectiveness of SDT for the treatment of solid tumours, as the primary 
mechanisms of action of SDT involves the production of ROS, which is 
significantly diminished in hypoxic environments. Much like PDT, SDT requires 
the systemic administration of a photosensitiser into the body. Therefore, the 
same common side effects associated with PDT will also be true for SDT. These 
side effects can be surprisingly unpleasant given the targeted nature of the 
treatment and include hypersensitivity to light. For example, a phase 1 study 
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investigating the effect of endoscopic US guided PDT for locally advanced 
pancreatic cancer noted adverse events including sun burn to the hands and skin 
hyperpigmentation. (185) Granted, these adverse events are significantly less 
severe than those associated with traditional systemic chemotherapy. However, 
through targeting the delivery of the sonosensitiser to the tumour site, 
administration of a lower dose may be possible, which would mitigate any 
adverse off-target side effects. 
 
1.4.3. Ultrasound for targeted drug delivery in cancer treatment 
US mediated drug delivery relies on the presence of a biocompatible drug carrier 
which responds to an US stimulus causing the active release of the payload at the 
target site. (186) The extent to which the drug carrier releases the drug is 
dependent upon two variables: (i) the type of US used and (ii) the responsiveness 
of the drug carrier. Depending on the type of US used for this application, the 
drug release from the carrier can be through either a thermal or mechanical 
process. The absorbance of US into tumour tissue can result in localised 
hyperthermia which can be used for thermal ablation surgery (187,188) or to 
trigger the  release of drugs from thermally responsive liposomes. (189) 
Thermally responsive liposomes have been the subject of recent clinical attention 
following the development of ThermoDox – a liposomal formulation of Dox 
which has been shown to release 80 – 100% of its drug load within 20-40 seconds 
upon mild US induced hyperthermia (41.3oC). (190) In addition to thermal 
mechanisms, enhancement of drug delivery through a mechanical mechanism 
has also been explored. Wang et al demonstrated that intratumoral delivery of 
the anticancer immunoglobulin drug trastuzumab could be enhanced through 
application of US (1 MHz, 8.95 MPa) prior to administration of the drug. (191) 
However drug delivery can also be mediated using much lower pressures (i.e. 1-
2 MPa) than those adopted in this study. This can be achieved through the use of 
cavitation nuclei which result from dissolved gases being removed from tissue 
or from the administration of US responsive gas filled particles. (192) 
 
 39 
1.4.3.1. Microbubbles 
Microbubbles (MBs) are gas-filled microparticles with a stabilised coating which 
can be made of a variety of materials such as phospholipids (193), polymers (194) 
or proteins (195). MBs currently have regulatory approval as diagnostic contrast 
agents (Table 1.5). As there is minimal difference in the acoustic impedance of 
the blood relative to other soft tissue, it is difficult to visualise critical vasculature 
including valves of the heart using traditional US techniques. Upon insonation, 
the high compressibility of the MBs gas core allows them to contract in the 
positive pressure phase and expand in the negative pressure phase of the US 
wave. (196,197) The non-linear oscillations of MBs exposed to low acoustic 
pressures, facilitates the production of acoustic radiation over a wide frequency 
range which can easily be detected by diagnostic hydrophones allowing the 
sonographer to distinguish between critical vasculature and the surrounding 
tissue. (198) 
Table 1.5. Overview of clinically approved microbubble contrast agents. Adapted from (199). 
Name Shell type Core gas Diameter 
(!m) 
Concentration 
(MBs/mL) 
 
SonoVue® 
 
Phospholipid 
DSPC: 0.038 mg/mL 
DPPG: 0.038 mg/mL 
DPPA: 0.008 mg/mL 
SF6 1.5 -2.5  1.5-5.6 x 108  
 
Definity® 
  
Phospholipid 
DPPC: 0.401 mg/mL 
DPPA: 0.045 mg/mL 
DPPE-mPEG5000: 
0.304 mg/mL 
C3F8 
 
1.1 – 3.3  
 
1.2 × 1010  
 
Optison® 
 
Protein 
Human serum 
albumin 
C3F8 
 
3.0 – 4.5  5.0-8.0 × 108  
 
Despite the wide variety of MB shell materials available (Figure 1.20), 
phospholipids remain the most popular. Phospholipid shells offer several 
advantages over protein or polymer shelled MBs.  Given the amphiphilic nature 
of phospholipids, they self-assemble into highly ordered monolayers with the 
hydrophilic head group pointing out towards the aqueous medium and the 
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hydrophobic acyl chains pointing in towards the carrier gas. The inherent curved 
surface of MBs induces a Laplace overpressure across the gas–liquid interface. In 
the case of uncoated MBs, this can lead to destabilisation of the MB through 
Ostwald ripening. (197) Phospholipids with saturated acyl chains are capable of 
forming tightly packed monolayers which decreases surface tension, stabilising 
the MBs against dissolution. As a result of their stability, phospholipid MBs are 
amenable to a wide variety of fabrication techniques including sonication, high-
shear emulsification, membrane emulsification, ink-jet printing, coaxial 
electrohydrodynamic atomisation and microfluidics. (193) 
Figure 1.20. Illustration showing the structure of a typical MB with different shell 
compositions including, but not limited to, phospholipids, polymers and proteins. Adapted 
from (200). 
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By far the most common method for MB fabrication is sonication which 
involves the rapid dispersion of gas within a medium containing the 
phospholipids using high frequency US. (193) The mechanism of MB formation 
using sonication is believed to proceed via two steps. The first involves the 
entrapment of gas within the aqueous medium. The phospholipids then 
subsequently self-assemble so to coat the gas bubble. The second step involves 
the break-up of the coated bubble into smaller bubbles as shown in Figure 1.21.  
  
Figure 1.21. Diagram illustrating the proposed mechanism of microbubble formation using 
sonication. The first step in the mechanism involves the entrapment of gas within the aqueous 
medium to form large bubbles. This is followed by subsequent breaking up of these large 
bubble into smaller bubbles. Adapted from (201). 
 
1.4.3.1.1. Interaction of MBs with US 
When exposed to an US wave, the compressibility of MBs allow them to 
compress in the high-pressure region of the wave and expand in the rarefaction 
region of the wave. (202) When insonated with relatively low acoustic pressures 
(<50 kPa), MB oscillations are described as being symmetrical or linear. When 
oscillating linearly, MBs are compressed in the in the rarefaction portion of the 
wave and expand in the positive portion of the wave, both to the same degree. 
When acoustic pressures are further increased (50-200 kPa), MBs become more 
resistant to compression than to expansion which leads to non-linear 
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oscillations.(203) The signals produced from these oscillations contain 
frequencies corresponding to the insonation frequency (fundamental) as well as 
other harmonic frequencies. When the acoustic pressure is further increased 
(>200 kPa), destruction of MBs can occur which typically results in broadband 
emissions. (203) These various MB emissions can be observed experimentally 
using passive cavitation detection (PCD).  
1.4.3.1.2. Factors affecting MB stability and dissolution 
MB stability is a critical consideration for formulation design. For a bubble in 
solution there exists a pressure differential between the inside and the outside of 
the curved bubble surface that forms at the gas-liquid interface. This pressure, 
known as the Laplace pressure, is determined using the Young–Laplace equation, 
expressed as ∆P = 2σ/R, where σ is the surface tension and R is the radius of the 
bubble. (199) This can then be used along with Epstein and Plesset’s model, to 
determine the dissolution rate for an uncoated MB. (204)  Despite the dependence 
of this model on the assumptions of constant hydrostatic pressure and 
temperature on an uncoated bubble, the model demonstrates how the core gas 
properties of a MB are critical in the determination of MB stability. The Epstein-
Plesset model predicts that an uncoated bubble will rapidly dissolve in 
unsaturated media. Measure can and have been taken to improve the stability of 
MBs against dissolution. These include the use of hydrophobic core gases such 
as perfluorocarbons which have aqueous solubilities which are orders of 
magnitude lower than air. The MB coating is also an important factor with an 
increase in shell packing or thickness decreasing the gas diffusion rate which 
strengthens MBs against the Laplace pressure. (204) 
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1.4.3.1.1. MBs as drug delivery vehicles  
The use of MBs as drug carriers provides the unique opportunity to 
simultaneously deliver both drug molecules and gas to the target site. The first 
report of drug loaded MBs was published in 1998 by Unger et al who described 
the preparation of acoustically active lipospheres (AALs) loaded with PTX. In 
this instance the drug was dispersed in soybean oil. This mixture was then added 
to a vial containing an aqueous suspension of phospholipids with a headspace of 
perflourobutane gas (PFB). The vial was mechanically agitated in a Vialmix® 
device to produce gas filled microparticles with an average size of 2.9 µm.  
 Despite the excellent drug loading capabilities of the AALs reported in 
this study (15 mg/mL), the thick oil layer provided rigid stability to the MBs 
meaning that high mechanical indices were required to initiate drug release. (205) 
PTX, among other hydrophobic drugs, has also been successfully loaded into 
MBs without the use of a thick oil layer. Xing et al reported the preparation of 
PTX loaded MB with PTX hydrophobically incorporated into the acyl chain layer 
of the MB shell. In a murine model of ovarian cancer these MBs proved to be 
effective, with mice treated with PTX-MB showing significantly greater tumour 
growth inhibition than mice treated with free PTX at the same dose. (206) 
Other studies have investigated the use of MBs with a net positive surface 
charge for gene delivery through the addition of cationic lipids into the MB shell. 
(207,208) Wang et al compared the loading capabilities of cationic versus neutral 
shelled MBs for gene delivery. Cationic MBs were prepared using 1,2-stearoyl-3-
trimethylammonium-propane (DSTAP) as a component of the lipid shell to 
create a positively charged surface with a zeta potential of +15.8 mV compared 
to – 0.3 mV for the neutrally charged MBs. Results revealed a loading of 14.9 
µg/5x108 MBs for cationic MBs compared to 0.27 µg/5x108 MBs for neutral MBs 
which subsequently resulted in a 2.4–3.2-fold higher mean drug delivery in vivo. 
(207) The utility of charged surface MBs has remained limited to the delivery of 
large biological molecules such as DNA or charge proteins. 
An alternative drug loading strategy for small molecule drug delivery is 
to load drugs to the surface of the MBs using covalent or non-covalent 
conjugation strategies. Nomikou et al reported the covalent attachment of RB to 
the surface of a phospholipid MB (RB-MB) using carbodiimide chemistry. In this 
study they reported an improved cytotoxicity profile for RB-MB conjugate 
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compared to RB alone which the authors attributed to cavitation induced energy 
transfer to the sensitiser. (209) Alternatively, drugs have been successfully 
attached the surface of MBs using a non-covalent avidin-biotin bridge, through 
the use of a biotin-functionalised phospholipid. The high biotin affinity of 
avidin/streptavidin enables rapid and facile binding to the terminal end of the 
phospholipid. Using this strategy biotinylated ligands can be loaded onto the 
surface of avidin-functionalised MBs. This strategy has also been used to load 
biotinylated liposomes onto the surface of biotin functionalised MBs. (210) Given 
the high drug loading capacity of liposomes and that one mole of MB-bound 
avidin is capable of binding to three additional moles of biotinylated payload 
means that large quantities of drug can be loaded onto MB using this strategy. 
Furthermore, liposomes are capable of encapsulating a variety of hydrophobic, 
hydrophilic and amphiphilic drugs. This strategy has proved effective in small 
preclinical investigations. However, the complexity of the manufacturing 
process has provided the greatest challenge towards clinical translation. (211–213) 
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Figure 1.22. Diagram showing different drug loading strategies for MBs. a) drugs can be 
covalently/non-covalently bound to the surface of the MB using a linker (e.g. avidin-biotin) 
(214) b) charged molecules (e.g. DNA) can be bound to the surface of charged MBs through 
electrostatic attraction (207) c) highly lipophilic molecules (e.g. PTX) can be loaded within the 
acyl chains of the phospholipid monolayer through hydrophobic interactions (215) d) 
lipophilic molecules can be dissolved/dispersed in an oil (e.g. corn oil, soy bean oil) 
surrounding a gas core and coated with phospholipids (e.g. AALs) (205) e) Nanoparticles (e.g. 
liposomes) can be bound to the surface of MBs using covalent/non-covalent binding (e.g. 
avidin-biotin) (216) f) MBs can be nested within nanoparticles (e.g. liposomes), along with a 
drug. Upon insonation, the MB can rupture the outer liposome, releasing the drug (217). Taken 
from (210). 
 
a) b)
c) d)
e) f)
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1.4.3.1.2. Sonoporation enhanced drug delivery 
Currently, the clinical use of MBs for drug delivery has been limited to the co-
administration of an already approved US contrast agent alongside a systemic 
dose of an approved chemotherapy agent. (218) The primary objective of these 
clinical studies is to improve the uptake of these drugs into tumours through a 
process known as sonoporation. As described earlier, during the rarefaction and 
compression cycles generated by an US field, MBs repeatedly expand and 
contract due to the change in acoustic pressure. Under a low acoustic pressure 
US beam, MBs oscillate with a relatively low amplitude about their equilibrium 
volume at the frequency of the US exposure in a process known as stable 
cavitation. When a MB is in close proximity to a cell, the expansion and 
contraction cycles can induce small openings in the cell membrane. (219) 
Additionally, MBs adjacent to a solid structure such as a cell are capable of 
generating high velocity fluid flow known as microstreaming. (220) The shear 
stresses, resulting from microstreaming, being exerted on the cells can be 
sufficient in some cases to cause sonoporation. A theoretical analysis by Wu et al 
found that when Optison MBs (3 µm) were insonated at 2 MHz and 0.4 MPa with 
an acoustic pressure of 0.4 MPa, the shear stress generated was calculated to be 
1.1 kPa. (221) 
 Above a defined pressure threshold, MBs undergo rapid expansion and 
subsequent collapse, known as inertial cavitation. As a result of this violent 
collapse, extremely high localised temperatures and pressures are generated 
which are often accompanied by shock waves and high-speed fluid microjets. 
The resultant shock waves and high-speed microjetting can cause pitting of cell 
membranes, facilitating the uptake of drugs. (222) Indeed MB inertial cavitation 
has also been shown to rupture to capillary walls thereby reducing the high 
interstitial fluid pressure which is a characteristic drug delivery barrier within 
tumours, thereby allowing drugs or resultant particles to extravasate into the 
surrounding tissue. (223,224) 
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Figure 1.23. Mechanisms of microbubble mediated sonoporation including acoustic 
microstreaming, oscillatory pulling and pushing, shockwave and micro-jet induced pore 
formation. Taken from (225). 
Kotopoulis and co-workers have exploited the biophysical effects of MB 
cavitation to aid in the delivery of chemotherapy to pancreatic tumours. Initial 
pre-clinical findings in orthotopic MIA-PaCa-2 xenografts treated with SonoVue 
MBs, co-administered with Gem (125 mg/kg) and insonated with US (1 MHz, 
0.688 W/cm2, PNP - 0.20 MPa) showed significantly lower primary tumour 
volumes when compared to mice treated with Gem alone.  (226) These promising 
pre-clinical results inspired a recent phase 1 clinical trial in PDAC patients, 
combining SonoVue MBs and Gem, using a clinical diagnostic platform for 
delivery of the US stimulus. The results from this study showed a near doubling 
in median survival for patients treated with US, MBs and Gem compared to 
patients treated with Gem alone. (227) However, the treatment protocol still 
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involved administering a clinical dose of Gem. As a consequence, these studies 
have done little to mitigate the severe side effects associated with systemic 
chemotherapy.  
 
1.4.3.1.3. Targeted microbubbles for cancer therapy  
A number of different active targeting strategies have been adopted in an effort 
to improve the retention of MBs within the tumour vasculature. This often 
involves incorporation of targeting ligands including antibodies, peptides, and 
small molecules into/onto the shell of the MB during or after MB fabrication 
through covalent or non-covalent conjugation. (228) Recently Bracco developed 
a MB contrast agent comprised of phospholipids covalently bound to a 5.5 kDa 
heterodimeric peptide which has a high binding affinity for kinase domain 
receptor (KDR) - an angiogenic marker overexpressed in many cancers. (229–233) 
Although this MB was designed for diagnostic purposes, the underlying 
targeting technology has vast potential for use in targeted drug delivery to many 
forms of solid tumour.  In another study, Villanueva and co-workers developed 
a phospholipid MB with an antibody (anti-ICAM-1) incorporated into the MB 
shell. The MB conjugate showed a 40-fold increase in targeting to interleukin-1B–
activated endothelial cells compared to non-targeted MBs in an in vitro model. 
(234) 
 An alternative strategy developed by Stride et al involved the 
incorporation superparamagnetic nanoparticles (SPIONs) into phospholipid 
MBs. Making the MBs magnetically responsive means it is possible to enhance 
their retention at a target site using a magnetic field prior to US mediated MB 
destruction. In a study by Stride et al, a number of different magnetic MB 
formulations were prepared, and their transfection efficiency determined using 
bioluminescence imaging. The results demonstrated that plain MBs mixed with 
a magnetic micelle or MBs prepared with magnetic material loaded directly into 
the shell proved much more effective than either the magnetic micelles or plain 
MBs alone. (235) In an in vivo study later conducted by the same group, animals 
were again injected with the magnetically responsive MBs along with the 
luciferin expressing plasmid, pGL4.13, and a small magnet was placed above the 
animal’s right lung. The results demonstrated that the bioluminescence signal 
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was confined to the right lung only, when the animal was exposed to both 
magnetic and US fields. (236) Despite the promising preclinical results for 
US/magnetically responsive MBs, current treatment strategies are hindered 
through the simultaneous application of magnetic and US fields which can be 
especially cumbersome and inaccurate in small animal models.  
 
1.4.3.1.4. MBs and SDT for cancer therapy 
As described in Section 1.4.2.4, the full potential of SDT as a clinical technique 
has two main limitations. The first is due to the need for systemic, untargeted 
administration of the sonosensitiser which can lead poor tumour uptake and 
unpleasant side effects caused by light sensitivity. The second limitation is due 
to the inherent hypoxic nature of most solid tumours. As SDT relies on the 
formation of cytotoxic ROS, the lack of available oxygen poses a therapeutic 
barrier towards an effective tumour response. In an attempt to overcome the first 
shortcoming, Nomikou et al covalently attached the sonosensitiser RB to the 
surface of a phospholipid MB through the use of carbodiimide chemistry. An in 
vitro DPBF (1,3-diphenylisobenzofuran) assay aimed at measuring ROS 
generation, revealed that the MB conjugate produced significantly more singlet 
oxygen than RB alone at the same concentration following US activation. The 
authors postulated that the enhanced singlet oxygen production was as a result 
of inertial cavitation of the MB resulting in sonoluminescence-mediated 
sensitiser activation. This translated into a significant decrease in tumour volume 
of 18% in a murine model of prostate cancer when compared to an increase in 
tumour volume of 50% observed in control mice treated with the same MB 
conjugate without US stimulation. In spite of this promising finding, the utility 
of this MB conjugate was limited by poor stability. (209) Further work by 
McEwan et al attempted to remedy this through the use of polymer shelled MBs. 
The polymer – poly(lactic-co-glycolic acid) (PLGA), was chosen as the shell 
material in this case, in light of its biocompatibility and widespread use in many 
formulations. In addition, it has also been suggested that polymeric coatings 
provide a greater degree of control over the MB destruction threshold. (193) As 
before, RB was covalently bound to the terminal end of the PLGA molecule using 
carbodiimide chemistry. For comparative purposes, phospholipid MBs were also 
prepared as described before. The study revealed a significantly enhanced 
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stability for PLGA MBs when compared to phospholipid MBs. Furthermore, in 
vivo studies revealed a significant decrease in tumour growth for PLGA RB-MBs 
in the presence of US when compared to the same in the absence of US. However, 
the overall drug loading ability of the polymeric MBs was approximately 34% 
lower than that of the phospholipid MB. (237) Despite significant progress being 
made to facilitate the delivery of sonosensitisers to the tumour site, the potential 
of SDT was still restricted through hypoxic conditions within solid tumours.   A 
2015 study by McEwan et al reported the development of oxygen carrying lipid 
MBs (O2MBs) with RB non-covalently bound to the surface using an avidin-biotin 
interaction. This was facilitated through the synthesis of a biotinylated derivative 
of RB which was bound to the surface of an avidin functionalised MB shell. When 
compared to MBs prepared with SF6 in the MB core, the O2MB generated 
significantly more singlet oxygen in degassed buffer. Furthermore, when the 
human pancreatic cancer cell line BxPC-3 was cultured in a hypoxic chamber and 
treated with O2MB-RB or SF6 loaded MB-RB plus US, a significantly lower cell 
viability was observed for the O2MB-RB formulation. A similar trend was also 
observed in vivo in mice bearing ectopic BxPC-3 xenografts, with O2MB-RB 
showing a 45% reduction in tumour volume 5 days following the initial treatment.  
The authors suggested that the in vivo effect was directly attributable to the 
presence of O2MB supplying additional oxygen as a substrate for SDT mediated 
ROS production. (214)  
 The concept of oxygen carrying MBs for the delivery of sonosensitisers 
was taken a step further in 2016 when McEwan et al successfully prepared O2MB 
bearing the antimetabolite drug 5-FU, in addition to O2MB bearing RB. A similar 
approach was adopted in this study with regards to drug conjugation, with both 
drugs being attached to the MB shell through avidin-biotin linkages. In contrast 
to their previous publications, a phospholipid with a longer acyl chain (PC 22:0) 
was used as the main lipid component of the MB formulation. (238) This was 
based on the finding by Borden et al, that increasing the acyl chain length can 
have a significant effect on the physiochemical characteristics of MBs and can 
prolong the dissolution time of MBs in a degassed medium. (239) Rather 
unsurprisingly, McEwan et al found that the MBs were more stable with respect 
to oxygen retention when compared to their earlier MB formulation (PC 18:0). 
Additionally, it was found that combined SDT and antimetabolite therapy using 
the O2MB showed an enhanced cytotoxicity profile in three different pancreatic 
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cancer cell lines cultured in an anaerobic cabinet when compared with either SDT 
or 5-FU treatments alone. In addition, when mice bearing ectopic BxPC-3 
tumours were treated with the combined therapy, a statistically significant 
reduction in tumour volume was observed when compared to the control mice. 
(238) A similar approach was also adopted by the same group but used Gem in 
place of 5-FU, as Gem has since superseded 5-FU as the antimetabolite of choice 
in clinical practice. (240) One shortcoming of the latter two studies was that two 
separate MB formulations were prepared: one bearing RB and the other bearing 
the antimetabolite derivative. These then had to be mixed in a 1:1 volume ratio 
which means that the effective dose of each active agent was reduced by 50%. 
This is especially significant when considering that the dose of antimetabolites 
administered using the MBs is orders of magnitude lower than their typical 
clinical dose. (241) 
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1.4. Overall aim and specific chapter objectives 
The overall aim of the work conducted in this thesis was to develop novel MB 
based formulations to enable targeted chemo-SDT treatment of breast / 
pancreatic cancer models. An overview of the aims for each chapter is provided 
below. More specifically to develop MB formulations capable of delivering 
multiple payload drugs on a single MB. A secondary aim is to improve the 
targeting potential of these MB formulations though the incorporation of 
magnetically responsive nanoparticles into the MB coating. A further aim is to 
develop MB formulations which are amenable to clinical translation through 
optimisation of MB fabrication protocols which do not involve post-production 
manipulation of MBs. 
1.4.1. Chapter 3 - Treatment of MCF-7 Breast Cancer Using Ultrasound 
Responsive Microbubbles Loaded with Paclitaxel, Doxorubicin and Rose 
Bengal. 
This chapter investigated the development of MBs carrying either PTX and RB or 
PTX and Dox. In both cases, PTX was loaded hydrophobically into the lipid shell 
of the MBs and RB / Dox was attached to the surface using the avidin-biotin 
interaction. By using a combination of the two MB formulations, the effect of 
targeted PTX / Dox / SDT treatment was established in an MCF-7 murine model 
of breast cancer. The results from this chapter have been published in (242). 
1.4.2. Chapter 4 - Targeted Delivery of Paclitaxel, Gemcitabine and Rose 
Bengal to Pancreatic Tumours Using a Multifunctional Microbubble Delivery 
Platform. 
Gem-Abraxane is a first line chemotherapy combination for pancreatic cancer. 
Previous work has also demonstrated the benefit of combining Gem with SDT in 
pre-clinical pancreatic cancer models. The aim of the work undertaken in this 
chapter was to develop a single MB formulation capable of carrying PTX /Gem 
/RB and determine how effective targeted chemo-sonodynamic therapy using 
this formulation was in a pre-clinical murine model of pancreatic cancer.  
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1.4.3. Chapter 5 - Magnetic Microbubble Mediated Chemo-Sonodynamic 
Therapy using a Combined Magnetic-Acoustic Device 
Previously published work has indicated that magnetically responsive Gem / RB 
loaded MBs enhanced the chemo-sonodynamic therapy treatment of murine 
pancreatic tumours that were exposed to both magnetic / US fields during 
treatment, compared to an US field alone. In this chapter, two shortcomings of 
this work were addressed by preparing a single MB formulation carrying both 
Gem / RB and using a single co-aligned probe to deliver the combined magnetic 
/ US fields.  The efficacy of this approach was determined in a murine model of 
pancreatic cancer.  
1.4.4. Chapter 6 - Microbubble Mediated Delivery of Novel Gemcitabine 
Phospholipid-Pro-drug and Paclitaxel 
When considering potential clinical translation of the work undertaken in 
Chapters 3-5, it became apparent that significant manipulation would be 
required at the treatment site to first generate the MB formulation and then attach 
any biotinylated payloads. To minimise the need for any post-MB manipulation, 
this chapter investigated the potential to generate MBs carrying both the 
hydrophobic PTX and the hydrophilic Gem without any post-MB manipulation. 
This involved the synthesis of a lipid functionalised with Gem and its assembly 
into MBs with PTX non-covalently incorporated in the lipid shell.  Efficacy of the 
Gem/PTX MBs following UTMD mediated release was determined in a murine 
model of pancreatic cancer.   
1.5. Statement of collaboration 
The synthesis of compound 12, discussed in chapter 4 and 5, was carried out by 
Dr Sukanta Kamila. The design and fabrication of the MAD device, discussed in 
chapter 5, was conducted by Dr Lester Barnsley and Dr Michael Gray. In vitro 
characterisation of the magnetic MBs, discussed in chapter 5, including drug 
delivery in agar phantoms and singlet oxygen generation, was performed by Dr 
Estelle Beguin.   
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Methodology 
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Chapter 2 - Methodology 
2.1. Materials and reagents 
Reagents and solvents were purchased from commercial sources at the highest 
possible grade. Panc-1, BxPC-3 and Mia Paca-2 cells were obtained from the 
American Type Culture Collection (ATCC) (Manassas, VA, USA) and Matrigel 
from BD Biosciences (San Jose, CA, USA). SCID mice (C.B-17/IcrHanHsd-
PrkdcSCID) were bred in house. All phospholipids were purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). Rose bengal and biotin were purchased from 
Sigma Aldrich (St. Louis, MO, USA). Doxorubicin, gemcitabine and paclitaxel 
were purchased from XABC (Shaanxi, China). Avidin from egg white was 
purchased from Thermo Fisher (Waltham, MA, USA). Iron oxide nanoparticles 
(IONPs) (50 nm hydrodynamic diameter) were custom conjugated by Ocean 
NanoTech (San Diego, CA, USA).  MBs were formed using a Microson ultrasonic 
cell disruptor, 100 W, 22.5 kHz, from Misonix Inc. (Farmingdale, NY, USA). 
Optical microscope images were obtained using a Leica DM500 optical 
microscope (Wetzlar, Germany). Analysis of MB size and concentration was 
determined using a bespoke MATLAB algorithm (2010B, MathWorks, Natick, 
MA, USA). UV-Vis spectra were recorded with a Varian Cary spectrophotometer 
(Palo Alto, CA, USA), using quartz cells (path length = 1 cm). UV absorbance of 
MTT was analysed using a Fluostar Omega plate reader (BMG Labtech, 
Ortenberg, Germany). NMR spectra were obtained on Varian 500 MHz 
instrument at 25.0 ± 1 °C (Palo Alto, CA, USA) and processed using TopSpin 
software (Bruker, Billerica, MA, USA). ESI-MS were obtained using a Finnegan 
LCQ-MS instrument (San Jose, CA, USA). HPLC analysis was carried out on a 
Shimadzu LC-8 preparative pump system (Shimadzu Corp., Kyoto, Japan). 
Statistical error in data was expressed as standard error of the mean (SEM), while 
statistical analysis was undertaken using either a 2-tailed Students t-test or a one-
way ANOVA followed by Tukey’s post hoc test. 
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2.2. Synthesis of biotinylated doxorubicin (5) 
Biotin-N-hydroxysuccinimide ester (3) was prepared by the reaction of biotin (1) 
and N,N-disuccinimidyl carbonate (2) following a literature procedure. (243) To 
an ice-cold solution of 3, (0.14 g, 0.41 mmol) in DMF (10 ml) was added 
doxorubicin hydrochloride (4, 0.3 g, 0.41 mmol) under a nitrogen atmosphere. 
After stirring for 30 min, triethylamine (0.5 ml, 2 mmol) was added to the reaction 
mixture and the contents stirred for 12 hrs at room temperature. The reaction was 
monitored by thin layer chromatography (TLC) (Merck Silica 60, HF 254, 
methanol-dichloromethane, 1:4). After completion of the reaction, excess diethyl 
ether (100 ml) was added to the reaction mixture. The resultant red precipitate 
was filtered and washed three times with diethyl ether (50 ml x 3). The solid was 
then subjected to preparative thin layer chromatography (PTLC) purification 
(methanol:dichloromethane, 1:4) to obtain 0.25 g (yield = 78%) of 5. 1H NMR 
(DMSO-d6) δ :7.84 (d, J = 7.5 Hz, 2H, aromatic), 7.58 (d, J = 7.5 Hz, 1H, aromatic), 
6.36 (s, 1H, NH), 6.29 (s, 1H, NH), 5.37 (brs, 1H, OH), 5.22 (brs, 1H, OH), 4.87 (s, 
2H, -CH2-OH), 4.51 (brs, 2H, OH X 2), 4.36-4.33 (m, 1H, CH), 4.25-4.22 (m, 1H, 
CH), 4.16-4.13 (m, 1H, CH), 3.99 (s, 3H, OCH3), 3.60-3.58 (m, 1H, CH), 3.55 (brs, 
2H, OH X2), 3.10-3.00 (m, 4H, CH2 X1, CH X 2), 2.88-2.54 (m, 3H, CH2 X 1, CH), 
2.20-2.00 (m, 1H, CH), 1.63-1.50 (m, 4H, CH2 X 2), 1.42- 1.22 (m, 11 H, CH3 X 1, 
CH2 X 4). 13C NMR (DMSO-d6): 177.6, 176.9, 174.8, 166.4, 163.0, 161.2, 153.7, 152.7, 
137.4, 132.4, 120.4, 119.4, 99.5, 97.8, 80.15, 75.1, 72.7, 66.4, 61.4, 59.5, 55.7, 47.8, 33.8, 
31.9, 28.9, 28.8, 28.5, 28.4, 24.9, 19.8, 17.6, 17.1. Negative mode ESI-MS: [M-H]: 
calculated for C37H43I2N3O13S = 769 Da, found = 768 Da. 
2.3. Synthesis of biotin rose bengal (8) 
2.3.1. Synthesis of rose bengal amine (7) 2-Aminoethyl 2,3,4,5-tetrachloro-6-(6-
hydroxy-2,4,5,7-tetraiodo-3-oxo-3H-xanthen-9-yl)benzoate: 
To a solution of rose bengal disodium (5, 1.0 g, 1.0 mmol) in anhydrous DMF (10 
mL) was added 2-bromoethylamine (0.32 g, 1.5 mmol) and the mixture was 
stirred at 80oC for 7 hrs. The DMF was then removed under reduced pressure 
and the residue stirred for 18 hrs in diethyl ether (200 mL). The solution was 
filtered and the resulting solid stirred in water (200 mL) for 18 hrs. The 
suspension was filtered and the solid was recrystallised from methanol to yield 
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the product as a dark red solid. 1H NMR (500 MHz, DMSO-d6): 2.42 (t, CH2, 2H), 
3.80 (t, OCH2, 2H), 7.26 (s, ArH, 2H), 7.60 (s, NH2, 2H). 13C NMR (500 MHz, 
DMSO-d6): 19.0, 37.5, 49.3, 56.5, 62.7, 76.6, 97.9, 129.6 130.6, 132.4, 133.4, 10.6, 110.9, 
134.7, 135.7, 136.4, 137.0, 139.6, 157.5, 163.2, 172.3. ESI-MS: calculated for 
C22H9Cl4I4NO2 = 1016.53, found 1016.13 
2.3.2. Synthesis of biotin rose bengal (8) 2-(5-(2-Oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)ethyl2,3,4,5-tetrachloro-6-(6-hydroxy-2,4,5,7-
tetraiodo-3-oxo-3H-xanthen-9-yl)benzoate:  
To a solution of rose bengal amine (74 mg, 74 !mol) in 2 mL DMF, 3 (25 mg, 74 
!mol) dissolved in DMF (2 mL) was added. Triethylamine (TEA, 10 !l, 0.71 !mol) 
was added to the mixture which was then stirred at room temperature for 12 hrs. 
The resulting solution was placed in a solution of hexane: chloroform (200 ml, 
4:1) and stirred for 24 hrs at room temperature. The solution filtered and the 
filtrate retained. The filtrate was washed three times with diethyl ether and dried 
in a vacuum oven to yield 8 as a red powder (14 mg, 10%). 1H NMR (500 MHz, 
DMSO-d6): 1.28 (m, CH2, 2H), 1.45 (m, CH2, CH, 3H), 1.57 (m, CH, 1H), 1.60 (t, 
CH2, 2H), 2.52 (q, CH, 1H), 2.58 (m, CH, 1H), 2.79 (q, CH, 1H), 2.97 (t, CH2, 2H), 
3.10 (m, SCH, 1H), 3.85 (t, OCH2, 2H), 4.09 (t, CH, 1H), 4.28 (t, CH, 1H), 6.34 (s, 
NH, 1H), 6.41 (s, NH, 1H), 7.46 (s, ArH, 2H), 7.56 (brs, NH, 1H). 13C NMR (125 
MHz, DMSO-d6): 8.98, 9.03, 25.52, 28.57, 29.45, 31.72, 35.52, 37.34, 46.07, 53.13, 
55.86, 59.66, 61.48, 64.65, 76.50, 97.69, 110.56, 124.271, 129.37, 130.48, 132.34, 134.79, 
135.50, 136.41, 139.79, 157.42, 163.13, 163.57, 172.23, 172.68, 228.31, 230.86. ESI-MS: 
calculated for C32H23Cl4I4N3O7S = 1243.0 found = 1241. 
2.4. Synthesis of biotin-Gem-RB (12) 
2.4.1. Synthesis of N-(2-(bis(2-aminoethyl)amino)ethyl)-5-(2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamide (10) 
To a stirred solution of tris(2-aminoethyl)amine (9) (0.22 g, 1.5 mmol) and 
trimethylamine (TEA) (catalytic amount) in anhydrous dimethylformamide 
(DMF) (5 mL), 3 (0.5 g, 1.5 mmol) was added and the reaction mixture was stirred 
at 0oC under a nitrogen atmosphere for 30 min. The solvent was removed under 
reduced pressure and the residue was triturated with diethyl ether. The crude 
product was purified by column chromatography on basic (TEA) silica gel 
(methanol: dichloromethane 1:9 to 3:7) to give 10 (0.33 g, 61% yield) as a white 
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semi solid. 1H NMR (DMSO-d6): δ 7.94 (brs, 1H, NH), 6.42 (brs, 1H, NH), 6.35 (brs, 
1H, NH), 4.49 (brs, 4H, NH2 X 2), 4.29 (s, 1H, CH), 4.12 (s, 1H, CH), 3.07-3.02 (m, 
6H, CH2 X 3), 2.88-2.82 (m, 1H, CH), 2.44-2.06 (m, 10H, CH2 X 5), 1.59-1.48 (m, 4H, 
CH2 X 2), 1.47-1.29 (m, 2H, CH2). ESI-MS: calculated for C16H32N6O2S, 372.23; 
found 373.31 (M + H)+.  
2.4.2. Synthesis of bis(2,5-dioxopyrrolidin-1-yl) 8,8'-((((2-(5-(2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl)azanediyl)bis(ethane-2,1-
diyl))bis(azanediyl))bis(8-oxooctanoate) (11) 
To a stirred solution of compound 10 (0.5 g, 1.3 mmol) and TEA (catalytic amount) 
in 10 mL anhydrous DMF was added disuccinimidyl suberate (1 g, 2.7 mmol) 
and the reaction mixture stirred at room temperature for 6 hrs under a nitrogen 
atmosphere. After completion of the reaction, excess diethyl ether (200 mL) was 
added to the reaction mixture. The white precipitate thus obtained was filtered 
and washed 3 times with diethyl ether (50 mL x 3). The crude product was 
purified by column chromatography on basic (TEA) silica gel 
(methanol:chloroform 1:4 to 1:1) to give 11 (0.83 g, 71% yield) as a white solid. 1H 
NMR (DMSO-d6): δ 7.94 (brs, 2H, NH X 2), 7.67 (brs, 1H, NH), 6.41 (brs, 1H, NH), 
6.34 (brs, 1H, NH), 4.29 (s, 1H, CH), 4.12 (s, 1H, CH), 3.06-3.04 (m, 3H, CH and 
CH2), 2.88-2.72 (m, 6H, CH2 X 3), 2.71-2.63 (m, 8H, CH2 X 4), 2.45-2.34 (m, 6H, CH2 
X 3), 2.20-2.06 (m, 10H, CH2 X 5), 1.60-1.21 (m, 22H, CH2 X 11). 13C NMR (DMSO-
d6): 172.5, 170.7, 163.1, 162.7, 61.4, 59.6, 55.8, 53.9, 39.9, 39.8, 39.6, 37.3, 36.2, 35.6, 
31.2, 28.7, 28.5, 25.8, 25.7, 25.6. ESI-MS: calculated for C40H62N8O12S, 878.4; found 
901.3 (M +Na)+. 
2.4.3. Synthesis of ((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-
difluoro-3-hydroxytetrahydrofuran-2-yl)methyl 4,11,19-trioxo-15-(2-(5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl)-1-((2,3,4,5-
tetrachloro-6-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3H-xanthen-9-
yl)benzoyl)oxy)-3,12,15,18-tetraazahexacosan-26-oate (12) 
To a stirred solution of 11 (0.4 g, 0.45 mmol) in anhydrous DMF (5 mL) was added 
gemcitabine hydrochloride (0.136 g, 0.45 mmol) and TEA (0.5 mL) and the 
reaction was stirred at 22oC for 24 hrs under a nitrogen atmosphere. After 
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completion of the reaction, 7 (prepared separately as described in Section 2.3.1) 
(0.43 g, 0.45 mmol) in anhydrous DMF (5 mL) and TEA (0.5 mL) were added to 
the reaction mixture and continued to stir for 24 hrs. Once the reaction was 
complete, excess diethyl ether (200 mL) was added to the solution and stirred for 
30 min. The pink red precipitate thus obtained was triturated with diethyl ether 
(100 mL), ethyl acetate (100 mL), acetone-water mixture (1:9, 100 mL) and finally 
with ethyl acetate-hexane mixture (1:1, 100 mL) respectively to afford a pink 
powder of compound 12 (0.26 g, 30% yield).  1H NMR (DMSO-d6): δ 7.95 (brs, 2H, 
NH2), 7.69 (s, 1H, CH, aromatic proton), 7.68 (s, 1H, CH, aromatic proton), 7.37(s, 
1H, CH), 7.32 (brs, 4H, NH X 4), 6.89 (s, 1H, CH), 6.42 (brs, 1H, NH), 6.35 (brs, 1H, 
NH), 6.22 (d, 1H, CH), 6.13 (brs, 1H, NH), 5. 78-5.77 (m, 1H, CH), 5.19 (s, 1H, CH 
X 2), 4.9 (brs, 1H, OH), 4.30 (s, 2H, -OCH2), 4.13 (s, 2H, -OCH2), 3.79-3.60 (m, 3H, 
CH, CH2), 3.39-3.32 (m, 2H, CH2), 3.07 (brs, 6H, N-NHCH2 X 3), 2.94-2.84 (m, 6H, 
NCH2 X 3), 2.81 (brs, 1H, OH), 2.45-2.46 (m, 3H, CH, CH2), 2.17-2.06 (m, 10H, CH2 
X 5), 1.60- 1.10 (m, 22H, CH2 X 11). 13C NMR (DMSO-d6): 171.8, 165.98, 163.2, 162.7, 
159.3, 155.0, 150.5, 145.8, 141.2, 131.0, 128.7, 123.5, 116.2, 95.0, 80.9, 69.3, 61.5, 59.6, 
59.4, 55.8, 51.7, 45.8, 40.2, 37.3, 37.05, 36.2, 35.5, 31.0, 28.7, 28.5, 28.2, 25.6. ESI-MS: 
calculated for C63H72Cl4F2I4 N10O15S, 1925.98; found 1925.90 (M - H)-. 
2.5. Synthesis of LipidGem (15) 
A chloroform solution (20 mL) of 1,2-dibehenoyl-sn-glycero-3-phosphocholine 
(500 mg, 480 !mol) was added to a stirred solution of gemcitabine hydrochloride 
(400 mg, 1.5 mmol) and phospholipase D from Streptomyces sp (3 mg, 900 units) 
in sodium acetate buffer (200 mM, pH 4.5, 5 mL) containing calcium chloride (200 
mM). The mixture was stirred vigorously at 45oC for 6 hrs after which a solution 
containing chloroform (10 mL) and methanol (15 mL) was added. The organic 
layer was separated, and the aqueous layer washed twice with a 
chloroform/methanol mixture (2:1). The organic extracts were combined, dried 
using anhydrous sodium sulphate, filtered and concentrated in vacuo to yield a 
waxy, off-white solid. The crude product was purified using preparative thin 
layer chromatography (chloroform: methanol: ammonium hydroxide (7N), 
65:25:4, Rf – 0.41) to give Lipid-Gem (25% yield).  
 
60 
2.6. Clonogenic assay in MCF-7 cells treated with Dox, PTX, SDT and 
combinations thereof 
The human breast adenocarcinoma cell line (MCF-7) was cultured in DMEM 
supplemented with 10% FBS, 100 µg/ml streptomycin and maintained in a 
humidified, 5% CO2 atmosphere at 37°C. MCF-7 cells were seeded (5 x103) into 
each well of a 96 well plate and 24 hrs later cells were treated with PTX (1 nM), 
Dox (10 nM), RB (10 nM) or combinations thereof for 3 h, followed by 
replacement of the media. Selected wells were treated with US for 30 s delivered 
using a Sonidel SP100 sonoporator (frequency - 1 MHz, power density - 3.0 
W/cm2, duty cycle - 50% PRF - 100 Hz). After 18 hrs, cells were pooled from 2 
wells and seeded in a 6 well plate containing 5 ml of complete media. Plates were 
placed in an incubator for 7 days. Medium was removed from wells and 
fixation/staining solution (1 mL) [consisting of crystal violet (0.05% w/v), 
formaldehyde (2.7% v/v), PBS (10% v/v), methanol (1% v/v) and distilled water 
(86.3% v/v)] was added to each well at room temperature for 20 min. The 
solution was removed, and wells were washed with water. Digital photographs 
were taken using a Canon EOS100D DSLR and colony formation was analysed 
using Image J software. 
2.7. In vitro treatment of BxPC-3 and Mia-PaCa-2 cells with Gem, 8 and 12.
The human primary pancreatic adenocarcinoma cell line BxPC-3 was maintained 
in RPMI 1640 medium which was supplemented with 100 U/mL penicillin, 100 
mg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified 5% CO2 
atmosphere at 37oC. The Mia-PaCa-2 cell line was maintained using Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 1 g/L glucose and supplemented 
with 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum 
(FBS) in a humidified 5% CO2 atmosphere at 37oC. These cells were seeded into 
96-well plates at a density of 5000 cells per well. The plates were then incubated
for 24 hrs followed by the addition of 100 !L of media spiked with Gem, 8 or 12 
at concentrations ranging from 0.001-1000 !M. The cells were then further 
incubated for 48 hrs before the cell viability was determined by an MTT assay. 
2.8. Preparation of drug loaded MBs  
For the preparation of MBs containing PTX in the shell, first 1,2-dibehenoyl-sn-
glycero-3-phosphocholine (DBPC) (4.0 mg, 4.44 µmol), 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N- [methoxy(polyethylene glycol) -2000] (DSPE-
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PEG(2000)) (1.35 mg, 0.481 µmol) and 1,2- distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000]   (ammonium salt) 
(DSPE-PEG (2000)-biotin) (1.45 mg, 0.481 µmol) were dissolved in chloroform in 
a glass vial at a molar ratio of 82:9:9. To this solution was added PTX (5 mg, 5.86 
µmol) dissolved in chloroform (100 µL). The solvent was removed under vacuum 
at room temperature yielding a translucent film. For MBs prepared using 15, the 
film was prepared as described above with the exception that 15 (5 mg, 4.71 
!mol), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (1.43 mg, 0.51 !mol) and PTX (2.5 mg, 2.93 
!mol)  were used. For MBs not containing PTX, the same procedure for thin film 
formation described above was used, with the exception that no PTX was added. 
The film was then reconstituted in 2 mL of a solution containing PBS (pH 7.4 ± 
0.1), glycerol and proplyene glycol (8:1:1 volume ratio) and heated in a water bath 
at 80oC for 30 min. The cloudy colloidal suspension was sonicated using a 
Microson ultrasonic cell disrupter at an amplitude of 22% for 1 min and then at 
an amplitude of 90% in a perflourobutane (PFB) atmosphere for 30 sec. The MBs 
were then cooled on ice for 10 min followed by centrifugation (100 RCF) for 3 
min and the liquid laying below the surface of the MB cake (infranatant) was 
removed. The MB-PTX cake was then washed a further 2 times with PBS (pH 7.4 
± 0.1). These MB were either used straight away (plain MB or MB-PTX) or avidin 
functionalisation was carried out through the addition of an aqueous solution of 
avidin (10 mg/mL). The MB suspension was then mixed using an orbital shaker 
for 10 min in an ice bath to allow for the reaction to take place. The MBs were 
then centrifuged (100 RCF) for 3 min, the infranatant removed and the MB cake 
washed with PBS solution (2 mL, pH 7.4 ± 0.1) which was again removed 
following centrifugation. The MB cake was again reconstituted in PBS solution 
(2 mL, pH 7.4 ± 0.1), mixed with an aqueous solution containing one of: (i) 5, (ii) 
8 or (iii) 12 (1 mL, 5 mg/mL) for 5 min. The drug loaded MBs were then 
centrifuged (100 RCF) for 3 min. Following removal of the infranatant, the MB 
cake was then washed with PBS (2 mL, pH = 7.4 ± 0.1), centrifuged, and the MB 
cake isolated. This washing / centrifugation procedure was repeated twice 
further with the final MB cake reconstituted in 2 mL of PBS. Drug loaded 
MagMBs were prepared following the protocol described above with the 
exception that 2-dibehenoyl-sn-glycero-3-phosphocholine coated IONPs (150 µL, 
3.75 mg iron) were added to the colloidal lipid suspension prior to MB formation. 
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In vitro, MagMB characterisation was completed using 8 to prevent wastage of 
the more difficult to synthesise 12. Drug-loaded MBs bearing 5, 8 or 12 were kept 
in reduced light conditions and on ice prior to use. When oxygenated MB were 
required, MBs were sparged with oxygen gas for a total of 2 mins to allow gas 
exchange to occur and these are referred to with the prefix O2MB- (e.g. O2MB-RB) 
(Figure A7). Otherwise, they are referred to with the prefix MB- (e.g. MB-RB). 
 
2.9. Determination of size distribution and concentration of MBs. 
An appropriate aliquot of freshly prepared MB suspension was diluted in PBS 
solution (2 mL, pH 7.4 ± 0.1). A 10 µL sample was then loaded into a 
haemocytometer and viewed under a microscope (x40 objective). Images (n=20) 
were taken of the MB suspension and saved as high resolution TIFF files. These 
images were then analysed using a bespoke MATLAB algorithm as described in 
(244). Based on the known area per pixel and known frame volume, the 
distribution of MB diameters and mean MB concentration could be determined. 
For calibration purposes, commercial MBs (SonoVue) were also analysed and 
compared to values provided by the manufacture (data not shown).  
 
2.10. Determination of PTX loading 
An appropriate volume of MB-PTX was removed and diluted in a mixture of 
acetonitrile and water (1:1 v/v). This sample was then sonicated to fully 
solubilise the MBs and the sample was then placed in a 2 mL HPLC vial. The 
drug loading for PTX was then determined using reverse phase HPLC. A volume 
of 50 µL was injected onto a Phenomenex C18 column (250 × 4.6 mm, 5 !m) and 
the sample was eluted using a mobile phase consisting of acetonitrile and water 
(1:1), a flow rate of 1.5 mL/min and a detection wavelength of 227 nm. The 
loading of PTX was calculated by the following equation:  
Equation 1. 
!"#$	&'()*+$	 = -(..	'/	012	*+	/*&3-(..	'/	&*4*)	3(56"*(&	*+	/*&3 ∗ 	100 
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2.11. Determination of drug loading of 5, 8, 12 and 15 
Using 1 mM stock solutions prepared in PBS solution (5% DMSO, 2 mL, pH 7.4 
± 0.1) for 5, 8 and 12 and a solution of methanol and chloroform (20:1) for 15, 
appropriate calibration standards were prepared. These standards were loaded 
into a quartz cuvette and the UV absorbances were read between 200 and 800 nm. 
Calibration curves for 5, 8, 12 and 15 were then constructed using the absorbance 
at the lmax. Samples were prepared from freshly synthesised MBs by taking an 
appropriate aliquot of the MB suspension and diluting in PBS solution (2 mL, pH 
7.4 ± 0.1). This suspension was then sonicated for 1 min to fully destroy MBs and 
solubilise 5, 8 or 12. This sample was then placed in a quartz cuvette and the 
absorbance was read at 480 nm, 560 nm and 280 nm for 5, 8/12 and 15 respectively.  
 
2.12. Characterisation of MB iron loading 
As DBPC-IONPs were incorporated within the MB coating, the functionalisation 
of MBs with drug products on its outer surface is unlikely to affect the iron 
loading of the MBs. The iron content of MagMBs was detected using inductively 
coupled plasma optical emission spectroscopy (ICP-OES, Perkin Elmer, Optima 
8000). Iron measurements were performed at a wavelength of 238 nm and a 
calibration curve was constructed for iron in 2% nitric acid solution (0-1 mg/L) 
with a R2 value of 0.9999 prior to sample measurements.  
 
2.13. Determination of MB stability 
MBs were prepared as described in Section 2.8. Immediately following synthesis, 
MBs were characterised in terms of MB concentration according to Section 2.9. 
Batches of MBs were then placed in a water bath in an incubator at 37oC and the 
MB concentration was determined at t = 10, t = 60, t = 120 and t =180 min.  
 
2.14. Production of singlet oxygen from MagO2MB-RB exposed to US 
The production of singlet oxygen (1O2) from activated RB exposed to US was 
determined using SOSG. A sample of 9 mL degassed PBS, ± 5x107 MB/mL, ± 541 
!M biotin-RB, and 1.25 !M SOSG was exposed to 1.17 MHz, 0.70 MPa peak 
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negative pressure, 30% duty cycle (DC), 100 Hz pulse repetition frequency (PRF) 
US for 3.5 minutes. Sample exposure was undertaken using a custom-made tank 
with the built-in transducer driven at 1.17 MHz. The sample was injected into a 
holder placed in the pre-focal region of the transducer to ensure a uniform 
pressure field at the top of the sample chamber. The fluorescence intensity of 
SOSG (Ex: 490 nm / Em: 520 nm) was measured for each sample with and 
without US exposure. To minimise the scattering from MBs in the sample 
without US exposure, increased hydrostatic pressure was applied to the sample 
using a sealed syringe to destroy the bubbles prior to fluorescence measurement. 
The generation of 1O2 was then calculated as a percent change in SOSG 
fluorescence intensity at 520 nm for a sample exposed to US compared to a 
control sample for each experimental run. In addition to measuring 1O2 
generation, the characterisation of MB acoustic emissions during US exposure 
were recorded using PCD focused on the top of the sample chamber. A 2 MHz 
analog high-pass filter was used to remove the drive frequency from the recorded 
signal before pre-amplification, digitization, and storage onto a computer drive. 
The power spectral density was calculated for each PCD signal acquisition. These 
results were used to quantify cavitation activity during each experiment (3.5 
minutes exposure) by determining the cumulative energy at ultraharmonic 
frequencies (f0*(n+0.5), with f0 = 1.17 MHz and n = 2,3...9), which are indicative 
of nonlinear bubble oscillations. 
 2.15. Magnetic-Acoustic-Device (MAD) and control device 
The MAD was designed as described by Barnsley et al. (245) Briefly, the magnetic 
body consisted of N52 grade NdFeB permanent magnet material whose 
geometry was optimized to have a maximum magnetic field of 0.2 T at a distance 
of 10 mm from the body’s leading edge. An integrated ultrasonic element with a 
focal distance also of 10 mm provided a pressure field that spatially overlapped 
with the magnetic field peak, with sufficient amplitude to cause inertial 
cavitation of MBs used in this study. An aluminium-bodied copy of the MAD 
(hereafter referred to as “aMAD”) was produced to provide an US-only control 
for in vitro and in vivo experimentation. In order to span the gap between the US 
element and the delivery site of interest in the present work, a coupling cone was 
cast from paraffin wax and secured with US gel. The cone material was chosen 
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for its ease of casting and minimal transmission loss in the 1 MHz frequency 
range as determined by through-transmission measurements. Since the acoustic 
boundary conditions for this configuration were different from those used in the 
initial characterization, both the MAD and the aluminium copy were recalibrated. 
 
2.16. Drug delivery comparison in agar between devices 
Drug delivery was quantified in vitro by flowing MagO2MB-RB (1.7 x108 ±0.6 x108 
MB/mL, [RB] = 500 ± 50 !M) through a tissue mimicking agar phantom. The 
phantom body was formed within a Delrin frame filled with 1.25% agar gel. The 
cured agar phantom was 7 mm thick and covered in clear and acoustically 
transparent Mylar films on each side. Each phantom contained at least one 
straight channel of 1.2 mm diameter, with fittings on the frame for connection to 
a syringe pump and drain tubing. A tube size of 1.2 mm diameter was chosen as 
this was consistent with the vasculature which surrounds pancreatic tumour 
lesions. (246) During testing, the phantom was partially immersed in a water bath 
heated to 36 ± 1°C, with the upper phantom surface in air so that acoustic 
boundary conditions would be similar to those in the in vivo experiments. The 
phantom assembly was free of ferrous metal parts in order to minimize the 
likelihood of secondary magnetic fields influencing the results. For acoustic 
treatments (MAD or aMAD), the device was held in place with a lab clamp, and 
the cone tip was coupled to the phantom face with water. Acoustic drive pulses 
(3000 cycles of 1.17 MHz, 30% duty cycle) were provided so that the peak 
negative pressure 10 mm in front of the device would be 0.7 MPa. This level 
matched the spatial peak value from a separate device that had been used in 
previous SDT experiments. (214,247) Ultrasonic emissions from the channel were 
recorded using a single PCD. Initial positioning of the agar flow channel and the 
acoustic instrumentation was guided by a crosshair laser to ensure proper 
alignment. The MAD was used for: (i) its co-aligned magnetic and acoustic fields 
(group: “MAD” ) (ii) its magnetic field only (US off) (group: “Mag”), and (iii) its 
magnetic field (MAD US off) with the acoustic field of the (aMAD) to study the 
non-coaligned fields (group: “US + Mag”). The aMAD was also used on its own 
for the US only control (group: “US”). For all treatment groups, MagMB-RB were 
injected at a flow rate of 0.2 mL/min which. This flow rate produced a Reynolds 
number of 2.65 which is physiologically relevant. US was applied for 3.5 minutes, 
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after which the treated channel was rinsed with 1 mL deionised water. The agar 
channel was immediately cut out (0.7 mL volume) and reserved for analysis after 
the experiment. After all groups were completed in a single test day, the reserved 
cut out agar channels were melted, sampled onto a pre-heated 96-well plate and 
left to equilibrate at 45°C for 15 minutes. Absorbance spectra were acquired at 
that temperature using a plate reader to measure the amount of RB delivered in 
the agar volume. Spectra were normalised to no-treatment controls and the 
samples’ absorption intensities at 559 nm were compared to a standard curve for 
biotin-RB in melted 1.25% agar at 45°C (R2 = 0.9991).  
 
2.17. Culture of MCF-7 spheroids 
MCF-7 cells were maintained using Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 1 g/L glucose and supplemented with 100 U/mL penicillin, 
100 mg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified 5% 
CO2 atmosphere at 37oC. Spheroids were generated by growing MCF-7 cells in 
96 well Carrier Plates (ULA) from PerkinElmer. Cells were seeded (8 x103, 100 
µL) in selected wells. After 24 hrs, 100 µL of media was added to each well and 
plates were incubated at 37°C in a humidified 5% CO2 atmosphere for a further 
3 days to allow the cells to aggregate. Media was replenished every 3 days by 
removing 100 µL of old media and replacing it with 100 µL of fresh media. 
 
2.18. Culture of Panc-1 spheroids 
The human primary pancreatic carcinoma cell line PANC-1 was maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 1 g/L glucose and 
supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% 
fetal bovine serum (FBS). Cells were incubated at 37oC in a humidified 
atmosphere with 5% CO2. Spheroids were prepared by seeding 2000 cells (200 uL) 
into a pre-coated 96-well plate (60 uL 1.5% agarose per well) for 4 days. 
 
2.19. In vitro cytotoxicity in MCF-7 Spheroids  
After 3 days of incubation following seeding, spheroids were allocated to groups 
and treated according to the following conditions: untreated (drug-free 
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medium), MB (no drugs), PTX/Dox only ([PTX] = 0.34 µM, [Dox] = 1 µM), and 
MB-PTX-Dox / MB-PTX-RB ([Dox] = 1 µM, [RB] = 10 µM). Where required, 
individual wells were then placed in direct contact with the emitting surface of a 
Sonidel SP100 sonoporator with US gel used to mediate contact. Each well was 
treated with US for 30 seconds (frequency - 1 MHz, power density - 3.0 W/cm2, 
duty cycle - 50%, PRF = 100 Hz). Plates were incubated in a humidified 5% CO2 
atmosphere at 37°C for 3 hrs and then wells were washed 3 times with PBS before 
fresh medium was added. 48 hrs after treatment, 5 spheroids per replicate from 
each condition were collected in an Eppendorf tube, washed with PBS and then 
incubated with trypsin/EDTA for 15 min at 37°C. The resultant cellular 
suspension was then incubated for 3 hrs with MTT [10 µL (5 mg/mL) in 100 µL 
of medium). The absorbance was then measured at 570 nm using FLUOstar 
Omega microplate reader. Data were expressed as % cell viability by comparison 
with untreated controls. In addition to MTT analysis, propidium iodide (P.I.) 
staining was also performed to determine cellular damage to the spheroid 
corona. Following treatment, spheroids were washed 4 times with PBS to remove 
excess medium and then incubated with a solution of P.I. in PBS (100 !g/mL). 
Spheroids were then incubated in the dark at room temperature for 40 min and 
then washed 3 times with PBS to remove excess P.I. Micrographic images were 
recorded using a NIKON Eclipse E400 Phase contrast microscope in bright field 
and fluorescence modes (540 nm band pass excitation and 570 nm long pass 
emission filter). Image J software was used to quantify P.I. fluorescence and it 
was expressed as a % of P.I. fluorescence intensity/µm2, i.e. the P.I. fluorescence 
was normalized according to the area of the spheroid. 
 
2.20. In vitro cytotoxicity in Panc-1 Spheroids 
Panc-1 spheroids were cultured as described above. The media in each well was 
replaced with either fresh drug-free media, MB-PTX ([5 µM]), MB-Gem-RB ([6.8 
µM]) and MB-PTX-Gem-RB ([PTX] – 5 µM, [Gem/RB] – 6.8 µM), MB-LipidGem 
([LipidGem] = 10 !M) or MB-LipidGem-PTX ([Lipid-Gem] = 10 !M, [PTX] = 6.2 
!M). Wells were then treated individually with US for 30 seconds (frequency - 1 
MHz, power density - 3.0 W/cm2, duty cycle - 50%, PRF – 100 KHz). Two days 
after initial treatment, Panc-1 spheroids were washed four times with PBS to 
remove excess drug and then incubated with a solution P.I. in PBS (100 !g/mL). 
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Spheroids were then incubated in the dark at room temperature for 40 min and 
then washed 3 times with PBS to remove excess P.I. Micrographic images were 
recorded using a NIKON Eclipse E400 Phase contrast microscope in bright field 
and fluorescence modes (540 nm band pass excitation and 570 nm long pass 
emission filters). Image J software was used to quantify P.I. fluorescence and it 
was expressed as a % of P.I. fluorescence intensity/µm2, i.e. the P.I. fluorescence 
was normalized according to the area of the spheroid. Additionally, total cell 
viability within the spheroid structure was determined suing an MTT assay. 
After 48 hrs following treatment, 5 spheroids per replicate from each condition 
were collected in an Eppendorf tube, washed with PBS and then incubated with 
trypsin/EDTA for 15 min at 37°C. The resultant cellular suspension was then 
incubated for 3 hrs with MTT [10 µL (5 mg/mL) in 100 µL of medium). The 
absorbance was then measured at 570 nm using FLUOstar Omega microplate 
reader. Data were expressed as % cell viability by comparison with untreated 
controls.  
 
2.21. In vivo cytotoxicity in MCF-7 xenografts treated with O2MB-PTX-Dox 
and/or O2MB-PTX-RB ± US 
All animals employed in this study were treated humanely and in accordance 
with licenced procedures under the UK Animals (Scientific Procedures) Act 1986. 
MCF-7 cells were maintained using Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 1 g/L glucose and supplemented with 100 U/mL penicillin, 
100 mg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified 5% 
CO2 atmosphere at 37oC. MCF-7 cells (5 x106) in 100 !L Matrigel were sub-
cutaneously implanted into the rear dorsum of 8-week old female SCID (C.B-
17/IcrHan®Hsd-Prkdcscid) mice. Palpable tumours appeared approximately 1-
2 weeks after cell implantation. Once tumours became palpable, dimensions 
were measured using Vernier callipers. Tumour volume was calculated using the 
equation: 
Equation 2. 
1#3'#"	:'&#36 = &6+$5ℎ ∗ <*)5ℎ ∗ ℎ6*$ℎ52  
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Once tumours reached approximately 65 mm3 animals were separated 
into the following groups: Group 1 remained untreated, groups 2 and 3 received 
an intravenous (IV) injection (50 µL) of a mixed suspension of O2MB-PTX-RB and 
O2MB-PTX-Dox (6.18 x107 MB, [PTX] = 1.13 ± 0.16 mg/kg, [RB] = 2.63 ± 0.35 
mg/kg, [Dox] = 0.97 ± 0.15 mg/kg with (group 2) or without (group 3) US 
exposure. Group 4 received an I.V injection (100 !L) of a Cremophor suspension 
containing PTX (4.7 mg/kg) and Dox (2.5 mg/kg). US was administered directly 
to the tumour site using a Sonidel SP100 sonoporator (3.5 W/cm2 , 1 MHz, 30% 
duty cycle, and PRF = 100 Hz; PNP = 0.48 MPa; M.I. = 0.48) during, and 30 min 
after I.V administration (for a total of 7.0 min) using US gel to mediate contact. 
Animals were treated on days 0, 7 and 21 and both the tumour volume and body 
weight measurements recorded at the indicated times.  
2.22. In vivo cytotoxicity experiments in BxPC-3 xenografts  
BxPC-3 cells were maintained in RPMI 1640 both supplemented with 100 U/mL 
penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum (FBS) in a 
humidified 5% CO2 atmosphere at 37oC. BxPC-3 cells (5 x106) in 100 !L Matrigel 
were sub-cutaneously implanted into the rear dorsum of 8-week old female SCID 
(C.B-17/IcrHan®Hsd-Prkdcscid) mice. Palpable tumours appeared 
approximately 1-2 weeks after cell implantation. Once tumours became palpable, 
dimensions were measured using Vernier callipers. Tumour volume was 
calculated using the equation outlined in Section 2.21. For experiments discussed 
in chapter 4 animals were treated with either an intravenous (IV) injection (100 
µL) of a suspension of O2MB-PTX-Gem-RB (6.86 x107 ± 1.99 x 106 MB) ([PTX] – 
2.44 ± 0.37 mg/kg, [Gem] - 0.5 ± 0.04 mg/kg, [RB]- 1.85 ± 0.14 mg/kg) or an I.P 
injection (100 !L) of gemcitabine hydrochloride in sterile PBS (120 mg/kg) or 
remained untreated. For experiments discussed in chapter 5 animals were treated 
with either an intravenous (IV) injection (100 µL) of a suspension of MagO2MB-
RB-Gem ([MB] = (1.25±0.41) x 109 MB/mL, [RB] – 2.54 ± 0.39 mg/kg, [Gem] - 0.69 
± 0.11 mg/kg) or an I.P injection (100 !L) of gemcitabine hydrochloride in sterile 
PBS (120 mg/kg). For experiments described in chapter 6 animals were treated 
with either an intravenous (IV) injection (100 µL) of a suspension MB-LipidGem 
(9.97 x108 MB/mL, 2.77 mg/kg),  MB-LipidGem-PTX – 8.6 x108 MB/ mL, 
[LipidGem] = 3.15 mg/kg, [PTX] = 1.98 mg/kg) or an I.P injection (100 !L) of 
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gemcitabine hydrochloride in sterile PBS (120 mg/kg)  For experiments 
discussed in chapter 6, US was administered directly to the tumour site using a 
Sonidel SP100 sonoporator (3.5 W/cm2 , 1 MHz, 30% duty cycle, and PRF = 100 
Hz; PNP = 0.48 MPa; M.I. = 0.48) during I.V/I.P injection. For experiments 
described in chapter 4, US was applied as described above with the addition of a 
second US treatment applied 30 min after I.V administration (for a total of 7.0 
min). For experiments described in chapter 5, US was applied using the 
MAD/aMAD devices. The drive instrumentation and settings were the same as 
those used for the in vitro drug delivery experiments described in Section 2.16. 
The cone of the MAD (or aMAD) was coupled to the skin of the subject using US 
gel. In order to minimize acoustic field uncertainties and tissue damage risk, the 
subjects were treated lying prone over a mat of US absorbing material (Aptflex 
F28, Precision Acoustics, Dorset, UK). To improve free transmission of sound into 
the absorber, the abdominal hair was removed from the subjects, and their skin 
coupled to the mat with US gel.  For experiments discussed in chapters 4 and 6, 
tumour volume was measured using callipers as described in Section 2.21 and 
for chapter 5, tumour volume was measured using the Peira TM900 tumour 
measuring device (Beerse, Belgium). The TM900 platform includes measurement 
software allowing visualisation of the tumour topography, allowing tumour 
dimensions (weight, length and height) to be automatically measured. For all in 
vivo experiments, subject weight was monitored closely for the entirety of the 
investigation.  
 
2.23. In vivo cytotoxicity experiments in MIA-PaCa-2 xenografts  
MIA-PaCa-2 cells were maintained in DMEM medium supplemented with 100 
U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum (FBS) in 
a humidified 5% CO2 atmosphere at 37oC. MIA-PaCa-2 cells (5 x106) in 100 !L 
Matrigel were sub-cutaneously implanted into the rear dorsum of 8-week old 
female SCID (C.B-17/IcrHan®Hsd-Prkdcscid) mice. Palpable tumours appeared 
approximately 1-2 weeks after cell implantation. Once tumours became palpable, 
dimensions were measured using Vernier callipers. Tumour volume was 
calculated using the equation outlined in Section 2.21. Group 1 remained 
untreated, group 2 received an I.V injection (100 µL) of a suspension of O2MB-
PTX-Gem-RB (6.47 x 107 ± 1.86 x106 MBs) ([PTX] - 3.38 ± 0.21 mg/kg, [Gem] – 0.82 
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± 0.06 mg/kg, [RB] – 3.02 ± 0.24 mg/kg). Group 3 received an intravenous (IV) 
injection (100 µL) of a suspension of O2MB-PTX (7.01 x 107 ± 1.5 x 106 MBs) ([PTX] 
- 4.69 ± 0.75 mg/kg). Group 4 received an I.P injection (100 !L) of gemcitabine 
hydrochloride in sterile PBS (120 mg/kg) and an I.V injection of a Cremophor 
solution containing PTX (4.7 mg/kg). US was administered directly to the 
tumour site using a Sonidel SP100 sonoporator (3.5 W/cm2, 1 MHz, 30% duty 
cycle,  PRF = 100 Hz, PNP = 0.48 MPa, M.I. = 0.48) during, and 30 min after I.V 
administration (for a total of 7.0 min) using US gel to mediate contact. Animals 
were treated on days twice weekly and both the tumour volume and body weight 
measurements recorded at the indicated times. 
 
2.24. In vivo safety determination and blood analysis in healthy non tumour 
bearing mice 
Healthy non-tumour bearing mice were separated into groups and treated with 
either US treatment only (Frequency = 1 MHz, power density = 3.5 W/cm2, duty 
cycle = 30%, PNP 0.4 MPa, duration 3.5 min) directed to the pancreas as would 
be the case in orthotopic tumour treatment, an intravenous (IV) injection (100 µL) 
of a suspension of O2MB-PTX-Gem-RB (6.58 x107 ± 1.25 x106 MB, [PTX] = 2.03 ± 
0.19 mg/kg [Gem] = 0.72 ± 0.07 mg/kg, [RB] = 2.66 ± 0.27 mg/kg), an intravenous 
(IV) injection (100 µL) of Gem, PTX and RB. PTX and RB were delivered by I.V 
injection with PTX pre-formulated in a cremaphor EL vehicle while Gem was 
administered by I.P injection ([Gem] = 120 mg/kg, [PTX] = 15 mg/kg, [RB] = 6 
mg/kg) or remained untreated. The body weights of the animals in each group 
were recorded daily and 14 days following treatment, blood samples were 
removed and analysed for several key biochemical and haematological markers 
in both whole blood and serum. These markers included urea and alanine 
aminotransferase (ALT) which are markers for kidney and liver function 
respectively. 
2.25. Ultrasound Parameters 
The US source used in chapters 3,4 and 6 was the Sonidel SP100 was used as the 
US source. The specific US parameters used in chapters 3-6 were consistent with 
previous publications. (238)(240)(214)(247)(237)  
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Chapter 3 - Treatment of MCF-7 Breast Cancer Using Ultrasound Responsive 
Microbubbles Loaded with Paclitaxel, Doxorubicin and Rose Bengal 
3.0. Introduction 
Breast cancer is the most prevalent form of cancer worldwide with 55,200 
new cases reported in the UK alone in 2015. (248) Mastectomy is a common 
treatment for breast cancer with approximately 19,000 mastectomy surgeries 
performed in the UK each year. (249) As the physical and psychological effects of 
this treatment can be considerable, there is a growing need for more effective 
non-surgical treatments to reduce the overall mastectomy rate. Approximately 
15% of patients will present with triple negative breast cancer. This type of cancer 
is characterised by the lack of lack of expression of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2). (250) Although this subtype of patient is not eligible for hormone drugs, 
they are more likely to respond to neo-adjuvant chemotherapy. Neoadjuvant 
chemotherapy involves treatment with chemotherapy prior to surgical resection. 
There are four main rationales for this type of therapy.  Firstly, it is expected to 
shrink the size of the primary tumour making an otherwise inoperable tumour, 
operable. Secondly, by reducing the size of the tumour, this should allow for the 
patient to undergo the less invasive and life altering breast conservation surgery 
(BCS). Thirdly, patients with locally advanced disease, who are at higher risk of 
developing metastases, could benefit from early, pre-operative chemotherapy. 
Finally, neoadjuvant chemotherapy gives provides the opportunity to observe 
potential tumour shrinkage, serving as a useful prognostic tool. (251,252) Neo-
adjuvant chemotherapy has been used successfully to downstage tumours in 
advance of surgery and enable their removal by less invasive lumpectomy 
procedures. (253,254). This approach has proven effective in increasing the 
number of patients eligible for BCS without posing a risk to the overall or 
progression-free survival rate. (255) However, the chemotherapies used in these 
regimens are non-targeted to tumour tissue hence large quantities are 
administered to achieve a therapeutic response which often leads to undesirable 
side effects for the patient. (256)  
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Despite the success of surgical resection in improving the overall 
progression free survival of patients suffering with breast cancer, localised 
recurrence of the cancer into the chest wall following operable breast cancer has 
a reported 10-year incidence rate of 4–10% for patients that have underwent a full 
mastectomy and 10–16% for patients who have underwent BCS followed by 
adjuvant radiation therapy. (257–259) Unfortunately for this group of patients, 
the treatment options are limited with further surgical resection proving 
ineffective in many cases. Additional treatment with chemotherapy has shown 
signs of promise however the effect on the quality of life for these patients is 
reported to be considerable. There is therefore a need for more targeted 
treatments which can enable the effective treatment of these cancers without 
considerably affecting the quality of life for the patient. 
As mentioned in Section 1.4.3.1.3, UTMD has been used previously in pre-
clinical experiments to deliver the sonosensitiser Rose Bengal (RB) in 
combination with the antimetabolite drugs 5-flourouracil (5-FU) or Gemcitabine. 
(238,240,247) This strategy proved effective in treating pancreatic 
adenocarcinoma (PDAC) in in vitro and in vivo models of the disease and was 
able show significant control of tumour growth. Furthermore, a significantly 
lower dose was required to achieve a better therapeutic outcome than the clinical 
standard control groups treated with free drugs (i.e. non-MB bound). However, 
these works were limited in that the co-delivery of both the chemotherapy and 
the sonosensitiser was achieved through mixing of two separately produced 
batches. This work was very much focussed on pancreatic cancer and therefore 
utilised drugs indicated for this disease as part of the MB platform. To broaden 
the scope of UTMD mediated chemo-SDT to other cancers, methods for 
incorporating different chemotherapy drugs within the MB platform are 
required.  To this end, the ability to incorporate two or more payloads within a 
single MB formulation would be hugely beneficial.   
Paclitaxel (PTX) and Doxorubicin (Dox) are two chemotherapies 
commonly used in the management of breast cancer. PTX is an anti-cancer drug 
from the taxane class. It was originally extracted from samples from the bark of 
the Pacific yew tree. PTX primarily acts upon microtubules which are polymers 
made up of a and b- heterodimers. It stabilizes them against depolymerization 
and inhibits cell replication. (260) It has also been shown to bind to the 
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antiapoptotic gene Bcl-2, thus inducing apoptosis. (261) Given the likelihood of 
resistance to chemotherapeutic agents, it is commonplace to administer 
combinations of anti-cancer drugs so that separate cellular mechanisms can be 
targeted and exploited. Dox has been shown to be remarkably effective when 
administered in combination with PTX. Dox is a member of the anthracycline 
class of anti-cancer drugs. The mode of action of Dox is still a matter of debate 
however the leading hypothesis is that it inhibits DNA synthesis through 
obstruction and inhibition of topoisomerase II. (125) Given that previous studies 
have demonstrated the benefit of combining chemotherapy and SDT in 
pancreatic cancer, it was of interest to determine the effect of UTMD mediated 
chemo-SDT in the treatment of breast cancer, using PTX and Dox as 
chemotherapies and Rose Bengal as the SDT sensitiser. For practical reasons, it is 
desirable to the minimise the number of separate MBs required to deliver these 
three payloads. While it was not possible to design a single MB formulation 
carrying all three payloads at this stage, it was possible to use two separate MB 
formulations instead of three. To this end, the hydrophobic oil layer of the MB 
shell was utilised to encapsulate PTX, while Dox or RB was attached to the MB 
surface using the biotin-avidin interaction. PTX is a notoriously hydrophobic 
drug (cLogP = 4.73) and is an ideal candidate for incorporation within the oil 
layer. In contrast, the hydrophilic nature of Dox (cLogP = -0.78) and RB (cLogP = 
3.46), meant they were not suitable for encapsulation in the MB oil layer and 
required derivatisation with biotin to enable attachment to the MB shell.  
In this chapter, the preparation of these two MB formulations is discussed, 
one carrying PTX in the MB oil layer and Dox attached to the surface (MB-PTX-
Dox) while the second also carried PTX in the oil layer but RB attached to the MB 
surface (MB-PTX-RB). Each formulation was characterised in terms of MB yield, 
stability and drug loading, while the efficacy of MB mediated chemo-
sonodynamic therapy was determined in a three-dimensional (3D) spheroid 
model of human breast cancer and in a murine model of the disease bearing 
subcutaneous MCF-7 tumours. 
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3.1. Hypothesis and specific objectives 
The main aim of this study was to determine whether O2MB with PTX 
incorporated into the lipid shell and with Dox or RB attached to the MB surface 
perform significantly better than either Dox/PTX or SDT treatment alone in in 
vitro and in vivo models of MCF-7 breast cancer. The specific objectives were to: 
1. determine the benefit of combining Dox / PTX with SDT in a MCF-7 breast
cancer cell line.
2. prepare and characterise MB with PTX hydrophobically incorporated into
the phospholipid shell (MB-PTX).
3. synthesise and characterise biotin functionalised Dox (biotin-Dox) and RB
derivatives (biotin-RB).
4. prepare and characterise MB-PTX with either biotin-Dox (MB-PTX-Dox)
or biotin-RB attached (MB-PTX-RB) to the MB surface.
5. determine the effectiveness of chemo-SDT using MB-PTX-Dox and MB-
PTX-RB in a 3D MCF-7 spheroid model of breast cancer.
6. determine the effectiveness of chemo-SDT using O2MB-PTX-Dox and
O2MB-PTX-RB in SCID mice bearing ectopic MCF-7 tumours.
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3.2. Results and discussion  
3.2.1. Effect of combining PTX, RB and Dox on MCF-7 cell colony forming 
ability  
In advance of preparing and testing the MB-PTX-Dox and MB-PTX-RB 
formulations, the effectiveness of combining PTX, Dox and SDT treatments on 
the viability of MCF-7 cells was investigated. In this experiment, the 
concentration of each individual drug used was intentionally sub-lethal (i.e. drug 
concentration < LD50), so that any benefit obtained by the combination treatment 
could easily be identified. In addition, as the action of US can influence the 
cellular uptake of drugs due to sonoporation, cells treated with Dox or PTX were 
also exposed to US, to control for any potential effects as a result of US exposure 
during SDT treatment. (227) Following treatment, the ability of cells in each 
treatment group to form colonies was investigated by performing a clonogenic 
assay. Cells from treated groups were seeded in 6 well plates and incubated for 
8 days after which they were fixed and stained with crystal violet solution. 
Images were then captured of each well and colony numbers were subsequently 
analysed using ImageJ image analysis software.  
The results are shown in Figure 3.4 and reveal no reduction in colony 
number for cells treated with a combination of PTX, Dox and RB in the absence 
of US compared to untreated cells. Treatment of cells with PTX + US, RB + US 
(i.e. SDT) or Dox + US reduced colony number by 7.3, 18.8 and 29.3% respectively 
compared to untreated cells, while cells treated with combined PTX, Dox and RB 
+ US reduced the colony number by 44.0%. The lack of efficacy for the combined 
drug group in the absence of US was not surprising as sub-lethal doses of the 
drugs were used. However, the significant improvement in efficacy following 
exposure to US may result from a sonoporative effect that improves the uptake 
of these drugs. The fact that the greatest reduction in colony number was 
observed for the combined PTX, Dox and SDT treatment group suggests that 
these three treatments complement each other and improve the overall cytotoxic 
effect observed. 
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Figure 3.4. Plot showing percentage of surviving MCF-7 cells for each of the treatment groups. 
Cells were treated with PTX +US (1 nM), Dox +US (10 nM), RB +US (10 nM) and PTX + Dox + 
RB +US ([PTX] = 1 nM, [Dox] = 10 nM, [RB] = 10 nM). Crystal violet staining of representative 
images are shown in the panel above each data bar. Error bars represent ± the standard error 
(n = 3). 
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3.2.2. Preparation and characterisation of MB with PTX hydrophobically 
incorporated into the phospholipid shell (MB-PTX). 
Encouraged by these results, the next step was to incorporate PTX, Dox and RB 
into the MB delivery vehicle as described in Section 2.8. Schematic 
representations of the MB-PTX-Dox and MB-PTX-RB formulations are shown in 
Figure 3.5 and illustrate the incorporation of PTX in the hydrophobic acyl layer 
of the MB shell with either biotin-Dox or biotin-RB attached to the MB surface 
using the biotin-avidin linkage.   
Figure 3.5. Schematic representation of (a) O2MB-PTX-DOX and (b) O2MB-PTX-RB 
3.2.2.1. Preparation of MB-PTX 
As described in Section 1.3.3.1, there are a variety of different protocols for 
synthesising lipid coated MBs. The first step in most cases involves the formation 
of a liposomal suspension through the hydration of a thin, dry phospholipid film 
in aqueous media, maintained above the lipid phase transition temperature. 
There are also several literature examples describing the synthesis of lipid-based 
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micro/nano-particles containing PTX. (262–267) In the majority of cases, PTX is 
either directly embedded into the MB shell or incorporated into liposomes which 
are subsequently conjugated to the MB surface. It was therefore hypothesised 
that PTX, being a highly hydrophobic drug, with a logP of approximately 3.96 
and an aqueous solubility of less than 0.01 mg/mL (~10 µM) (268), should 
become embedded within the hydrophobic acyl chains of the amphiphilic 
phospholipids which coat the MB, providing the potential to load a second drug 
onto the surface of the MB.  
 The first step in the synthesis of MB-PTX was to form a phospholipid 
suspension containing PTX using the thin film hydration technique discussed 
previously.  This was achieved by dissolving DBPC, DSPE-PEG (2000), DSPE-
PEG (2000)-biotin and PTX in chloroform. After evaporation of the solvent the 
dried film was re-hydrated in a mixture of PBS, glycerol and propylene glycol 
and heated at 80oC to enable vesicle formation. The contents were then sonicated 
using a probe sonicator at low amplitude (22%) to enhance dispersion of the PTX 
within the particle suspension. To form the MBs, the PTX-lipid suspension was 
sonicated at a higher amplitude (89%) under an atmosphere of PFB gas. The 
solubility of PFB gas in aqueous media is relatively low and so helps to provide 
stability to the MB suspension prior to oxygenation. The newly formed MB-PTX 
suspension was then isolated by low-speed centrifugation and the infranatant 
(liquid below the MB cake) discarded to ensure non-incorporated PTX or lipids 
were removed. The MB-PTX were washed by mixing with PBS and again isolated 
by centrifugation. 
3.2.2.2. Characterisation of MB-PTX 
After each batch of MB-PTX were prepared, a sample was removed and the 
concentration and size of the MBs were analysed. This was achieved by loading 
a small diluted sample of the MB suspension into a haemocytometer chamber 
and capturing images using an optical microscope. The images were then 
analysed using a bespoke MATLAB image analysis algorithm as described in 
Section 2.9. A representative analysis is given in Figure 3.6 and reveals that PFB-
MB-PTX have a mean diameter of 1.14 ± 0.73 µm and a mean concentration of 
1.72x109 ± 2.91 x108 MB/mL. These results were consistent with previous studies 
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where drug loaded MBs were synthesised suggesting that the addition of PTX 
has little effect on the MB concentration or morphology. (267,269) 
Figure 3.6. a) representative image of MB-PTX taken with 40x objective lens (1:25 dilution in 
PBS); b) corresponding size distribution analysis produced using a custom MATLAB 
algorithm (n=20 images). Scale bar represents 50 µm. 
At this stage in the development process it was desirable to identify the 
amount of PTX that could be loaded into the MBs. To this end, three batches of 
MB-PTX were prepared with 0, 2.5 or 5 mg of PTX loaded into the lipid film prior 
to MB formation. A sample was taken from each batch and the MBs dissolved 
through the addition of acetonitrile. This sample was then diluted and was 
analysed using reverse phase HPLC. A calibration curve for PTX (Figure 3.7b) 
was constructed following the methods described in Section 2.10 using known 
concentrations PTX. Good linearity was observed between 0 and 0.6 mg/mL with 
an R2 value of 0.9997. The equation of the line along with the peak area of the 
unknown sample was used to determine the amount of PTX within each of the 
batches.   
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Figure 3.7. (a) Representative RP-HPLC-UV chromatogram of PTX and (b) Plot of peak area at 
227 nm against concentration for PTX (n=3). 
The loading of each batch of MB was normalised to MB concentration (i.e. 
µg / 108 MB). The mean PTX loading for the 2.5 mg loaded batches was 24.85 ± 
5.78 µg/108 MB while for the 5 mg loaded batch PTX it was 62.75 ± 10.86 µg/108 
MB (Figure 3.8). While no higher loadings were attempted, there may be capacity 
to further increase the loading of PTX in the MB shell by increasing the amount 
of the drug added during the film formation step. Loadings of higher than 5 mg 
have not been reported in the literature. In addition, 5 mg of PTX equates to 
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approximately the same total moles of phospholipid in the formulation. It is 
therefore likely that increasing this molar ratio further will have a minimal effect 
on drug loading.   
Figure 3.8. Graph showing the normalised loading of PTX in MB as the amount of PTX added 
to the lipid film increases from 2.5 to 5 mg (n=3). (2.5 mg batch: [PTX] = 24.85 ± 5.78 µg/108 MB, 
MB No = 8.69 x108 ± 2.77x107 MB and 5 mg batch: [PTX] = 62.75 ± 10.86 µg/108 MB, MB No = 
9.79x108 ± 4.39 x107 MB). 
3.2.2.3. Investigating the effect of PTX on MB stability at 37oC 
The circulation half-life of commercial phospholipid contrast agents is typically 
less than 5 mins (270) so it is important that the MB concentration does not drop 
significantly over this time. It is also advantageous to ensure that if MB are 
prepared for clinical use (i.e. at the bedside), they have sufficient stability should 
any delay occur between preparation and use. Therefore, to identify if the 
addition of PTX into the phospholipid shell would reduce particle stability, a 
study was undertaken where normal MBs (i.e. prepared without PTX in the film) 
and O2MB-PTX (prepared with 5 mg PTX in the film) were counted at various 
time-points following incubation at 37oC. The results are shown in Figure 3.9 and 
reveal a small but non-significant decrease in MB number for PTX-containing MB 
when compared to plain MB without PTX. However, more than 85% of the total 
MB population remained after 10 minutes incubation. This suggests that the 
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addition of PTX within the lipid monolayer does not significantly compromise 
MB stability.  
Figure 3.9. Plot showing % MB count of MBs containing no PTX (dark bars) or 5 mg of PTX 
(light bars) within the lipid film. (5 mg batch: [PTX] = 54.87 ± 10.28 µg/108 MB, MB No = 8.41x108 
± 2.78 x108 MB). 
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3.2.3. Synthesis of biotin-Dox and biotin-RB 
To facilitate the attachment of Dox and RB to the surface of the microbubble, the 
biotin-avidin interaction was utilised as this has proven effective in previous 
studies.(238,240) It was therefore necessary to synthesise both biotin-Dox and 
biotin-RB to allow their attachment to the MB surface.  
3.2.3.1. Synthesis and characterisation of biotin-Dox (5). 
Biotin-Dox was synthesised according to the protocol outlined in Figure 3.10 and 
detailed in Section 2.2. 
Figure 3.10. Synthetic procedure for the synthesis of biotin-Dox (5). 
The first step of the reaction involved preparing the N-succinimidyl ester 
of biotin (3) (271) by reacting biotin (1) with N,N’-succinimidyl carbonate (2) in 
the presence of triethylamine (Et3N) as a catalytic base. The activated ester of 
biotin was then reacted with the Dox daunosamine moiety (4) to form a 
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hydrolysable amide bond. The crude material was then purified using 
preparative thin layer chromatography (PTLC) to produce 5 in 70% yield. 
The structure of biotin-Dox was confirmed using ESI-MS, 1H-NMR and 
13C-NMR which are shown in Figures 3.11 – 3.14. The 1H NMR spectrum is shown 
in Figure 3.11 and reveals a group of resonances between 1.27 and 1.56 ppm that 
represent the six methylene protons that are closest to the core biotin ring 
structure with the characteristic carbamide protons appearing as two sharp 
doublets between 6.29 and 6.36 ppm. The remaining two methylene protons 
appeared further downfield at 2.05 ppm due to their proximity to the amide bond. 
The 3 aromatic protons, corresponding to the anthraquinone unit, appeared on 
resonances centred at 7.59 and 7.84 ppm with the newly formed amide proton at 
appearing at 7.49 ppm. The stacked spectra shown in Figure 3.12 clearly shows 
the disappearance of the acidic proton from biotin (top spectrum, 12 ppm) and 
the appearance of the newly formed amide proton (bottom spectrum, 7.49 ppm). 
The 13C NMR spectrum is shown in Figure 3.13 and reveals a resonance at 172 
ppm corresponding to the newly formed amide carbonyl carbon. The remaining 
resonances in both the 1H NMR and 13C NMR spectra were assigned as indicated 
on the labelled structures accompanying each spectrum and this was facilitated 
by reference to the spectra of biotin and doxorubicin. The molecular weight of 5 
was confirmed using ESI-MS. The ESI-MS spectrum is shown in Figure 3.14 and 
reveals a base peak of 792.2 Da corresponding to the [M+Na]+ ion. These 
combined spectroscopic techniques confirmed the formation of 5. 
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3.2.3.2. Synthesis and characterisation of biotin-RB (8) 
Biotin-RB was synthesised according to a literature procedure (214) as shown in 
Figure 3.15. 
Figure 3.15. Synthetic procedure for the synthesis of biotin-RB (8). 
The first step involved the formation of an ester bond between 6 and 2-
Bromoethylamine hydrobromide through an SN2 type reaction to yield 7. This 
was then directly coupled with 3, through an amidation reaction to produce the 
target compound 8. 
The structure of 8 was again confirmed using ESI-MS, 1H-NMR and 13C-
NMR which are shown in Figures 3.16 – 3.19. The 1H NMR is shown in Figure 
3.16 and reveals the two characteristic aromatic ring protons from RB appearing 
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as a sharp singlet at 7.30 ppm with the four methylene protons closest to the RB 
ring appearing at 2.79 and 3.85 ppm. The characteristic carbamide protons from 
biotin appeared at 6.30 and 6.40 ppm while the 6 methylene protons closest to 
the biotin core were centred on resonances between 1.30 and 1.80 ppm. The 
remaining two methylene protons adjacent to the amide carbonyl group were 
observed as a resonance centred at 1.95 ppm. The stacked spectra shown in 
Figure 3.17 shows the disappearance of the amino protons of 7 (top spectrum, 7.7 
ppm) and the new amide proton at 7.6 ppm indicating the formation of an amide 
bond between the amino group and the carboxyl group of biotin (middle 
spectrum). The 13C NMR spectrum is shown in Figure 3.18 and reveals 
resonances in the upfield region between 20 and 70 ppm corresponding to the 
aliphatic carbons of biotin and the methylene carbons of the linker between RB 
and biotin. Resonances further upfield between 70 and 200 ppm were assigned 
to carbonyl carbons and the aromatic carbons of 6. The remaining protons and 
carbons were assigned as annotated on the structure accompanying each 
spectrum. The molecular weight of 8 was confirmed using ESI-MS. The ESI-MS 
spectrum is shown in Figure 3.19 and reveals a base peak of 1241.4 Da 
corresponding to the [M+H]+ ion.  These analytical data were consistent with data 
from previous publications and confirm the formation of 8.
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3.2.4. Preparation of MB-PTX-RB and MB-PTX-Dox 
Having confirmed the loading and stability of the MB-PTX, the next step was to 
add the biotinylated payloads to the MB surface. This was facilitated by first 
adding a solution of avidin to the PTX-MB that binds to the biotin of the DBPC-
PEG-biotin lipid that comprises the MB lipid shell. As this lipid is functionalised 
with a PEG unit to which the biotin is attached, the biotin will be positioned on 
the exterior of the MB shell during the self-assembly process ensuring the MB 
surface can bind avidin. The interaction between biotin and avidin is one of the 
strongest non-covalent interactions known in nature. (272) In addition, the non-
covalent interaction between them is facile and does not require extensive 
reaction time making it ideally suited for this application. As avidin possesses 
four binding sites for biotin, three remain available for conjugation to the 
biotinylated payloads 5 or 8 to produce MB-PTX-RB or MB-PTX-Dox. 
3.2.4.1. Characterisation of MB-PTX-Dox and MB-PTX-RB 
The loading of 5 and 8 on the two MB formulations was determined using UV-
Vis spectrophotometry. A UV-Vis calibration curve was constructed for 5 and 8 
using standards of known concentrations (Figure 3.20 and Figure 3.21). Good 
linearity was observed for both 5 and 8 over the concentration ranges tested with 
R2 values of 0.9999 and 0.9957 respectively. 
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Figure 3.20. a) UV-Vis spectra for 8 at concentrations ranging from 2.5 – 20 µM and b) Plot of 
absorbances of 8 against concentration. 
a)
b)
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Figure 3.21. a) UV-Vis spectra for 5 at concentrations ranging from 10 – 80 µM and b) Plot of 
absorbances of 5 against concentration. 
Analysis of optical microscope images (Figure 3.22) confirmed the 
presence of spherical MB-PTX-Dox and MB-PTX-RB with mean particle 
diameters of 2.82 ± 0.05 and 2.61 ± 0.02 µm respectively and mean microbubble 
concentrations of 1.20 x 109 and 1.35 x 109 MB / mL respectively. Both MB-PTX-
Dox and MB-PTX-RB also exhibited bright red fluorescent shells when analysed 
using fluorescent microscopy consistent with the successful attachment of the 
inherently fluorescent Dox and RB respectively (Figure 3.22). 
a)
b)
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Figure 3.22. Representative bright field (left panel) and fluorescence (middle panel) 
micrographs and corresponding size distribution analyses (right panel) of (a) PTX-RB MB and 
(b) PTX-Dox MB (n=20 images). Scale bar represents 50 µm.
The mean loading of PTX, Dox and RB in the final MB preparation was 
determined to be 51.8 ± 8.3 !g / 108 MBs, 41.3 ± 2.6 µg / 108 MBs and 140.0 ± 23.4 
µg /108 MBs respectively. It is unclear as to why the loading for RB was 
significantly greater than Dox despite being similar in size but may be due to 
some non-specific binding of RB to the MB surface (i.e. not bound through 
avidin-biotin linkage). The loading for PTX compares favourably with previous 
studies where PTX was loaded hydrophobically within the MB shell. (206,265)  
Indeed, the loadings achieved for both PTX and DOX using the approach 
adopted in this chapter suggest it would be possible to deliver clinically relevant 
doses of both agents PTX (175 mg/m2) (273) and DOX (25 mg/m2) (274) as a part 
of the MB platform whilst remaining within the maximum tolerated MB dose, 
which was determined to be 1 x1013 MB for MRX-115 contrast agent in primates 
(i.e. 3.31 x 1011 MBs to deliver 175 mg/m2 PTX and 6.09 x 1010 MBs to deliver 25 
mg/m2 DOX). (275,276) Off course, targeted delivery using UTMD means it 
should be possible to use much lower concentrations of these toxic chemotherapy 
drugs while maintaining an effective therapeutic outcome. 
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3.2.4.2. Effect of PTX on the loading capability of biotinylated payloads.  
One potential complication of loading PTX in the MB shell is that it could 
compromise the subsequent loading of biotinylated payloads to the MB surface. 
To investigate any potential effect on MB loading, batches of MBs with or without 
5 mg of PTX added into the lipid film prior to MB synthesis were prepared and 
the ability of each batch to attach 8 to the surface determined. Compound 8 was 
chosen for this experiment as its synthesis is more trivial and less expensive than 
that of 5. Consequently, if there was any effect on the loading capacity for 8 we 
could assume that the same would be true for 5. The results are shown in Figure 
3.23 and reveal no significant change in the loading of 8 in the absence or 
presence of PTX.  
Figure 3.23. Plot of loading of 8 (normalized to 108 MBs) in the absence (0 mg) and presence (5 
mg) of PTX incorporated within the lipid layer during MB formulation (final PTX loading = 
51.8 ± 8.3 !g/108 MB) (n = 4). 
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3.2.5. Efficacy of MB-PTX-DOX and MB-PTX-RB in MCF-7 spheroids 
Having successfully prepared and characterised the MB-PTX-Dox and MB-PTX-
RB conjugates, the next step was to determine their efficacy in a three-
dimensional (3D) spheroid model of breast cancer. Standard two-dimensional 
(2D) cell culture lacks the necessary cell to cell and cell to extracellular matrix 
interactions required to bridge the gap between in vitro cell experimentation and 
in vivo animal models of cancer. 3D cell models of cancer, particularly spheroids, 
incorporate many important characteristics associated with the in vivo cellular 
environment such as tumour morphology and heterogeneity, growth kinetics, 
gene expression and response to anticancer agents into a high throughput and 
cost-effective in vitro setting and thus is a valuable tool in the screening of new 
drugs and drug delivery systems. (277,278) 
Spheroids were prepared by growing MCF-7 cells in ultra-low attachment 
96 well plates which have a rounded bottom causing cells to migrate towards the 
middle of each well where they can aggregate together. Cells were seeded at a 
density of 8000 cells per well and incubated for three days to allow spheroid 
formation to take place. Once formed, spheroids were treated with MB only (i.e. 
no drugs attached), PTX / Dox only (i.e. not MB bound) and the MB-PTX-Dox / 
MB-PTX-RB conjugates in the presence and absence of US (1 MHz, 3.0 W/cm2, 
duty cycle = 50% PRF = 100 Hz) which was placed below each well (Figure 3.24). 
Untreated spheroids and spheroids treated with US only were also included for 
comparative purposes. Following treatment, the spheroids were trypsinised to 
break up cell aggregates before the extent of cell viability was determined using 
an MTT assay. In a separate experiment, intact spheroids were stained with 
propidium iodide (P.I.) following treatment and imaged using fluorescence 
microscopy according to the protocol outlined in Section 2.19. 
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Figure 3.24. Diagram illustrating the set-up used for all in vitro cell experiments (not to scale). 
Results from the MTT assay are shown in Figure 3.25 and reveal a 
moderate reduction in the viability of cells following exposure to US alone 
(28.03%, p < 0.05), which was similar to the reduction observed for the MB + US 
treatment (29.40 %). Treatment with PTX / Dox alone reduced viability by 21.98% 
(p < 0.05) relative to untreated spheroids, which was broadly unchanged in the 
presence of US (23.67%). However, when spheroids were treated with the MB-
PTX-Dox / MB-PTX-RB conjugates and US, the cell viability decreased by 72.6% 
which was significantly greater than treatment with the MB-PTX-Dox / MB-PTX-
RB conjugates in the absence of US (8.2%) or the other groups. This improved 
cytotoxicity is most likely due to both SDT and the ability of MB induced 
cavitation to enhance dispersion of the drugs within the spheroid matrix. (279–
281) Indeed, MB cavitation is known to create associated microstreaming and
microjetting events that have been attributed to improved tumour uptake and 
efficacy of chemotherapy drugs in several pre-clinical and clinical studies 
(Section 1.3.3.1.2). (218,227,282,283)  
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Figure 3.25. Plot of cell viability for 3D MCF-7 spheroids following exposure to (i) no treatment 
(ii) MB only (no drugs), (iii) PTX/Dox only (i.e. no MBs) or (iv) MB-PTX-Dox/MB-PTX-RB in
the presence or absence of US: *p < 0.05, ***p < 0.001 for treatment groups compared to
untreated group. &&p < 0.01 for MB-PTX-Dox/MB-PTX-RB + US v PTX/Dox + US.  $$$p < 0.001
for MB-PTX-Dox/MB-PTX-RB + US v MB-PTX-Dox/MB-PTX-RB – US. Error bars represent ±
standard error of mean (n = 3).
Results from the P.I staining experiments revealed a slightly different 
trend from those obtained using the MTT assay. P.I is a DNA-selective permeable 
dye that passes freely through compromised plasma membranes of dead cells 
and does not permeate the membrane of living cells. (284) In contrast to the MTT 
assay experiments, where a single cell suspension of cells derived from spheroids 
was analysed post-treatment, intact spheroids were examined following 
treatment using P.I staining. This means that cell damage can only be detected 
on the outer cell surface of the spheroid structure. The brightfield and fluorescent 
images from each treatment group are shown in Figure 3.26a with the 
fluorescence intensities quantified and plotted in Figure 3.26b. Bright red P.I 
fluorescence was observed for spheroids treated with the MB-PTX-Dox / MB-
PTX-RB + US group which was visibly more intense than any of the other groups. 
It was also observed that the mean volume of spheroids treated with MB-PTX-
Dox / MB-PTX-RB + US was significantly smaller than in any of the other groups 
including those spheroids treated with MB-PTX-Dox / MB-PTX-RB in the 
absence of US. To account for this reduction in size, the P.I fluorescence was 
normalised according to the size of each individual spheroid. This particular 
study was limited in that there was no control for the scattering of the unfocused 
US signal from the plastic surface of the well plate. This could have been 
improved through the use of an acoustically transparent cell culture container. 
Untreated MB only PTX/Dox MB-PTX-Dox/
MB-PTX-RB
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Nevertheless, when combined, the intense P.I fluorescence and size reduction 
observed for spheroids treated with MB mediated chemo-sonodynamic therapy, 
in addition to the reduced cell viability observed from the MTT assay 
experiments, highlight the effectiveness of this treatment in this particular model 
of breast cancer. 
Figure 3.26. Optical (left panel) and fluorescence (right panel) micrographs of MCF-7 
spheroids exposed to: (i) no treatment, (ii) US only (iii) MB only, (iv) MB + US (v) PTX/Dox 
only ([PTX] = 0.34 µM, [Dox] = 1 µM), (vi) PTX / Dox + US (vii) MB-PTX-Dox / MB-PTX-RB 
([Dox] = 1 µM, [RB] = 10 µM) and (viii) MB-PTX-Dox / MB-PTX-RB + US. Spheroids were 
stained with P.I. following treatment. (b) plot of P.I. intensity per µm2 for each of the groups 
shown in (a) (normalized to 100% by comparison with MB-PTX-Dox / MB-PTX-RB + US 
group). *p < 0.05, **p < 0.01, ***p < 0.001 significance for treatment groups relative to untreated 
group. $$p < 0.01 significance for MB-PTX-Dox / MB-PTX-RB + US v MB-PTX-Dox / MB-PTX-
RB / PTX/Dox + US. &&&p < 0.001 significance for MB-PTX-Dox / MB-PTX-RB + US v PTX/Dox 
+ US. Error bars represent ± the standard error (n = 3).
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3.2.6. In vivo efficacy of O2MB-PTX-DOX and O2MB-PTX-RB in ectopic MCF-
7 tumour bearing mice 
While encouraged by the results obtained from the 3D spheroid experiments 
discussed above, the full utility of O2MBs as a delivery vehicle can only be 
determined in vivo. To this end, subcutaneous MCF-7 tumours were established 
in recipient mice and once tumours reached a mean volume of 150 mm3, a mixed 
suspension of the O2MB-PTX-Dox/O2MB-PTX-RB formulations was 
administered to animals by IV injection through the tail vein. During injection, 
US was positioned at the tumour to disrupt the O2MB, releasing the anticancer 
payloads and activating the sonosensitiser, where appropriate (Figure 3.27). To 
evaluate the effectiveness of the O2MB delivered treatments, a group of animals 
were also treated with a combination of free PTX / Dox (i.e. not O2MB attached). 
PTX was delivered using Cremophor EL as a solubilising agent which is 
commonly used clinically for the delivery non-albumin based PTX formulations. 
Figure 3.27. Diagram illustrating of the set-up used for all in vivo experiments (not to scale). 
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The tumour growth delay plot is shown in Figure 3.28a and reveals a 
significant reduction in tumour volume for animals treated with O2MB-PTX-Dox 
/ O2MB-PTX-RB + US (p<0.001), with tumours still 6.96% smaller than the pre-
treatment size 25 days after the initial treatment. In contrast, tumours in animals 
treated with the same O2MB-PTX-Dox / O2MB-PTX-RB formulation in the 
absence of US increased in volume by 43.15% over the same time period. Indeed, 
the effect of O2MB-PTX-Dox / O2MB-PTX-RB + US was also significantly better 
than that observed following treatment using the free PTX / Dox combination 
which increased in volume by 24.77% at day 25, despite receiving a 16.8% and 
98.4% increased dose of PTX and Dox respectively. Combined, these results 
corroborate the in vitro efficacy results and highlight the effectiveness of O2MB 
delivered chemo-sonodynamic therapy as a targeted treatment for breast cancer. 
In addition to the improved efficacy offered by this approach, the treatment was 
also well tolerated with the body weight of animals in the O2MB treated groups 
mapping closely to that of untreated animals (Figure 3.28b). In contrast, there 
was a 12.1% drop in body weight for animals treated with free PTX / Dox over 
the course of the experiment. This reduction in body weight most likely as a 
result of toxicity exhibited by the free drugs or the Cremophor EL vehicle 
required to deliver PTX. Cremophor EL is known to produce undesirable side-
effects and while poorly tolerated, (285,286) is necessary to enable the dispersion 
of hydrophobic PTX in aqueous solution. Therefore, the ability to avoid the use 
of such a toxic vehicle by incorporating PTX within the O2MB shell is an added 
advantage of the MB-based drug delivery system. 
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Figure 3.28. (a) Tumour growth delay plot for mice bearing MCF-7 xenograft tumours. Control 
animals received no treatment. Groups were treated with a mixed suspension (50 µL) of O2MB-
PTX-RB and O2MB-PTX-Dox (6.18x107 MB, [PTX] = 1.13 ± 0.16 mg/kg, [RB] = 2.63 ± 0.35 mg/kg, 
[Dox] = 0.97 ± 0.15 mg/kg) delivered by IV in the presence and absence of  US.. A group was 
also treated with Cremophor EL solution containing free PTX and Dox ([PTX] = 4.7 mg / kg, 
[Dox] = 2.5 mg / kg) (b) Plot of animal weights recorded over the course of the experiment for 
each group.    For plot (a) and (b) **p < 0.01, ***p < 0.001. Error bars represent ± SEM (n = 5). 
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3.3. Conclusions 
In summary, MBs containing the hydrophobic anticancer drug PTX, loaded into 
the lipid shell, were successfully synthesised. In addition, biotinylated 
derivatives of Dox and RB were synthesised and successfully attached to the 
surface of avidin functionalised PTX-loaded MBs. In in vitro experiments, 
spheroids treated with MBs containing a combination of PTX, Dox and RB 
showed an improved response when compared to cells treated with either free 
drug or MB-PTX-RB and MB-PTX-Dox administered separately. 
A similar trend was observed during in vivo experiments where a 
significant reduction in tumour volume in mice treated with the combination of 
O2MB-PTX-RB and O2MB-PTX-Dox was observed when compared to each of the 
MB conjugates alone and with each of the anticancer drugs delivered 
systemically. Furthermore, mice treated with systemic clinical dose of PTX/Dox 
displayed a significant drop in body weight over the course of the 25-day 
experiment when compared to mice treated with MB delivered PTX / Dox. 
The improved efficacy of O2MB delivered chemo-sonodynamic therapy, 
when compared to standard PTX / Dox treatment demonstrates its potential as 
a neo-adjuvant therapy to downstage tumours in advance of surgery, or, as a 
treatment for locally recurrent chest wall disease. An added advantage of this 
approach is that each component of the treatment (i.e. the MBs, PTX, Dox, RB and 
US) has been safely used in humans previously thus providing the opportunity 
for rapid clinical translation. Furthermore, using O2MB as a delivery vehicle 
allows for the use of much lower doses of toxic chemotherapy thereby causing 
fewer undesirable side effects. MB mediated delivery of Dox has been achieved 
through its loading into the shell of polymeric MBs through hydrophobic 
interactions. (287) However, in this study a low loading of Dox was achieved (6 
µg drug/mg of MB). As a consequence, dangerously high concentrations of MBs 
would therefore be needed to achieve a therapeutic dose of the payload drug. In 
comparison, the work described herein describes the first single MB formulation 
capable of delivering both PTX and Dox at therapeutically relevant doses of these 
agents while remaining within a safe concentration of MBs. While the results 
presented in this chapter were encouraging, it was limited in that two separate 
batches of MBs had to be prepared and mixed in equal ratio which reduced the 
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effective dose of each agent. It would therefore be beneficial to incorporate 
multiple payloads on a single MB. 
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Chapter 4 – Targeted delivery of Paclitaxel, Gemcitabine and Rose Bengal to 
Pancreatic Tumours Using a Multifunctional Microbubble Delivery Platform 
 
4.0. Introduction 
There is a growing trend within oncology for the use of a combination of 
chemotherapy drugs in an effort to produce a synergistic response leading to 
improved patient outcome. One such combination which has been successful in 
the treatment of PDAC is Gem plus nabPTX. This particular regimen is currently 
a standard of care, alongside FOLFRINOX, for patients with advanced or 
metastatic pancreatic cancer and has also shown promise in several clinical 
studies as an effective neo-adjuvant treatment. (288–292) 
Despite their widespread use in the treatment of PDAC, their non-targeted 
nature means large quantities of these cytotoxic agents must be administered to 
the patient to achieve a therapeutic response (Gem = 1000 mg/m2 nabPTX = 125 
mg/m2. (105) This often leads to a host of unpleasant side effects such as fatigue, 
alopecia, and nausea. (105) This problem is further compounded when 
considering the average age of pancreatic cancer patients is approximately 70 
years old. (293) If treatment of patients with neoadjuvant chemotherapy is to be 
successful in making more patients eligible for life saving surgery, then it is 
important that these patients are healthy enough to undergo the surgical 
procedure. 
 As described in chapter 3, the MB-mediated delivery of PTX along with 
the anthracycline anticancer drug Dox and the sonosensitiser RB showed 
promise for the treatment of MCF-7 tumours. However, the technique was 
limited as two separate MB formulations had to be prepared separately and 
mixed prior to use which made controlling the delivery of each drug to the target 
site more challenging. The synergistic activity of combination therapy requires 
confidence that both drugs are being simultaneously delivered in known, 
controlled quantities to the target site. In addition, the use of a single formulation 
is also more attractive from a manufacturing, regulatory and clinical translation 
perspective. 
In this chapter, a single tripodal ligand was synthesised which 
incorporated the antimetabolite drug Gem and the sonosenistiser, RB, together 
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with a biotin anchor which enabled attachment to the MB shell. This ligand was 
then conjugated to the surface of avidin-functionalised MB-PTX, prepared as 
described in Section 3.2.2.1.  The in vitro efficacy of the MB-PTX-Gem-RB was 
established in two common pancreatic cancer cell lines using both 2D and 3D cell 
culture techniques and the in vivo efficacy was determined in two ectopic mouse 
models of PDAC. In addition, a safety study was undertaken to examine the 
toxicity of the MB conjugate in healthy non-tumour-bearing mice. 
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4.1. Hypothesis and specific objectives 
The hypothesis of the work undertaken in this chapter was that a UTMD 
mediated chemo-SDT using a single MB formulation carrying PTX, Gem and RB 
is more effective and better tolerated than the systemic delivery of PTX/Gem in 
in vitro and in vivo models of pancreatic cancer. 
The specific objectives were to: 
1. synthesise and fully characterise a novel tripodal ligand containing biotin,
RB and PTX within its structure.
2. determine the efficacy of this compound when compared to commercially
available Gem in BxPC-3 and MIA-PaCa-2 cell lines.
3. prepare and characterise MBs loaded with the tripodal ligand and also
carrying PTX in the lipid shell (i.e. MB-PTX-RB-Gem).
4. determine the efficacy of this MB conjugate when compared to MB-PTX
and MB-RB-Gem in 3D Panc-1 spheroids.
5. determine the in vivo effectiveness of O2MB-PTX-RB-Gem when
compared to commercial Gem and PTX controls.
6. examine the effect of O2MB-PTX-RB-Gem on key blood biochemical
markers in healthy non-tumour bearing mice.
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4.2. Results and discussion 
4.2.1. Synthesis of biotin-Gem-RB (12) 
Compound 12 was designed as a target molecule containing both RB and Gem 
with biotin also present to permit attachment to the surface of avidin coated MBs 
(Figure 4.1).   The first step in this scheme involved reacting the N-
hydroxysuccinimde ester of biotin (3) with tris(2-aminoethyl)amine (9) in a 1:1 
molar reaction to encourage only one of the primary amines of biotin (1) to form 
an amide bond with 9. This product was characterised by ESI-MS and 1H NMR 
and these are presented in Figure A1 and A2 (appendices). Both the mass and 1H 
resonances were consistent with the structure of 10.  The product (10) was then 
reacted with disuccinimidyl suberate in a 1:2 molar ratio forming amide bonds 
with the two remaining amine residues of 10 yielding compound 11 which also 
contained two pendant active esters. 
 
 116 
 
 
Figure 4.1. Scheme for the synthesis of biotin-Gem-RB. The biotin, Gem and RB moieties are 
highlighted in blue, green and red respectively. 
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The ESI-MS spectrum of 11 is shown in Figure A4 (appendices) and 
reveals a base peak of 901.3 which corresponds to the [M+Na]+ ion. The 1H NMR 
spectrum is shown in the stacked plot in Figure 4.2c and shows resonances 
associated with the carbamide protons (6.35 and 6.41 ppm) and the two protons 
of the fused rings of biotin (4.12 and 4.30 ppm) in addition to characteristic 
succinimide methylene protons appearing at 2.73 ppm.  The active esters of 11 
were then reacted in turn with gemcitabine hydrochloride and amine 
functionalised Rose Bengal (7) which was prepared as described in Section 2.3.1, 
generating ester and amide linkages respectively with 11 to form target 
compound (12). Compound 12 was subsequently characterised using ESI-MS, 1H 
NMR and 13C NMR shown in Figure 4.3 – 4.5. The ESI-MS spectrum shown in 
Figure 4.3 reveals a base peak of 1925.9 consistent with the [M+H]+ ion. To aid in 
the identification of resonances associated with Gem, a previously synthesised 
derivative of Gem harbouring a ester linkage was used for comparative purposes 
and is shown in the stacked plot in Figure 4.2b along with compound 7, 11 and 
12. While the 1H NMR spectrum of 12 is complex, the stacked plot reveals that
the two equivalent sets of methylene protons belonging to the pendant
succinimide functionalities of 11 at 2.73 ppm are no longer visible in the spectra
of 12 indicating the absence of the succinimide groups in 12 and suggesting that
Gem and 7 reacted at this position.  Furthermore, a newly formed amide proton
from the reaction of 7 and one of the activated carboxylic acids was observed at
7.37 ppm, just downfield of the two aromatic RB protons. The 1H NMR spectrum
shown in Figure 4.4 also reveals a group of resonances in the upfield region
corresponding to methylene protons on the aliphatic chain of biotin as well as on
the two tripodal aliphatic arms of the appearing between 1.10 and 2.36 ppm. The
methine protons attached to the sp2 hybridised carbons on the cytosine moiety of
Gem appeared as to distinct resonances at 5.78 and 7.68 ppm while the ring amine
appeared furthest downfield at 7.95 ppm. The 13C NMR spectrum shown in
Figure 4.5 revealed resonances between 162 and 165 ppm corresponding to the 5
newly formed amide carbonyl carbons. The sp2 hybridised carbons of RB
appeared as a group of resonances between 95 and 171 ppm. The two
characteristic aromatic carbons of the cytosine moiety of Gem appeared at 95 and
145 ppm. Resonances corresponding to 3 carbons from the aliphatic chain of
biotin appeared between 25 and 28 ppm while the remaining carbon closest to
the amide carbonyl group appeared at 35 ppm. The two adjacent chiral carbons
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of the biotin ring appeared at 59 and 61 ppm respectively while the remaining 
chiral carbon next to the sulfur atom appeared further upfield at 55 ppm. The 
remaining resonances have been assigned as shown in Figure 4.4 and 4.5.  
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4.2.2. In vitro efficacy of 12 in BxPC-3 and MIA-PaCa-2 cell lines 
Following the preparation and characterisation of compound 12, the next step 
was to determine its efficacy in two pancreatic cancer cell lines, to ensure that 
derivatising Gem for incorporation within 12 did not impair its efficacy. BxPC-3 
and MiaPaCa-2 cells were incubated with 12 at a range of concentrations from 
0.001 µM to 100 µM in the absence of light to ensure that there was limited 
activation of RB. Cell viability was determined 48 hours later using an MTT assay. 
As a comparison, cells were also treated with the same concentrations of 
commercial Gem HCl. 
 
Figure 4.6. MTT assay comparing the efficacy of 12 (red circles) and Gem HCl (blue squares) 
in (a) BxPC-3 and (b) Mia-PaCa-2 cell lines (n=6). 
 
The results are shown in Figure 4.6 and reveal very similar toxicity profiles 
between 12 and Gem in both cell lines with the median lethal dose (LD50) values 
determined as 0.71 ± 0.16 µM and 0.74 ± 0.19 µM in MiaPaCa-2 and 362.30 ± 0.12 
µM and 474.40 ± 0.13 µM in BxPC-3 cells respectively. These results suggest that 
the ester bond connecting Gem in 12 is rapidly hydrolysed by endogenous 
esterase enzymes to liberate free Gem. It has been shown that many PDAC cell 
lines express markedly high levels of carboxylesterase 2. (294) Carboxylesterases 
are ubiquitous enzymes responsible for the hydrolysis of numerous clinically 
useful drugs including the commonly used PDAC drug, irinotecan. (295) 
a) b)
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Furthermore, while it is important for cellular cleavage of Gem to enable its 
activation by deoxycytidine kinase mediated phosphorylation, rapid cleavage of 
RB from 12 is less important, as the mechanism of action for SDT does not require 
the sensitiser to bind to a receptor or be metabolised for ROS to be generated.   
In an effort to verify whether any additional contribution to the 
cytotoxicity of 12 by RB was occurring in the absence of light or US stimulation, 
BxPC-3 cells were treated with increasing concentrations of 8 which was 
prepared as described in Section 2.2 with no light or US stimulus applied. The 
results are shown in Figure 4.7 and reveal no decrease in cell viability between 0 
and 10 µM, with a modest 15% decrease in viability observed when the 
concentration was increased to 100 µM. This suggests that the small decrease in 
viability for 12 at 100 µM compared to Gem HCl, was likely caused by RB. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. MTT assay to determine the toxicity of 8 (0 – 100 µM) in BxPC-3 cells. 
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4.2.3. Synthesis and characterisation of MB-PTX-Gem-RB 
Having established the activity of 12 relative to Gem HCl, the next step was to 
incorporate the ligand onto the surface of PTX-loaded MBs (Figure 4.8). 
Figure 4.8. Schematic representation of O2MB-PTX-Gem-RB. 
The preparation of avidin-functionalised MB-PTX has been described in 
Chapter 3. MB-PTX was then subsequently mixed with 12 to generate the MB-
PTX-Gem-RB. The resulting MB size and concentration was determined through 
analysis of optical images taken of MBs in a haemocytometer chamber as 
described in Section 2.9. A representative analysis is shown in Figure 4.9 and 
reveals the mean concentration of MB-PTX-RB-Gem to be 1.14 x109 ± 1.34 x108
MB/mL and a mean particle diameter of 1.47 ± 1.09 µm which is comparable with 
previous data presented in Section 3.2.4 in which RB and Dox were loaded onto 
PTX-MB. As 12 contains the RB fluorophore in its structure, its successful loading 
onto the surface of PTX-MB-Gem-RB could be visualised using fluorescence 
microscopy, as was the case for PTX-MB-Dox and PTX-MB-RB in chapter 3. A 
representative image is shown in Figure 4.9a and again shows bright red 
fluorescence on the MB surface indicating the successful attachment of 12 to the 
MB shell. 
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Figure 4.9. a) Optical and b) brightfield images of MB-PTX-Gem-RB taken with 40x objective 
lens (1:25 dilution in PBS); c) image size distribution analysis produced using a custom 
MATLAB algorithm (n=20 images). 
 
RB and Gem exist in a 1:1 ratio within 12 making it possible to determine 
the concentration of both agents in a suspension of PTX-MB-Gem-RB using UV-
Vis spectroscopy. A UV-Vis calibration curve was constructed for 12 using 
standards of known concentrations (Figure 4.10a). Good linearity was observed 
over the concentration range tested (2.5 – 40 µM) with an R2 value of 0.9998 
Following the preparation of MB-PTX-RB-Gem, a small sample was taken, and 
the absorbance compared to the calibration curve. Additionally, the loading of 
PTX was determined using HPLC, as described in Section 2.10.  The mean 
loading of PTX and of 12 was determined to be 58.38 ± 6.74  µg/108 MB and 191.34 
± 20.43 µg/108 MB respectively. This compares favourably with previous studies 
where both RB and Gem were separately loaded onto the surface of MBs. (240) 
However, as MB-PTX-Gem-RB has both Gem and RB attached to a single MB, the 
loading of each ligand per MB is effectively doubled as no dilution is required to 
deliver both agents. This clearly demonstrates the effectiveness of combining 
multiple payloads on a single MB, as there is a limit to the quantity of MB that 
can be injected at any one time (6.4 x 1010 MB /kg based on preclinical studies of 
MRX-115 contrast agent in primates) (276).  
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Figure 4.10. UV-Vis spectra for 12 at concentrations ranging from 2.5 – 40 µM and b) Plot of 
absorbances of 12 against concentration (n=3). 
 
a)
b)
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4.2.4. Efficacy of MB-PTX-RB-Gem in Panc-1 spheroids 
Following the preparation of MB-PTX-RB-Gem, the next step was to determine 
the effectiveness of this formulation in a 3D Panc-1 spheroid model. As discussed 
in Section 3.2.5, the use of 3D spheroid models provides significant advantages 
over traditional 2D cell models including tumour-mimicking morphology and 
response to chemotherapy. 96-well plates were coated with 60 µL of 1.5% agarose 
solution to create a non-adherent meniscus coating at the bottom of each well 
which induced spheroid formation through aggregation of cells in the middle of 
each well. Panc-1 cells were subsequently seeded at a density of 2000 cells per 
well and incubated for 4 days to allow spheroids form. Once formed, spheroids 
were treated with either a suspension of MB-RB-Gem (i.e. no PTX), MB-PTX or 
MB-PTX-RB-Gem in the presence and absence of US. The US conditions and 
experimental set-up adopted for this study were the same as described in Section 
3.2.5. Following treatment, cell viability was determined using either an MTT 
assay or P.I stain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. MTT assay comparing the cell viability of Panc-1 spheroids treated with of MB-
Gem-RB ([Gem/RB] = 5 µM), MB-PTX ([PTX] = 6.6 µM) and MB-PTX-Gem-RB ([PTX] = 6.6 µM, 
[Gem/RB] = 5 µM) in Panc-1 spheroids with (grey) and without (black) US exposure. . *p < 0.05, 
**p < 0.01, ***p < 0.001. Error bars represent ± SEM (n = 5). 
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 Results from the MTT assay are shown in Figure 4.11 and reveal no 
statistically significant reduction in cell viability for spheroids treated with US 
alone. This was surprising as in previous studies using MCF-7 spheroids, US 
alone caused a 28.03% reduction in cell viability. This difference may be due to 
stronger cell-cell interactions in Panc-1 spheroids compared to MCF-7 spheroids. 
All three MB formulations showed modest reductions in viability in the absence 
of US with values of 68%, 72% and 60% for MB-Gem-RB, MB-PTX and MB-PTX-
Gem-RB respectively. In the presence of US activation, this increased to 54%, 41% 
and 28% for the same groups respectively. This improvement in cytotoxicity 
upon US activation is most likely attributed to the physical effects that 
accompany MB destruction such as micro-jetting and microstreaming. Indeed, 
representative optical microscope images of the spheroids from each group are 
shown in Figure 4.12 and reveal visible changes in morphology for spheroids that 
were treated with MBs + US, with no change observed for spheroids treated with 
US alone. Spheroids treated with the MBs + US were less densely packed and 
appeared shredded when compared to untreated or US only treated spheroids. 
This loss of structural integrity may be due to cell death throughout the body of 
the spheroid structure resulting from the enhanced drug penetration achieved 
using US. Combined with sonoporation effects, the reduction in spheroid 
integrity following MB cavitation most likely further enhances cellular uptake of 
the PTX, Gem and RB resulting in improved efficacy. Furthermore, the reduction 
in cell viability observed for the MB-PTX-Gem-RB + US group was also 
significantly better than both the MB-Gem-RB + US (p ≤0.05) and MB-PTX + US 
groups (p ≤ 0.05). This suggests that MB mediated PTX treatment compliments 
Gem/SDT treatment resulting in a potent combination treatment.  
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Figure 4.12. Representative images of Panc-1 spheroids treated with of MB-Gem-RB 
([Gem/RB] = 5 µM), MB-PTX ([PTX] = 6.6 µM) and MB-PTX-Gem-RB ([PTX] = 6.6 µM, 
[Gem/RB] = 5 µM) in panc-1 spheroids with (right) and without (left) US exposure. 
When the spheroids were stained with PI following treatment and 
subsequently imaging using fluorescence spectroscopy, a slightly different 
pattern of results was observed when compared to the MTT experiment (Figure 
4.13). Most noticeable was the lack of PI fluorescence observed for MB-PTX + US 
group with a minor 3% enhancement in intensity relative to the control group. 
However, the MB-Gem-RB + US group did produce a substantial enhancement 
in P.I fluorescence which was significant when compared to the same treatment 
in the absence of US (p ≤ 0.05) or US alone (p ≤ 0.001). Again, the most potent 
treatment was  MB-PTX-Gem-RB + US which was also significantly better than 
both the MB-Gem-RB + US (p ≤ 0.05) and MB-PTX +US (p ≤ 0.01) groups as well 
as the MB-PTX-Gem-RB (i.e without US) (p ≤ 0.01).  
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Figure 4.13. Propidium Iodide (P.I) assay comparing the cell viability of Panc-1 spheroids 
following treatment with MB-Gem-RB ([Gem/RB] = 6.8 µM), MB-PTX ([PTX] = 5 µM) and MB-
PTX-Gem-RB ([PTX] - 5 µM, [Gem/RB] = 6.8 µM) with (grey) and without (black) US exposure.  
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent ± the standard error (n=5) 
Indeed, images of the spheroids following treatment with MB-PTX-Gem-
RB + US were intensely red and visibly brighter than any of the other groups 
(Figure 4.14). The lack of spheroid shredding which was observed in previous 
spheroid experiments (Figure 4.12) was due to the fact that spheroids were 
washed to remove excess drug and P.I which likely also removed any cell debris 
around the spheroid. The lack of effect observed for MB-PTX + US from the P.I 
experiment is difficult to explain but it must be remembered that P.I staining of 
intact spheroids can only detect cell death on the surface of the spheroid structure 
whereas MTT staining of a cell suspension, derived from treated spheroids, is 
capable of detecting cell viability of the entire spheroid. Furthermore, MTT and 
P.I staining detect cell death through distinctly separate mechanisms, with MTT 
being primarily an indicator of metabolic function and P.I being an indicator of 
cell membrane permeability. (296,297) Nonetheless, it is clear from both the MTT 
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and P.I experiments that the best performing treatment was MB-PTX-Gem-RB + 
US. 
Figure 4.14. Representative images of Panc-1 spheroids following treatment with MB-Gem-RB 
([Gem/RB] = 6.8 µM), MB-PTX ([PTX] = 5 µM) and MB-PTX-Gem-RB ([PTX] - 5 µM, [Gem/RB] 
= 6.8 µM) with (right) and without (left) US exposure. 
4.2.5. Efficacy of O2MB-PTX-Gem-RB in vivo 
Encouraged by the efficacy of MB-PTX-Gem-RB in vitro, the next step was to 
determine the efficacy of O2MB-PTX-Gem-RB in an in vivo model of pancreatic 
cancer. To this end BxPC-3 tumours were established in the rear dorsum of SCID 
mice. Once tumours reached an average volume of 230 ± 104 mm3 a suspension 
of O2MB-PTX-Gem-RB (6.86 x107 ± 1.99 x 106 MB, [PTX] = 2.44 ± 0.37 mg/kg, 
[Gem] = 0.5 ± 0.04 mg/kg, [RB] = 1.85 ± 0.14 mg/kg) was administered via a tail 
vein injection. US (Frequency = 1 MHz, power density = 3.5 W/cm2, duty cycle 
= 30%, PNP = 0.4 MPa, 3.5 min) was then applied to the tumour immediately 
after injection to facilitate MB destruction and delivery of O2 and drug payloads 
to the tumour region. A further dose of US, using the same parameters, was 
applied 30 min later in order to activate the sonosensitiser within the tumour 
Untreated
MB-PTX
MB-Gem-RB
MB-PTX-Gem-RB
Brightfield
+US-US
Fluorescence Brightfield Fluorescence
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tissue. For control purposes, two separate groups of animals were either left 
untreated or administered with a clinical dose of Gem (120 mg/kg) via 
intraperitoneal injection (I.P).  To determine tolerability of the treatments, mouse 
body weight was also recorded. Previous studies have indicated that 
administration of drug loaded MBs without any US stimulus provided no 
significant benefit compared to untreated controls. For this reason and to reduce 
the number of animals used, US only controls were excluded from these 
experiments. (238) 
The BxPC-3 tumour growth delay curve is shown in Figure 4.15a and 
reveals a significant regression of 12% (p < 0.005) in tumour volume 3 days after 
the initial treatment for animals treated with O2MB-PTX-Gem-RB + US. Indeed, 
the tumours remained below their pre-treatment size for a total of 9 days. In 
contrast, animals treated with the scaled clinical dose of Gem increased by 53% 
by day 10 and at no stage did the tumours fall below their pre-treatment volume. 
It was also of interest to determine how well tolerated the MB mediated 
treatment was in comparison to the clinically scaled Gem dose. These results are 
shown in Figure 4.15b and reveal no significant difference in the weight of 
animals treated with O2MB-PTX-Gem-RB +US compared to the control group. 
However, animals treated with the clinically scaled Gem dose displayed a 
significant 11.70% reduction (p < 0.05) in body weight 5 days after the initial 
treatment indicating acute toxic effects. Combined, these results illustrate that 
chemo-SDT treatment using the O2MB-PTX-Gem-RB formulation is both 
effective and well tolerated when used to treat this particular model of pancreatic 
cancer.   
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Figure 4.15. Plot of (a) % change in tumour volume and (b) average body weight for BxPC-3 
tumour bearing mice treated with (i) no treatment (circles) (ii) O2MB-PTX-Gem-RB (squares) 
(iii) gemcitabine (triangles). The MB suspension (6.86 x107 ± 1.99 x 106 MB) was delivered as a
100 µL I.V injection ([PTX] = 2.44 ± 0.37 mg/kg, [Gem] = 0.5 ± 0.04 mg/kg, [RB] = 1.85 ±0.14
mg/kg). Gemcitabine hydrochloride was dissolved in sterile PBS and administered as a 100 µL
I.P injection (120 mg/kg). US treatment was delivered for 3.5 mins at frequency of 1 MHz, an
US power density of 3.5 W/cm2 and a duty cycle of 30% immediately after injection and 30
minutes following.  *p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent ± the standard error
(n=5).
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To determine the robustness of these results the experiments were 
repeated in a second murine model of pancreatic cancer. In this particular 
experiment, an additional group was including involving treatment using O2MB-
PTX in an attempt to differentiate any difference between the MB mediated PTX 
treatment and MB mediated PTX/Gem/SDT treatment. Mia-PaCa-2 cells were 
implanted in the rear flank of SCID mice and when the average tumour volume 
reached 150 ± 47 mm3 the animals were randomly allocated to 4 groups. Group 1 
contained untreated animals, group 2 animals treated with O2MB-PTX-Gem-RB 
+ US, group 3 animals treated with O2MB-PTX + US while group 4 involved 
animals treated with a clinically scaled dose of Gem / PTX respectively (i.e. non-
MB bound). As was the case in the BxPC-3 model, the O2MB-PTX-Gem-RB + US 
treatment had the most potent effect on tumour growth with a 105% increase, 22 
days following the initial treatment (Figure 4.16). Again, a regression of 12.9% in 
tumour was observed for this group 3 days after the initial treatment which was 
not observed in any of the other groups. The effect on tumour growth delay for 
this group was significantly better (p≤0.05) than for the animals treated with 
O2MB-PTX (group 3) which grew by 218% at day 22, and also significantly better 
(p≤0.001) than the untreated animals that grew by 533% over the same time 
period. Unfortunately, it was not possible to compare between the O2MB-PTX-
Gem-RB + US and clinically scaled Gem/PTX groups for the entirety of the 
experiment for toxicity reasons, with animals in this group displaying significant 
weight loss by day 12 that required them to be removed from the study for ethical 
reasons. Nonetheless, up until this point, there was no significant difference in 
tumour growth between these groups. Encouragingly, no significant change in 
body weight was observed for those animals treated with the MB formulations 
(groups 2 & 3) again suggesting the treatment was well tolerated. These results 
very powerfully reflect the toxicity of systemic non-targeted Gem/PTX treatment 
and how UTMD mediated chemo-SDT can produce superior results in terms of 
tumour growth control while at the same time causing no significant acute toxic 
effects. 
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Figure 4.16. Plot of (a) % change in tumour volume and (b) average body weight for MIA-PaCa-
2 tumour bearing mice treated with (i) no treatment (circles) (ii) O2MB-PTX-Gem-RB (squares) 
(iii) O2MB-PTX (↑triangles) (v) Gem HCl + PTX in cremophor EL (diamonds). The MB
suspensions (O2MB-PTX-Gem-RB – 6.47 x 107 ± 1.86 x106 MBs, O2MB-PTX – 7.01 x 107 ± 1.5 x
106 MBs) were delivered as a 100 µL I.V injection (O2MB-PTX-Gem-RB – [PTX] = 3.38 ± 0.21
mg/kg [Gem] = 0.82 ± 0.06 mg/kg [RB] = 3.02 ± 0.24 mg/kg, O2MB-PTX – [PTX] = 4.69 ± 0.75
mg/kg). Gem HCl was dissolved in sterile PBS and administered as a 100 µL I.P injection (120
mg/kg). PTX was dissolved in 1 mL of ethanol, 1 mL of Cremophor and 8 mL of sterile PBS
and administered as a 100 µL I.V injection. US treatment was delivered for 3.5 minutes at
frequency of 1 MHz, an US power density of 3.5 W/cm2 and a duty cycle of 30% immediately
after injection and 30 minutes following. Error bars represent ± standard error of the mean
(n=4).
a)
b)
0 3 5 8 10 12 15 17 19 22
0
50
100
150
200
250
300
350
400
450
500
550
600
650
700
*
**
Time (Days)
Tu
m
ou
r g
ro
w
th
 (%
)
0 3 5 8 10 12 15 17 19 22
60
65
70
75
80
85
90
95
100
105
110
115
120
***
Time (Days)
Bo
dy
 W
ei
gh
t C
ha
ng
e 
(%
)
137 
4.2.6. Determination of toxicity associated with O2MB-PTX-Gem-RB in 
healthy, non-tumour bearing mice 
The results of combined systemic Gem/PTX treatment in the BxPC-3 model 
described in the preceding section clearly illustrate the acute toxic effects 
exhibited this treatment. Nonetheless, these drugs are clinically approved for use 
in humans. The targeted nature of UTMD as a delivery platform also ensures that 
lower doses of chemotherapy can be administered to achieve the desired 
therapeutic response. Following consultation with the UK medicines regulator 
(MHRA) regarding future translation of this technology to the clinic, a small 
single species safety study was requested to ensure no deleterious effects were 
observed by combining the O2MB platform with the active payloads.  To this end, 
healthy non-tumour-bearing mice were separated into four treatment groups as 
detailed in Table 1. 
Table 4.1. Safety study treatment groups. (n=10 animals per group) 
Group Treatment 
1 Untreated 
2 US only at abdomen 
3 PTX + RB I.V plus Gem HCl I.P 
4 O2MB-PTX-Gem-RB conjugate 
Group 1 included untreated animals while group 2 included US treatment 
only (frequency = 1 MHz, power density = 3.5 W/cm2, duty cycle = 30%, PNP 0.4 
MPa, 3.5 min). As these animals were non-tumour bearing, the US was directed 
to the pancreas as would be the case in orthotopic tumour treatment. Group 3 
included animals treated with Gem, PTX and RB. PTX and RB were delivered by 
I.V injection with PTX pre-formulated in a Cremophor EL vehicle while Gem was
administered by IP injection ([Gem] = 120 mg/kg, [PTX] = 15 mg/kg, [RB] = 6 
mg/kg). Group 4 involved treatment with O2MB-PTX-Gem-RB again delivered 
by I.V injection (6.58 x107 ± 1.25 x106 MB, [PTX] = 2.03 ± 0.19 mg/kg [Gem] = 0.72 
± 0.07 mg/kg, [RB] = 2.66 ± 0.27 mg/kg).  The body weights of the animals in 
each group were recorded daily and 14 days following treatment, blood samples 
were removed and analysed for several key biochemical and haematological 
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markers in both whole blood and serum. The body weight measurements are 
plotted in Figure 4.17 and reveal no significant difference between any of the 
treatment groups indicating that all treatments were well tolerated with no acute 
adverse effects. This is in contrast to previous results where the clinical standard 
dose of PTX and Gem showed high levels of toxicity. However, in those 
experiments, animals were treated twice weekly for a total of 4 treatments 
whereas in the current study animals were only treated once weekly for a total 
of two treatments. This would have given animals enough time to recover 
between treatments. Additionally, animals used for the current safety study were 
healthy non-tumour bearing mice whereas in the efficacy study immunodeficient 
mice were used which may be a contributing factor. Results from the blood 
biochemistry analysis are plotted in Figure 4.18. Two key biochemical markers 
involved in blood analysis are urea and alanine aminotransferase (ALT) with 
increased levels of these markers suggesting damage to the kidneys and liver 
respectively. The results reveal no significant difference in levels of urea or ALT 
for any of the treatment groups when compared to untreated animals. Similarly, 
all the other biochemical markers remained largely unchanged between the four 
groups. These results corroborate a previous pre-clinical safety study where a 
similar O2MB delivery platform was used to deliver both RB and Gem. In this 
study, further histological analysis of liver and kidney sections harvested from 
treated animals also revealed no evidence of toxicity, with only a minor increase 
liver steatosis caused by the MB groups and an increase in glomerular cellular 
for animals treated with free Gem. (240)  While further histological analysis 
would be required to confirm the safety of O2MB-PTX-Gem-RB treatment, the 
blood biochemistry results, and the lack of acute weight loss would support the 
tolerability of this treatment. 
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Figure 4.17. Plot of % change in body weight against time during treatment.  Mice were 
separated into 4 groups; untreated, US only, I.V injection of RB and PTX and I.P injection of 
Gem, and I.V injection of a suspension of O2MB-PTX-Gem-RB (n=10). 
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4.3. Conclusion 
In summary, a novel tripodal ligand was synthesised comprising RB and Gem 
connected to a biotin anchor to facilitate conjugation of both payloads to the MB 
shell. The ligand was then added to the surface of MB-PTX, which were prepared 
as described in chapter 3.  Cell viability studies confirmed that modification of 
Gem at the 5’ hydroxyl position in 12 did not compromise its toxicity with similar 
LD50 values observed when compared to unmodified Gem in both Mia-PaCa-2 
and BxPC-3 cell lines. The ligand was also successfully attached to the surface of 
MB-PTX with drug loading which compared favourably with that of MB-PTX-
RB prepared in chapter 3. The resulting MB-PTX-Gem-RB caused a significant 
change in the morphology of Panc-1 spheroids following US treatment with the 
cells also displaying intensely red PI fluorescence indicating a large quantity of 
non-viable cells. This conclusion was supported when the same cellular 
suspension was analysed using an MTT assay.  The effectiveness of MB mediated 
chemo-SDT treatment using the O2MB-PTX-Gem-RB formulation was also 
demonstrated in two murine models of pancreatic cancer with improved efficacy 
and better tolerability when compared to clinically scaled doses of the free (i.e 
non-MB bound) chemotherapies. It should be noted however, that this improved 
efficacy for the MB mediated treatment was obtained using substantially lower 
doses of chemotherapy when compared to normal systemic doses with 155-fold 
lower Gem and 8-fold lower PTX respectively. In addition, no deleterious effects 
on key blood biochemistry markers or acute changes to bodyweight were 
observed when the O2MB-PTX-Gem-RB were administered to healthy non-
tumour bearing mice, also confirming the tolerability of the treatment. 
The ability of O2MB to deliver chemo-SDT for the treatment of pancreatic 
tumours has been established in the literature. (214,238,240,242)   However, to 
the best of our knowledge, a single O2MB formulation to deliver chemo-SDT and 
PTX/Gem chemotherapy has not yet been described in the published literature. 
Previous attempts at using UTMD mediated delivery to pancreatic tumours 
involved the use of a mixed MB suspension meaning that simultaneous delivery 
of both drug to the target site could not be guaranteed. The fact that all three 
drugs used in this study were delivered in a single MB formulation offers a 
significant advantage to previous methods as it is well established that for 
multiple payload drugs to act synergistically, they must be simultaneously 
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delivered to the target site. (298) The results outlined from the in vivo studies 
also demonstrate the potential of the chemo-SDT using the O2MB-PTX-Gem-RB 
formulation to cause an initial regression in tumour volume that may be of 
benefit when considering use in a neo-adjuvant setting.  
Collectively, the results described in this chapter make a positive step-
forward in the development of single MB formulations for the delivery of 
multiple payloads. While the context of the work in this chapter was focussed on 
pancreatic cancer, a similar strategy could also be adopted for other indications 
using alternative drug combinations. 
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Chapter 5 
Magnetic Microbubble Mediated 
Chemo-Sonodynamic Therapy using 
a Combined Magnetic-Acoustic 
Device 
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Chapter 5 – Magnetic Microbubble Mediated Chemo-Sonodynamic Therapy 
using a Combined Magnetic-Acoustic Device 
5.0. Introduction 
As has been described in previous chapters, drug-loaded MB can be targeted to 
the tumour site using an external US stimulus, enabling the deposition of drug 
payloads into the surrounding tissue. Several targeting techniques have also 
been developed to further increase the localised concentration of drug loaded 
MBs. For example, MBs have been functionalised through the attachment of 
targeting ligands such as peptides and antibodies, enabling receptor binding and 
subsequent accumulation of MBs within the tumour endothelium. (299,300) 
However, the short half-life of MBs (< 5 min in circulation) has limited the 
application of this method. Acoustic radiation force has also been used alongside 
targeted MBs in an effort to remotely control the flow of MBs in circulation and 
encourage accumulation of targeted MBs at the endothelial lining, thereby 
increasing their binding to target sites. (299,301)  
A more recent approach has been to incorporate magnetic particles into 
MBs. This strategy enables the capture and retention of MBs in the target region 
using an external magnetic field. (302) This often involves the incorporation of 
iron oxide nanoparticles (IONPs) into the formulation. IONPs have the capacity 
for functionalisation with various coatings such as polymers, carbohydrates and 
phospholipids. (303) Phospholipid coated IONPs, due to their amphiphilic 
nature, are capable of embedding within the hydrophobic fatty acid chains of MB. 
There are several methods for accomplishing this. IONPs can be incorporated 
into an oil phase which can be subsequently formulated into acoustically active 
lipospheres (AALs). Although this method has the advantage of excellent IONP 
loading, it suffers from low magnetic retention as a result of a poor half-life under 
flow. In addition, it has also been shown that the thick oil shell renders the AALs 
more stable to US meaning that higher mechanical indices are required to induce 
drug release. Alternatively, IONPs can be functionalized with biotin enabling the 
use of avidin-biotin binding chemistry to allow conjugation to the outer surface 
of the MB. Much like the AALs, this approach has the advantage of excellent 
IONP loading, and, in contrast, has a high magnetic retention. However, as this 
approach uses surface functionalisation, it is likely that there would be limited 
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binding sites available for drug loading onto the exterior of the MB using an 
avidin-biotin bridge. Another approach is to incorporate IONPs into the 
phospholipid shell. While this method provides a relatively low magnetic 
response, it may provide a more favourable compromise between targeting 
efficiency, stability, acoustic response and surface loading potential for 
hydrophilic drugs. (304) The latter approach was used in a 2017 study in which 
magnetically responsive O2MBs (MagO2MBs) in combination with the 
antimetabolite drug 5-FU and the sonosensitiser, RB, were delivered to 
pancreatic tumours. (247)   
Figure 5.1. Schematic representation of the MagO2MB-5FU and MagO2MB-RB conjugates. 
Taken from (247). 
In this study, two separate MagO2MB formulations were prepared, each 
bearing either 5-FU or RB, attached to the surface of the MB through the use of 
an avidin-biotin bridge. In vitro retention studies using a flow chamber with 
physiologically relevant flow rates showed a significantly increased retention in 
MagO2MB when a magnetic field was applied to the flow chamber compared to 
when no magnetic field was applied. When tested in a panel of pancreatic cancer 
146 
cell lines, a significant improvement in cytotoxicity was observed in cells treated 
with MagO2MB-5FU plus MagO2MB-RB, in the presence of US, indicating that 
the presence of IONPs in the MB shell did not hamper their efficacy. This effect 
was also apparent in vivo, when studies using an orthotopic BxPC-3 model in 
SCID mice, treated with the mixed MagO2MB-5-FU / MagO2MB-5-RB 
formulation in the presence of US and an external magnetic field, displayed a 
significant 48.3% reduction in tumour growth (p≤0.05) compared to untreated 
animals. In contrast, tumours in animals treated with the mixed MagO2MB-5-FU 
/ MagO2MB-5-RB formulation and US in the absence of a magnetic field reduced 
by 27.9%  
While the combination of magnetic and US fields demonstrated an 
improved tumour growth delay and increased apoptotic cell signalling 
compared to treatment with US only, this study had two important shortcomings. 
First, the simultaneous application and alignment of magnetic and US fields 
represented a significant practical challenge in vivo. This problem is particularly 
acute in small animal models due to space constraints and may greatly limit the 
potential synergistic benefits of magnetic-acoustic targeting. Second, it was 
necessary to use a mixture of MBs: (i) with 5-FU and (ii) with RB bound to the 
surface. This meant that upon injection it was impossible to control the delivery 
of each individual agent to the target site.  
In the present chapter, the first shortcoming was addressed by using a 
prototype probe enabling co-aligned US and magnetic fields to be applied 
simultaneously. (245) The second was addressed through the ligand discussed in 
chapter 4, wherein both the SDT and chemotherapy drugs were linked to a single 
biotin moiety, thereby enabling the attachment of both drugs to a single O2MB.  
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5.1. Hypothesis and specific objectives 
The hypothesis for the work undertaken in this chapter is that a magnetically 
responsive O2MB formulation, carrying both Gem and RB, can be targeted and 
activated using a combination of externally applied magnetic and US fields, 
delivered via a combined acoustic-magnetic device (MAD). The work presented 
in this chapter is currently under review for publication at the time of writing. 
The specific objectives were to: 
1. prepare and fully characterise magnetically responsive MB functionalised
with ligand 12.
2. determine the singlet oxygen production and acoustic emission
characteristics of MagO2MB-RB.
3. determine the effectiveness of the MAD device at enabling the delivery of
MagO2MB-RB in agar phantom models.
4. determine the effectiveness of the MAD device at enabling the delivery of
MagO2MB-Gem-RB in ectopic BxPC-3 xenografts.
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5.2. Results and discussion 
5.2.1. Preparation and characterisation of MagO2MB-RB and MagO2MB-Gem-
RB 
Avidin-functionalised magnetically responsive MBs (MagMB) were prepared as 
previously described. (247) However, in the current work, 1,2-dibehenoyl-sn-
glycero-3-phosphocholine coated IONPs were used (3.75 mg iron) instead of 
FluidMAG-Lipid nanoparticles, in order to use the same lipid as the one 
comprising the MB coating. First, a liposomal suspension was prepared as 
described in Section 2.8. DBPC-IONPs were then added and the suspension was 
further sonicated using a probe sonicator to fully disperse the lipids and IONPs. 
The headspace of the vial was then filled with PFB gas and the liquid-gas 
interface was sonicated to produce MagMB. Following preparation of MagMB, 
either 8 or 12 was attached to the surface of the MB using an avidin-biotin bridge 
as previously described in section 4.2.3. In an effort to preserve the limited stock 
of 12, and given its relatively complicated synthesis, for all in vitro 
experimentation including in vitro activation and drug delivery in agar 
phantoms, 8 was used as a surrogate drug as it is significantly more 
straightforward to prepare. 
Figure 5.2. Schematic of MagO2MB-Gem-RB. 
5.2.2 Characterisation of MagMB-RB and MagMB-Gem-RB 
Following preparation, MB were characterised in terms of size, concentration and 
drug loading as described previously in Sections 2.9 and 2.11 as well as IONP 
loading. The mean MB concentration was determined to be 2.1 ± 0.3 x 109 MB/mL 
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with a mean diameter of 1.6 "m. Purification of MBs through centrifugation 
decreased the MB concentration to an average of 7.2 ± 2.0 x 108 MB/mL, with a 
mean diameter of 1.8 "m. A comparison of the size distributions from before and 
following conjugation with 12 suggest that the loading and subsequent washing 
mostly removes the smallest MBs (Figure 5.3). However, MBs with a diameter 
between 1 and 8 µm appeared stable during this process. The drug loading for 8 
and 12 after washing was determined using UV-Vis as described in Section 2.11 
and was determined to be 82.87 ± 62.15 µg/108 MB and 139.10 ± 48.15 µg/108 MB 
for 8 and 12 respectively. These loadings are slightly lower than in previous 
chapters where 8 and 12 were loaded onto PTX-MB and may be as a result of the 
relatively large IONPs within the lipid monolayer inhibiting the avidin-biotin 
interaction. 
Figure 5.3. Size distribution of MagMBs before and after loading of 12 obtained from analysis 
of optical microscope images for each batch. The concentration of MagMB-RB-Gem after 3x 
centrifugation cleaning was on average 7.2 ± 2.0 x108 MB/mL. (n = 20 images). 
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5.2.3 Determination of iron content of MagMB-Gem-RB 
As the iron content of MagMB is generally proportional to the magnetic 
responsiveness and hence targeting ability of the MB, it was crucial to determine 
the loading of IONPs within the formulation. (304) This was done indirectly 
through the determination of the iron loading. Iron content was determined 
using inductively coupled plasma-optical emission spectrometry (ICP-OES) 
measurements of samples diluted in 2% nitric acid at a wavelength of 238 nm. A 
calibration curve was produced using standards containing known 
concentrations of iron (Figure 5.4). Good linearity was observed over the 
concentration range tested (0-1 mg/L) with a R2 value of 0.9997. Using the 
calibration curve and the emission intensity of the unknown samples the mean 
iron loading was determined to be 0.07 rg/MB. This compares favourably with 
a previous study where DBPC-IONPs were loaded into MB in which a loading 
of 0.04 rg/MB was achieved. The reason for the increase is not fully understood 
but could be partly due to due to the variation in the centrifugal washing steps 
used in their preparation. (304) 
Figure 5.4. Inductively coupled plasma-optical emission spectrometry (ICP-OES) calibration 
curve of Fe measured at 238 nm in 2% nitric acid. 
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5.2.4. Combined magneto-acoustic device (MAD) 
The MAD was designed as described by Barnsley et al. and assembled as shown 
in Figure 5.5. (245) The main magnetic body consisted of a N52 grade 
neodymium permanent magnet (NdFeB) with geometry which was optimized to 
have a maximum magnetic field strength of 0.2 T at a distance of 10 mm from the 
body’s leading edge. An integrated ultrasonic element with a focal distance also 
of 10 mm provided a pressure field that spatially overlapped with the magnetic 
field peak, with sufficient amplitude to cause inertial cavitation of MBs used in 
this study. This was key as it meant that MagO2MB-Gem-RB could be both 
optimally retained and destroyed at the same focal depth. An aluminium-bodied 
copy of the MAD (aMAD) was produced to provide an US-only control for in 
vitro and in vivo experimentation.  
Figure 5.5. (A) MAD configuration illustration and (B) photograph as tested, with Perspex 
holder. 
An important constituent of any type of therapeutic/diagnostic US device 
is the mechanism for coupling the acoustic beam into the tissue. The efficient 
transfer of US energy from the transducer to the treatment site is reliant on good 
acoustic coupling. The ideal acoustic coupler needs to be a homogeneous 
material with low attenuation and acoustic impedance similar to that of the tissue 
being treated. For this reason, a coupling cone (Figure 5.5), cast from paraffin wax, 
was secured onto the leading edge of the US element with US gel. The cone 
(A) (B)
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material was chosen for its ease of casting and minimal transmission loss in the 
1 MHz frequency range. 
5.2.5. In vitro activation and delivery 
Before further work could be done with MagO2MB-Gem-RB it was deemed 
prudent to evaluate the ability of MagO2MB in combination with 8 to produce 
singlet oxygen (1O2), as Fe(II) is redox active and could potentially participate in 
electron transfer reactions with the excited sensitiser. This was done using singlet 
oxygen sensor green (SOSG) which is a commercially available fluorescent probe 
selective for 1O2. SOSG comprises a fluorescein fluorophore connected to an 
anthracene quencher. Under normal conditions the anthracene moiety quenches 
the fluorescein emission through a photoinduced electron transfer (PET) process 
as shown in Figure 5.6. However, in the presence of 1O2, the anthracene unit is 
oxidised to the corresponding endoperoxide (SOSG-EP), increasing its oxidation 
potential and cancelling the PET process. Thus, the interaction of SOSG with 1O2 
generates a strong fluorescein emission at 530 nm following excitation at 490 nm, 
the intensity of which is dependent on the amount of 1O2 present.  
Figure 5.6. Schematic showing the chemical structure of SOSG and the formation of SOSG-EP 
upon reaction with singlet oxygen to produce fluorescence. Taken from (305). 
For the singlet oxygen generation experiments, a sample of degassed PBS 
containing either MagO2MB (5x107 MB/mL), MagO2MB-RB (5x107 MB/mL, 541 
"M)  or 8 (541 "M) and SOSG (1.25 "M) was exposed to US (1.17 MHz, PNP = 
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0.70 MPa, duty cycle = 30%, PRP = 100 Hz, 3.5 min). The fluorescence intensity 
of SOSG at 520 nm was measured for each sample with and without US exposure. 
In addition to measuring 1O2 generation, the characterisation of MB acoustic 
emissions during US exposure were recorded using a passive cavitation detector 
(PCD) focused on the top of the sample chamber. The results are shown in Figure 
5.7 and reveals that the generation of cytotoxic 1O2 was significantly enhanced 
when MagO2MB-RB were exposed to US, compared to MagO2MBs or 8 alone (p 
< 0.01), thereby indicating a more effective activation of the sensitiser. This is 
likely as a result of O2MB providing the oxygen substrate needed to facilitate the 
generation of 1O2 by RB in the otherwise degassed medium. Further, the presence 
of exogenous MBs has been shown to facilitate sonoluminescence thereby 
activating the sensitiser. (174) 8. A similar result was observed in the 
ultraharmonic energy of MB emissions recorded from the PCD, but the emissions 
from the two types of MB and 8 alone were all significantly different (p < 0.01). 
The reason for the increased cavitation activity of MagO2MB-RB compared to 
MagO2MBs is not fully understood but could be explained by an enhanced 
stabilisation of MagO2MB-RB due to the surface functionalisation of 8 that 
prevents bubble dissolution in the degassed medium akin to that of Pickering 
stabilisation. (306) 
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Figure 5.7. Singlet oxygen production (orange, n=3) from activation of 8 after US exposure, 
with associated ultraharmonic emissions from MBs (blue) undergoing nonlinear oscillations. 
** = p < 0.01 determined through a 1-way ANOVA with Tukey’s post hoc test. A sample was 
prepared with ± 5x107 MB/mL, ± 541 !M biotin-RB, and 1.25 !M SOSG in degassed PBS. US 
parameters were 1.17 MHz, 0.7 MPa PNP, 30% duty cycle, 100 Hz PRF for 3.5 minutes.  
5.2.6 Drug delivery comparison in agar between devices 
The performance of the MAD compared to the use of separate magnetic / US 
devices and the contributions of US and of the magnetic fields individually were 
assessed in an agar phantom model. Ultrasonic phantoms are often used to 
mimic the US properties of biological tissues such as US propagation, velocity, 
density, attenuation and acoustic impedance allowing the study of its 
interactions with US. In soft tissue like that of the pancreas, the values 
corresponding to these properties are very similar to that of agarose and so this 
was the ideal material for the tissue mimicking phantom. The phantom body was 
made up of 1.25% agarose with a straight, 1.2 mm diameter channel running 
through it. Into this channel was injected either MagMB-RB ([MB] = (1.74±0.62) x 
108 MB/mL or free 8 ([8] = 506±53 "M) at a flow rate of 0.2 mL/min. The top of 
the agar phantom was then treated according to Table 1 using both the MAD 
device and a separate device with only magnetic functionality (aMAD) (US: 1.17 
MHz, 30% duty cycle, peak negative pressure 0.7 MPa, 3.5 minutes, magnet 
strength: 0.2 T at 10 mm). The combination of MAD and aMAD was used to 
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mimic previous studies where US and magnetic fields were applied separately. 
(247) 
Figure 5.8. In vitro flow phantom set-up for (A) the MAD with co-aligned fields compared to
(B) the separate but simultaneous application of magnetic (MAD with US element turned off)
and US (aMAD) fields. Phantom is shown cutaway to visualize the 1.2 mm diameter channel
through which MMBs were flown. The underlying water bath is not shown.
Table 5.1. Treatment groups for drug delivery comparison in agar between devices. 
Group Name Water MagMB-RB* US** Magnet*** 
Untreated X 
MB X 
US X X (aMAD) 
Mag X X (MAD) 
US + Mag X X (aMAD) X (MAD) 
MAD X X (MAD) X (MAD) 
* MagMB-RB: MB = (1.7±0.6) x108 MB/mL and [8] = 500±50 !M
** US: 1.17 MHz, 30% duty cycle, peak negative pressure 0.7 MPa, 3.5 minutes
*** Magnet: 0.2 T at 10 mm
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Following treatment, the channel was rinsed with deionised water and the 
agar channel was immediately cut out. The concentration of 8 delivered was then 
determined based on the absorbance of a set volume of agar gel surrounding a 
channel after flowing 100 "L of MagMB-RB through it while exposed to one of 
the device configurations. Figure 5.9 shows the concentration of 8 delivered for 
the various groups tested, and when US was used, the associated cavitation 
activity is provided. A significantly higher quantity of 8 was delivered (p < 0.01) 
using the MAD compared to all other groups; more specifically a 1.6 and 1.4-fold 
increase in 8 was measured compared to the US only and US + Mag groups 
respectively. Moreover, a comparison between the MAD and US only groups 
indicate a significant increase in delivery (p < 0.01) from the addition of magnetic 
targeting, but the minimal enhancement observed for the US + Mag group 
compared to US highlights the difficulty in optimally aligning devices when two 
separate units are used. The delivery recorded for MagO2MB-RB alone (i.e no 
magnet or US)  could be associated with residual 8 (i.e. non-MB bound) in the 
suspension diffusing across pores in the agar gel (307) and was found to be 
significant compared to the untreated group (p < 0.01). Individually, US and Mag 
fields enhanced delivery to a similar degree, in agreement with previous results 
from Stride et al (235) where combined US and magnetic fields enhanced the 
transfection of DNA into Chinese hamster ovary cells.  
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Figure 5.9.  Delivery of 8 (orange, n=3) in a volume of 0.7 mL agar (1.25% w/w) with different 
US and magnetic device configurations as listed in Table 5.1. ** = p < 0.01 determined through 
a 1-way ANOVA with Tukey’s post hoc test. The corresponding ultraharmonic emissions of 
MBs (blue) are shown. For the treatment-receiving groups, 100 !L of MagMB-RB ([MB] = 
(1.74±0.62) x 108 MB/mL, [8] = 506±53 !M) were administered and flown at 0.2 mL/min. When 
a magnet was used, a 0.2 T magnetic field from the MAD was applied at the US focus. When 
US was applied (MAD or aMAD), the parameters were: 1.17 MHz, 0.7 MPa PNP, 30% duty 
cycle (DC), 100 Hz PRF for 3.5 minutes. The ultraharmonic emissions plotted for the untreated 
group reflect the background noise recorded with water flowing in the agar channel.  
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5.2.7. In vivo efficacy in BxPC-3 xenografts 
To fully assess the utility of the MAD as a platform for the delivery of combined 
magnetic and US fields in vivo, 25 SCID mice were implanted with ectopic 
human pancreatic BxPC-3 tumours and randomly distributed into 4 groups for 
treatment as described in Table 5.2. 
Table 5.2. In vivo drug delivery experiment groups. 
Group 
Name 
No 
treatment 
MagO2MB-RB-
Gem* 
US** Magnet*** 
Untreated X 
MB X 
US + Mag X X (aMAD) X (MAD) 
MAD X X (MAD) X (MAD) 
* MagO2MB-RB-Gem: [MB] = (1.3±0.4) x 109 MB/mL, [12] = 520±80 !M
** US: 1.17 MHz, 30% duty cycle, peak negative pressure 0.7 MPa, 3.5 minutes
*** Magnet: 0.2 T at 10 mm
The results in Figure 5.10 reveal a 37% reduction in tumour volume 
relative to the pre-treatment volume 4 days after the initial treatment for animals 
treated with MagO2MB-RB-Gem and the MAD, compared to a 9% reduction 
when combined magnetic and US fields were simultaneously delivered using 
separate probes (US + Mag). This difference was maintained for four days, and 
12 days following the initial treatment, tumours treated with MagO2MB-RB-Gem 
and the MAD were still 9% smaller than their pre-treatment volume and 54% 
smaller than tumours treated with MagO2MB-RB-Gem and separate probes. 
Compared to the untreated group, the MAD enabled a more significant reduction 
in tumour volume sustained to day 12 with a p-value of 0.0028, while the US + 
Mag group produced a p-value of 0.0346. In addition, while tumours treated with 
MagO2MB-RB-Gem in the absence of magnetic or US fields (MB) were smaller 
than untreated animals, the difference was not significant. It is important to note 
that BxPC-3 tumours treated with a clinically relevant dose of Gem (120 mg/kg) 
showed no significance at controlling the tumour volume compared to the 
untreated control. The combined treatment was not only effective at reducing 
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tumour burden but was also well tolerated, as the animals remained healthy and 
exhibited no weight loss over the duration of the study (Figure 5.11).  
Furthermore, the clinical standard Gem group lost an average of 7.29% on Day 8, 
indicating toxicological stress.    
The observed differences between treatments performed with the MAD, 
and physically separate but simultaneous magnetic and ultrasonic field 
generating devices, illustrate the importance of field alignment. When co-aligned 
as in the MAD, the tendency of bubbles to be pushed away from the US focus by 
radiation force is counteracted by the pulling force of the magnet. This effect, 
which helps maintain a population of bubbles in the US beam, is weaker and 
potentially becomes detrimental to MB availability in the US focus when the 
ultrasonic and magnetic fields are separated by a large angle, as with the separate 
device tests.  
Figure 5.10. In vivo results with (A) % tumour growth over time relative to day 0. Arrows 
indicate treatment days. * p<0.05, ** p<0.01 compared to the untreated group determined with 
a 1-way ANOVA followed by Sidak’s post hoc test on the tumour volume data (n = 5 for 
untreated and n = 4 for MAD, MB, and US + Mag) from day 12. (B) Images of xenograft ectopic 
BxPC-3 tumours on day 0, 6, and 12 from the start of treatment. 
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Figure 5.11. Group-average body weight of mice bearing xenograft ectopic BxPC-3 tumours 
(n=5). 
Taken together, these results demonstrate an improved therapeutic effect 
obtained from the co-aligned application of magnetic and acoustic fields using a 
single device compared to the use of two separate devices. Additionally, the 
chemo-sonodynamic therapy delivered using the MAD provided a rapid, 
substantial and stable reduction in tumour volume, suggesting that this approach 
may be ideal as a neo-adjuvant treatment to downstage pancreatic tumours in 
advance of surgery.  
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5.3 Conclusions 
Use of the MAD device in combination with MagO2MB-RB-Gem demonstrated 
enhanced efficacy in a pre-clinical animal model of pancreatic cancer when 
compared to activation using separate devices delivering US and magnetic fields. 
The use of ligand 12 also enabled both Gem and RB to be delivered as a single 
MB formulation.  
The ability of sensitizer loaded MagO2MB, to produce 1O2 was clearly 
demonstrated using the SOSG assay indicating the presence of the IONPs do not 
hinder ROS generation. In addition, the use of MAD significantly increased the 
delivery of attached payloads by 1.6- fold in an agar flow phantom (p < 0.01) 
compared to the use of two separate devices, and an increase in the energy of MB 
ultraharmonic emissions was also observed. These results indicate that the MAD 
enabled a more precise application of both targeting and activation fields to 
promote drug delivery. The advantages of the combined MAD were further 
demonstrated in vivo and showed a significant decrease in tumour size after 12 
days of treatment (p < 0.05) compared to the use of two separate devices. In 
addition, a substantial decrease in tumour size of 37% after 4 days of treatment 
was observed for animals treated using the MAD when compared to pre-
treatment values. Furthermore, previous studies performed with the MAD have 
demonstrated that this technology can be adapted for the larger length scales 
relevant for human applications. (245) 
The work presented in this chapter demonstrates a clear progression from 
work undertaken in chapters 3 and 4 with the addition of an extra layer of 
targeting, enabling the delivery of significant quantities of cytotoxic agents to the 
tumour and clearly highlights the potential of this approach as an ideal neo-
adjuvant therapy to downstage tumours prior to surgery.  
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Microbubble Mediated Delivery of 
a Novel Gemcitabine 
Phospholipid-Prodrug and 
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Chapter 6 – Microbubble mediated delivery of a Novel Gemcitabine 
Phospholipid-Prodrug and Paclitaxel. 
6.0. Introduction 
In chapters 3-5, the active drugs Dox, RB and Gem were modified with biotin to 
enable attachment to pre-formed MBs using the biotin-avidin interaction. 
Despite the utility of this conjugation technique for preliminary preclinical 
evaluations it has two main shortcomings. First, several synthetic steps are 
required following MB preparation to first add avidin and then the biotinylated 
payload. This not only increases the overall complexity and cost of the synthetic 
process, but also reduces the yield of loaded MB, as a washing step is required 
following each conjugation procedure. Second, as the loading capability of a 
particular ligand is dependent upon its physiochemical characteristics such as 
aqueous solubility, this strategy also provides a limited degree of control over 
loading levels of the therapeutic agent onto the MBs. Therefore, an alternative 
method for the preparation of drug loaded MBs for use in targeted anti-cancer 
therapy would be highly beneficial. More specifically, there is a need for methods 
which minimise the need to manipulate the MBs once formed and/or which 
permit greater control over the loading levels of the therapeutic agent. 
There are a number of techniques described in the literature to facilitate 
drug loading onto the surface of MBs (Figure 6.1). One method is the use of a 
covalent bonding between the therapeutic agent and the MB. This can be 
achieved in a number of ways including the use of carbodiimide chemistry, 
maleimide-thiol chemistry and click-chemistry. Carbodiimide chemistry 
involves the use of a carboxyl functionalised lipid within the MB. 
(209,237,308,309) The carboxyl functionality is then often activated using the 
water soluble 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC) in the 
presence of N-Hydroxysulfosuccinimide (sulfo-NHS) to produce the N-
hydroxysulfosuccinimide ester which is highly reactive to primary amines. 
However, the efficiency of this method is often limited by multiple competing 
side reactions. Firstly, the unstable O-acylisourea is capable of undergoing 
isomerisation to the stable N-acylisourea, essentially preventing further binding. 
In an effort to prevent this, the N-hydroxysulfosuccinimide ester is formed using 
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sulfo-NHS. (310) This reactive intermediate can also be rapidly hydrolysed in 
basic conditions (i.e. PBS) back to the relatively unreactive carboxyl functionality. 
These side reactions therefore severely limit the practicality and loading 
capability of the MBs. Alternatively, ligands bearing a thiol functionality can be 
covalently bound to MB using thiol-maleimide chemistry. (311–315) This method 
has the advantage of improved aqueous stability and high coupling yields. 
However, residual maleimide groups, are capable of reacting with cysteine 
residues found on serum proteins, leading to a loss of targeting, premature 
clearance, and hypersensitivity reactions. (316) 
More recently there has been a growing interest in the use of click-
chemistry such as strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC) to 
enable covalent binding to the surface of the MB. (316–318) However, this 
technique, much like the beforementioned strategies, is undertaken following 
MB preparation. This complicates the synthetic process and limits the potential 
for rapid clinical translation.  
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Figure 6.1. Schematic illustrating techniques used to covalently conjugate ligands to the 
surface of MBs. a) Reaction of EDC with carboxylic acid functionalised MB to produce 
unstable O-acylisourea intermediate followed by reaction with sulfo-NHS to produce highly 
reactive sulfo-NHS derivative which subsequently reacts with a ligand bearing a primary 
amine functional group b) Reaction of a thiol functionalised ligand with a MB bearing a 
maleimide group (e.g. DSPE-PEG-2000-maleimide) to produce thioester linkage c) Reaction of 
azide functionalised ligand with MB bearing a dibenzocyclooctyne (DBCO) functionality (e.g. 
DOPE-N-DBCO). 
In this chapter, the shortcomings described above have been addressed 
through the preparation of MBs using pre-functionalised precursor 
phospholipids. More specifically, a novel phospholipid conjugate of Gem 
(LipidGem) was synthesised using an enzyme catalysed transphosphatidylation 
reaction. This conjugate was then formulated into MBs with / without the 
anticancer drug PTX, which was incorporated into the acyl chain layer of the MB. 
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6.1. Hypothesis and specific aims 
The overarching hypothesis of this study was that a phospholipid bearing a 
choline polar head group could be modified to include the anticancer drug Gem 
in a single step enzymatic reaction and that this novel phospholipid-conjugate 
could be formulated into an US-responsive MB formulation. A secondary aim 
was to further load this preparation with PTX in the hydrophobic layer of the MB 
shell and test the effectiveness of this formulation in 3D spheroid and murine 
models of pancreatic cancer. The specific aims were to: 
1. synthesise, purify and fully characterise a novel phospholipid conjugate
of Gem (Lipid-Gem) using a single step enzymatic transphosphatidylation
reaction.
2. generate MBs prepared from Lipid-Gem with / without PTX
hydrophobically incorporated into the lipid shell and fully characterise
the resulting formulations.
3. assess the stability of the MB formulations at 37oC compared to
unmodified MBs.
4. determine the efficacy of the MB formulations in Panc-1 spheroids.
5. determine the efficacy of the MB formulations in a BxPC-3 ectopic
xenograft model of pancreatic cancer.
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6.2. Results and Discussion 
6.2.1. Enzyme catalysed Synthesis and Characterisation of LipidGem 
Chemical manipulation of Gem is often troublesome due to the multiple potential 
reactive sites identified in Figure 6.2. This is particularly problematic when an 
amide/ester coupling strategy is proposed given the different sites capable of 
this reaction. The presence of hydroxyl moieties at the 3’ and 5’ positions make it 
difficult to construct ester bonds with these groups in a regiospecific manner. The 
presence of the primary amine moiety also provides the possibility of amide 
formation with carboxylic acids or reactive derivatives. This means that any 
attempt to couple Gem with another compound using this strategy will 
inevitably lead to a mixture of compounds which need to be separated through 
laborious chromatography. This lack of selectivity often results in a very low 
yield of the desired compound and is therefore unsuitable for scale up and 
clinical translation.  
Figure 6.2. Chemical structure of Gem with the 3’ hydroxyl, 5’ hydroxyl and cytosine amine 
highlighted in red. 
Shuto et al developed a simple, one-step enzymatic reaction, to 
selectively synthesise 5’-phosphatidyl nucleosides. (319–322) This reaction was 
achieved through the use of the enzyme, phospholipase D from Streptomyces sp 
in a reaction known as a transphosphatidylation. This reaction is carried out in a 
biphasic reaction mixture composed of an aqueous buffer layer containing the 
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acceptor alcohol (Gem) and the enzyme, and an organic layer containing the 
donor phospholipid - a phosphatidylcholine. Under these conditions, 
phospholipase D is selective for primary alcohols and therefore is capable of 
catalysing the coupling of the 5’ hydroxyl group of Gem with the phosphatidyl 
group of any phosphatidylcholine in a single step without the need of protecting 
group chemistry. 
The exact mechanism for this reaction is not fully understood. However, 
it has been theorised that the reaction proceeds as shown in Figure 6.3. The first 
step is thought to involve the formation of a phospholipid-enzyme intermediate 
through a nucleophilic attack on the phosphorus atom of the lipid by a histidine 
(His-1) residue on the enzyme and protonation of the leaving group by a second 
His residue (His-2). The next step involves the deprotonation of a water molecule 
by His-2 and another nucleophilic attack on the phosphorus atom by the 
resultant hydroxide. From this hypothetical mechanism, it can be assumed that 
the acceptor alcohol (i.e. Gem) will compete with surrounding water molecules 
in the reaction mixture, for the phosphatidyl group. (323) For this reason, it is 
important that the concentration of the acceptor alcohol in the reaction mixture 
remains as high as possible to reduce enzymatic hydrolysis of the 
phosphatidylcholine to the undesirable phosphatidic acid side product. 
Figure 6.3. Hypothesised mechanism for the transphosphatidylation reaction. X1 = choline, X2 
= Gem and Y = diacyl glycerol moiety. Reproduced from (323). 
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In an effort to be consistent with work presented in previous chapters 
(Chapter 3-5), DBPC was chosen as the phosphatidylcholine donor compound. 
The scheme for the reaction of Gem with DBPC is shown in Figure 6.4. Gem is 
first dissolved in a buffer of sodium acetate and acetic acid at pH 4.5 and 
Phospholipase D added as a lyophilised powder. This aqueous phase is then 
added to a solution of DBPC in chloroform at 45oC and this mixture is stirred 
vigorously to emulsify the biphasic mixture. Vigorous stirring was essential as 
the reaction takes place at the interface between the organic and aqueous phases. 
Figure 6.4. Synthetic scheme for the synthesis of LipidGem. 
Following completion of the reaction, the organic layer was removed 
and concentrated to dryness. The crude solid was then washed with water to 
remove excess Gem and purified using PTLC as described in Section 2.5. The 
success of the separation and estimation of purity was determined using 
analytical TLC. As Gem contains a chromophore within the cytosine moiety, the 
purified conjugate could be easily visualised under UV irradiation. As an added 
control, TLC plates were sprayed with Dittmer-Lester reagent which selectively 
stains phosphate groups blue. As the starting material or side product (DBPC or 
DBPA) are not UV active, the presence of a dark spot under UV along with a blue 
spot once stained with Dittmer-Lester reagent, strongly indicates the presence of 
the target compound (Figure 6.5). 
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Figure 6.5. Images of a TLC plate after a) irradiation under UV light and b) stained with 
Dittmer-Lester reagent (left spot – Gem free base standard, middle spot – 15 standard prepared 
previously, right spot – purified 15). 
 The purified 15 was characterised by MALDI-TOF-MS, 1H NMR and 
13C NMR. The MALDI-TOF-MS spectrum is shown in Figure 6.6 and reveals three 
main peaks at 1084.7758 (base peak), 1062.7800 and 1106.7753 corresponding to 
the [M+Na]+, [M+H]+ and  [M+2Na- H]+ ions respectively. The assigned 1H NMR 
spectrum is shown in Figure 6.7 and reveals the characteristic resonances 
associated with the terminal methyl groups of the lipid chains appearing at 0.8 
ppm, the main block of lipid methylene protons between 1.0 and 1.4 ppm and 
the lipid methylene protons in the alpha and beta positions to the carbonyl group 
appearing at 2.3 and 1.5 ppm respectively. A cluster of resonances associated 
with diastereotopic glycerol/Gem methylene protons in addition to methine 
protons from the Gem furanose ring appeared between 3.9 and 4.5 ppm. The 
methine proton attached the chiral glycerol moiety appeared downfield at 5.2 
ppm while the methine proton of the furanose ring on the carbon directly bonded 
to the cytosine ring nitrogen atom of Gem appeared at 6.2 ppm. Finally, the 
cytosine ring methine protons attached appeared separately as two distinct 
resonances at 6.0 and 7.8 ppm.  
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To further illustrate the differences between 15 and the starting 
materials, a stacked spectra of 1,2-dibehenoyl-sn-glycero-3-phosphocholine 
standard (top), Gem standard (middle) and 15 (bottom) is presented in Figure 6.8 
and clearly shows that the resonances corresponding to the choline methyl 
groups (3.15 ppm) and methylene protons (3.6 and 4.0 ppm) protons present in 
the spectrum of DBPC are absent in the spectrum of 15, confirming this unit has 
been cleaved during the reaction as described in Figure 6.4. In addition, the 
resonance corresponding to the Gem furanose methylene protons appearing at 
3.75 ppm in Gem shifted downfield to 4.15 ppm in 15, reflecting their new 
environment adjacent to phosphoester bond. In addition, other resonances 
associated with Gem, such as the two cytosine ring methine protons at 5.9 and 
7.8 ppm respectively which were not present in the spectrum of DBPC, are clearly 
visible in the spectrum corresponding to 15.  The structure of 15 was further 
confirmed using 13C NMR (Figure 6.9) with the carbons of the lipid chains 
appearing between 10 and 35 ppm. The methylene carbons of the glycerol moiety, 
as well as the Gem furanose methine carbon and adjacent methylene carbon, 
appeared as a small cluster of resonances between 50 and 70 ppm. The Gem 
cytosine ring carbons appeared at 85 and 141 ppm while the neighbouring 
carbonyl carbon appeared at 156 ppm. The two carbonyl carbons from the acyl 
chain groups of the phospholipid appeared furthest downfield at 174 ppm. When 
combined these analyses confirmed the formation of 15. 
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6.2.2. Synthesis and characterisation of MB-LipidGem and MB-LipidGem-PTX 
Following the successful synthesis of 15, the next step was to investigate whether 
the lipid was capable of producing stable MBs. MB-LipidGem were prepared 
using the same protocol discussed in previous chapter. MBs prepared using only 
LipidGem were unstable and rapidly dissolved after synthesis. This was likely 
due to a combination of (i) poorer lipid packing when compared to 
phosphatidylcholine MBs due to the bulkier Gem head group and (ii) coalescence 
of MBs through an Ostwald ripening-type process. In an effort to improve 
stability by reducing MB coalescence, the polymeric phospholipid, DSPE-PEG 
(2000), was introduced into the formulation. Both 15 and DSPE-PEG (2000) were 
dissolved in a mixture of chloroform and methanol. The solvents were removed 
to from a thin film which was hydrated in a solution of glycerol and propylene 
glycol in PBS. As the phase transition temperature of 15 was not known, the 
solution was heated to 10oC above the phase transition temperature of the 
precursor lipid (DBPC). The MB-LipidGem were then formed as described 
previously by sonication at 22% to form a colloidal suspension followed by 
sonication at 90% in a PFB headspace to form a milky white suspension of MB.  
Following the preparation of MB-LipidGem, the MBs were characterised 
in terms of mean size, mean concentration and drug loading as described in 
previous chapters. A representative microscope image of the MB suspension 
along with the corresponding size distribution is shown in Figure 6.10.  The mean 
diameter of MB-LipidGem was determined to be 1.84  ± 1.57 µm with a mean 
concentration of 1.8 x109 ± 1.5 x108 MB/mL. These are comparable with MBs 
prepared using the commercially sourced phospholipids described in previous 
chapters.  
177 
Figure 6.10. a) a representative optical micrograph of MB-LipidGem (x40 
magnification) (n=20) b) representative size distribution analysis of images of MB-
LipidGem (n=20 images). Scale bar represents 50 µm. 
As the cysteine moiety of 15 contains a chromophore, the extent to which 
15 was incorporated into the MB was evaluated by UV-Vis spectroscopy. A UV-
Vis calibration curve was constructed for 15 using standards of known 
concentrations (Figure 6.11b). Good linearity was observed over the 
concentration range tested (0 – 100 µM) with an R2 value of 0.9974. The mean 
loading of 15 within the MB shell was 68.49 ± 6.99 µg/ 108 MB. This represents a 
loading of 24.7% of the total amount of lipid used to form the film. 
50 µm 
a) b)
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Figure 6.11. a) UV-Vis spectra for 15 at concentrations ranging from 0 – 100 µM and b) Plot of 
absorbances of 12 against concentration (n=3). 
The next step was assessing whether PTX could be hydrophobically 
incorporated into the acyl chain layer of the MB shell. As the acyl chain length of 
15 is the same as that of DBPC which was used in previous chapters, it should 
also be possible to incorporate PTX within the shell of MB made from 15.   This 
was achieved using the protocol outlined in Chapter 3. As before, these MB were 
characterised in terms of mean concentration, mean diameter and mean drug 
concentration. A representative microscope image of the MB suspension along 
with the corresponding size distribution is shown in Figure 6.12.  The mean 
diameter of MB-LipidGem was determined to be 1.86  ± 1.62 µm with a mean 
concentration of 1.7 x109 ± 1.1 x108 MB/mL. This indicated that the addition of 
PTX into the shell had little effect on the MB forming ability of 15. The loading of 
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15 within these MB was determined to be 79.97 ± 10.36 µg/108 MBs which is 
comparable with MBs containing no PTX. The loading of PTX within these MB 
was determined using an HPLC method described in Section 2.10. The PTX 
loading within these MB was determined to be 48.57 ± 5.13 µg/108 MB. This 
represents a loading of 16.6% which is comparable with previous studies 
(Chapter 3-4).  
Figure 6.12. a) representative optical micrograph of MB-LipidGem-PTX (1:25 dilution, x40 
magnification) b) representative size distribution analysis of images of MB-LipidGem-PTX 
(n=20 images). Scale bar represents 50 µm. 
50 µm 
a) b)
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Following the preparing of MB-LipidGem-PTX, it was important to 
determine the relative stability when compared to MB-LipidGem containing and 
unmodified MBs (i.e carrying no payloads). This was achieved by counting the 
MB number immediately after preparation and then placing the MB suspensions 
in an incubator at 37oC. The MB number was then measured every 15 minutes 
for a total of 1 hour. The results are shown in Figure 6.13 and reveal a small yet 
insignificant decrease in relative MB number for MB-LipidGem and MB-
LipidGem-PTX compared to the unmodified MBs. However, there was no 
significant decrease in MB number observed between either MB-LipidGem or 
MB-LipidGem-PTX over the time investigated. These results suggest that 15 is 
capable of producing MBs with stability comparable with that of standard DBPC 
MBs and that have the capacity to load hydrophobic drugs into the shell at 
comparable quantities.  
  
Figure 6.13. Plot showing % MB count of plain DBPC MB (8.81 x108 MB/mL) (left), MB-
LipidGem ([LipidGem] – 55.55 ± 5.72 µg/108 MB, 9.97 x108 MB/mL) (middle) or MB-LipidGem-
PTX ([LipidGem] –  73.26 ±  3.12 µg/108, [PTX] - 45.96 ± 4.95 µg/108 MB, 8.6 x108 MB/mL) (right) 
(n=4). 
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6.2.3. In vitro efficacy of MB-LipidGem and MB-LipidGem-PTX in Panc-1 
spheroids. 
Following the preparation of MB-LipidGem and MB-LipidGem-PTX, the next 
step was to determine efficacy in a 3D panc-1 spheroid model. Spheroids were 
prepared as described in Section 2.18. Once formed, spheroids were treated with 
either a suspension of MB-LipidGem or MB-LipidGem-PTX in the presence and 
absence of US. The US conditions and experimental set-up adopted for this study 
were the same as described in Section 3.2.5 (30 s, frequency - 1 MHz, US power 
density - 3.0 W/cm2, duty cycle - 40%). Following treatment, cell viability was 
determined using an MTT assay. 
Optical images of the treated and untreated spheroids are shown in Figure 
6.14 and reveal no visually apparent effects on spheroid morphology for those 
treated with US in the absence of MBs. Similarly, spheroids treated with MB-
Lipid-Gem in the absence of US also appeared visually intact. However, 
spheroids treated with MB-LipidGem and US appeared less cohesive in structure 
than those treated with MB-LipidGem alone (i.e. no US).  This effect was 
amplified for spheroids treated with MB-LipidGem-PTX + US where a significant 
disruption in spheroid morphology was apparent with small areas of cellular 
debris evident around the perimeter of the spheroid corona. Indeed, changes in 
morphology were also evident in spheroids treated with MB-LipidGem-PTX 
alone (i.e. no US) indicating that the addition of PTX to the MB-LipidGem 
induces significantly more spheroid damage even in the absence of US. When 
spheroid viability was determined using a MTT assay (Figure 6.15), the 
proportion of viable cells remaining following treatment with MB-LipidGem + 
US or MB-LipidGem-PTX  + US were significantly reduced relative to untreated 
spheroids or spheroids treated with US alone or with the respective MB 
formulation alone (i.e no US). Indeed, while the reduction in viability for 
spheroids treated with MB-LipidGem + US was 38.13%, this reduced further to 
69.70% for MB-LipidGem-PTX + US, consistent with the visual effects apparent 
from the optical images shown below in Figure 6.14.  
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Figure 6.14. Representative images of human pancreas ductal adenocarcinoma cell line (Panc-
1) spheroids treated with a) no drug ± US b) MB-LipidGem ([LipidGem] = 10 !M, 3.40 x107 
MB) ± US c) MB-LipidGem-PTX ([LipidGem] = 10 !M, [PTX] = 6.2 !M, 2.61 x107 MB) ± US. 
(US parameters - frequency - 1 MHz, US power density - 3.0 W/cm2, duty cycle - 40%, time- 30 
sec). 
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Figure 6.15. Plot of cell viability of spheroids treated with a) human pancreas ductal 
adenocarcinoma cell line (Panc-1) spheroids treated with a) no drug ± US b) MB-LipidGem 
([LipidGem] = 10 !M, 3.40 x107 MB) ± US c) MB-LipidGem-PTX ([LipidGem] = 10 !M, [PTX] 
= 6.2 !M, 2.61 x107 MB) ± US. (US parameters - frequency - 1 MHz, US power density - 3.0 
W/cm2, duty cycle - 40%, time- 30 sec) (n=4). 
Shuto et al attributed the apparent effectiveness of phospholipid-
nucleoside prodrugs to two main mechanisms. First, due to the hydrophobic 
nature of the molecule, it may be transported into the cell more readily through 
passive diffusion through the phospholipid bilayer. This effect may be further 
improved through the application of US mediated sonoporation. Second, once 
inside the cancer cell, a phospholipid-nucleoside prodrug must undergo 
metabolic activation to either unmodified Gem or to the active metabolite Gem-
monophosphate. This could theoretically be achieved via multiple possible 
activation mechanisms outlined in Figure 6.16. The prodrug could be directly 
transformed into Gem-monophosphate via cleavage of the diacyl glycerol moiety 
by phospholipase C or into Gem via cleavage at the 5’ hydroxyl position. Gem 
can then be further metabolised by a kinase enzyme into the active Gem 
monophosphate. Alternatively, Gem and Gem-monophopshate can be indirectly 
produced through a series of enzymatic manipulations by phospholipase A, 
phosphodiesterase and lysophospholipase. Of course, further work is needed to 
clarify the intracellular activation of LipidGem. (320) 
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Figure 6.16. Scheme showing hypothetical, intracellular, enzyme-mediated activation 
pathways for 15. Reproduced from (320). 
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6.2.4. Efficacy of MB-LipidGem-PTX in mice bearing BxPC-3 tumours.  
Having established the efficacy MB-LipidGem-PTX in vitro, the next step was to 
determine its efficacy in an in vivo model of pancreatic cancer. To this end BxPC-
3 tumours were established in the rear dorsum of SCID mice as described in 
previous chapters. Once the tumours had reached an average volume of 150 mm3 
animals were randomly assigned into treatment groups. Animals were 
anaesthetised using isoflurane with medical grade oxygen as the carrier gas. 
Animals were treated with a 100 !L I.V. injection of either MB-LipidGem 
([LipidGem] = 70.1 !g/108 MB) or MB-LipidGem-PTX([LipidGem] = 75.1 !g/108 
MB, [PTX] = 48.57 !g/108 MB). As control groups, animals were treated with a 
100 !L I.P injection Gem (120 mg/kg). As is described in Section 4.2.5, the 
combination of Gem and PTX at clinically relevant concentrations resulted in 
severe toxicity. Therefore, for ethical reasons, animals were not treated with this 
combination.  Immediately following injection, US (Frequency = 1 MHz, power 
density = 3.5 W/cm2, duty cycle = 30%, PNP 0.4 MPa, duration 3.5 min) was then 
applied to the tumour to facilitate MB destruction and delivery drug payloads to 
the tumour region.  
The tumour growth plot in Figure 6.17a reveals, unsurprisingly, that the 
scaled clinical dose of Gem HCl significantly controls tumour growth 
progression. MB-LipidGem without PTX showed a significant improvement in 
tumour growth control compared to free Gem (p< 0.05). The greatly enhanced 
tumour inhibitory effect delivered by treatment with the MB-LipidGem clearly 
demonstrates one of the advantages of UTMD since the amount of Gem in this 
formulation is some 120-fold lower than that administered to the group treated 
with the clinical dose of Gem (i.e. Gem HCl). There was a further small but non-
significant decrease in tumour growth progression for mice treated with MB-
LipidGem-PTX compared to animals treated with non-PTX containing MB. The 
plot in Figure 6.17b of % change in body weight against time during treatment 
shows that no significant reduction in body weight was observed in any animal 
from any of the treatment groups. This was in contrast to previous findings that 
showed that the clinical dose of Gem caused a significant drop in body weight 
(Figure 4.15 and 4.16). These results again clearly demonstrate the advantage of 
UTMD mediated chemotherapy, producing superior tumour growth control 
while at the same time causing no significant acute toxic effects. 
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Figure 6.17. Plot of (a) % change in tumour volume and (b) average body weight for BxPC-3 
tumour bearing mice treated with (i) no treatment (triangle) (ii) MB-LipidGem (circle) (iii) MB-
LipidGem-PTX (square) (v) Gem HCl (diamond). The MB suspensions (MB-LipidGem - 9.97 
x108 MB/mL, MB-LipidGem-PTX - 8.6 x108) were delivered as a 100 µL I.V injection (MB-
LipidGem – [LipidGem] = 2.77 mg/kg, MB-LipidGem-PTX – [LipidGem] = 3.15 mg/kg, [PTX] 
= 1.98 mg/kg). Gem HCl was dissolved in sterile PBS and administered as a 100 µL I.P injection 
(120 mg/kg). US treatment was delivered for 3.5 min at frequency of 1 MHz, an US power 
density of 3.5 W/cm2 and a duty cycle of 30% immediately after injection. Error bars represent 
± standard error of the mean. For plot (a) and (b) *p < 0.05 **p < 0.01, ***p < 0.001. Error bars 
represent ± SEM where n = 4.
a)
b)
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6.3. Conclusion 
The phospholipid-based prodrug strategy is an emerging field for overcoming a 
number of biopharmaceutical and drug delivery challenges. Owing to their 
structure, phospholipid-based prodrugs are capable of participating in 
endogenous phospholipid metabolic pathways therefore leading to improved 
pharmacokinetic and pharmacodynamic properties of the drug. Additional 
advantages include drug targeting by enzyme-mediated drug release and 
overcoming drug resistance. Phospholipid prodrugs are also ideally suited to 
formulation into both liposomes and MBs. The work undertaken in this chapter 
demonstrates the effectiveness of the co-delivery of a phospholipid-Gem 
prodrug and PTX using UTMD. (324,325) 
In summary a novel phospholipid derivative of Gem has been successfully 
synthesised through a single step enzymatically catalysed 
transphosphatidylation reaction. This novel compound was shown to form MB 
using common MB forming methods and was capable of loading significant 
quantities of PTX within the acyl chain layer of the MB. Importantly, this did not 
require any post MB manipulation. MB-LipidGem and MB-LipidGem-PTX 
displayed comparable stability at 37oC to plain unloaded MBs. In vitro testing 
using Panc-1 spheroids showed that MB-LipidGem and MB-LipidGem-PTX had 
little effect on cell viability in the absence of US stimulation, but upon US 
application, showed significant levels of cell death with MB-LipidGem-PTX 
having the greatest effect. The in vivo effectiveness of the MB conjugate was 
determined in an ectopic BxPC-3 murine model and showed that the 
combination of LipidGem and PTX was significantly more effective at controlling 
tumour growth compared with untreated controls and mice treated with a scaled 
clinical dose of Gem at significantly lower doses (120-fold). This once again 
highlights the advantage of UTMD, in that lower concentrations of cytotoxic 
agent are required to achieve an improve therapeutic response. As described in 
Section 6.1, a variety of techniques for conjugating drugs to shell of MBs have 
been described in the published literature. However, to the best of our 
knowledge, pre-conjugation of an anticancer drug to the precursor 
phospholipids prior to MB formation has not yet been communicated in the 
literature. The work described in this chapter allows provides means of tighter 
control of drug loading onto the MB leading to reduced batch to batch variability. 
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This coupled with improved ease of preparation, make this strategy more 
amenable to scale up and clinical translation.   
Collectively, the results described in this chapter make another positive 
step-forward in the development of single MB formulations for the delivery of 
multiple payloads. Given the simplistic nature of the synthesis discussed herein, 
this strategy can be applied to a wide variety of other clinically approved drug 
candidates.  
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Chapter 7 
General Conclusions and Future 
Outlook 
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Chapter 7 - General Conclusions and Future Outlook 
The work described in this thesis explored novel techniques for the synthesis and 
subsequent drug loading of novel US-responsive MB delivery platforms and 
their application for UTMD in the treatment of solid tumours with particular 
focus on PDAC, which is one of the deadliest forms of cancer. 
Work conducted in chapter 3 explored the potential of loading MBs with 
multiple payloads and was based upon previous research conducted in the area 
of combined chemo-SDT delivered using O2MBs. The hydrophobic anticancer 
drug PTX was successfully loaded into the hydrophobic region of the MB 
monolayer. This enabled the subsequent unhindered surface functionalisation of 
the MB with either RB of Dox through avidin-biotin conjugation chemistry. In 
vitro models of breast cancer (MCF-7) the combination of MB-PTX-Dox and MB-
PTX-RB performed significantly better than either of the MB conjugates alone 
and free dug groups at the same concentration with the combination of MBs 
reducing cell viability by 72.6% in the presence of US as determined by an MTT 
assay. This translated into a significant regression in tumour growth (6.96%) in 
an in vivo model of the same cell line while being comparatively well tolerated 
by the animals in contrast to animals treated with the free drug combination. The 
primary limitations with this study were that two separate MB formulations had 
to be prepared and mixed prior to treatment. This not only made the preparation 
more laborious but also limited the dose which could be administered. Due to 
the limited treatment options, besides surgical resection and large doses of 
systemic chemotherapy, triple negative breast cancer still remains one of the 
main challenges in the treatment of breast cancer. Further work in this area 
should build upon results presented in this chapter and focus on in vitro/ in vivo 
models of triple negative breast cancer as this subgroup of patients could benefit 
greatly from a delivery system which can improve drug uptake and efficacy 
while remaining non-toxic to the patient. 
As previously mentioned, the main limitation why work conducted in 
chapter 3 was that only two agents could be loaded on a single MB meaning that 
multiple formulations had to be prepared separately and mixed prior to use. 
Work conducted in chapter 4 aimed to address these shortcomings through the 
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preparation of MB-PTX, surface functionalised with a novel tripodal ligand 
composed of Gem and RB with a biotin anchor facilitating the loading of three 
components onto the MB. This approach allowed for the simultaneous delivery 
of all three active agents on a single MB therefore increasing the control of drug 
deposition into the tumour. Prepared MBs showed high loadings of all three 
active agents and in vitro experiments in Panc-1 spheroids revealed a synergistic 
affect between the three active agents contained within MB-PTX-Gem-RB with a 
reduction in cell viability of 72%. In vivo experiments in both BxPC-3 and MIA-
PaCa-2 xenografts revealed a significant reduction in tumour growth when 
compared to clinically relevant doses of free Gem and PTX. In spite of the 
encouraging in vitro/ in vivo results described in chapter 4, the utility of 15 as a 
MB surface ligand in a clinical setting could be limited due to its complex 
chemical structure and difficult synthetic route. Future work in this area should 
focus on developing an efficient and scalable synthetic procedure for 15. This 
could also be extended to include other clinically relevant drug combinations for 
the use in a variety of other cancers.  Stemming from the prevalence of metastatic 
disease in the pancreatic cancer patient pool, there is a particular interest in the 
use of MB mediated delivery of chemo-SDT in combination with immunotherapy 
aimed at reducing primary tumour burden while also tackling systemic disease. 
Chapter 5 progressed the work from previous chapters through the 
addition of an extra layer of targeting by incorporating magnetically responsive 
nanoparticles into the hydrophobic region of the MB shell, in combination with 
a prototype magneto-acoustic device enabling simultaneous coalignment of 
magnetic and acoustic fields. In vitro phantom experiments showed 1.6-fold 
increase in uptake of RB with the MAD device when compared to magnetic and 
acoustic filed applied separately. In in vivo models the MagMBs loaded with 15, 
described in chapter 4, showed an enhanced reduction in tumour growth (37%) 
when treated with the MAD device when compared to animals treated with the 
MB conjugate with acoustic and magnetic fields applied separately (9%). 
However, the in vivo study was limited by the low number of animals used (n=4) 
per treatment group which lowered the statistical power of the study. 
Additionally, it would also be highly beneficial to include cavitation monitoring 
in future iterations of the MAD device as this would provide significant feedback 
as to the effectiveness of the treatment. Further work could involve the 
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examination of the MAD device in a setting representative of human length 
scales.  
Finally, chapter 6 described the synthesis of a novel prodrug of Gem 
capable of assembling into stable MBs using techniques common in the literature 
for MB preparation. The novel MBs were further powered through the addition 
of PTX into the hydrophobic shell. This MB conjugate showed improved efficacy 
in in vitro Panc-1 spheroids with a reduction in cell viability of 69.7%. In vivo 
experiments revealed significant reduction in tumour growth when compared to 
untreated controls. The distinct advantage of this method of production is that 
the drug is preloaded onto the lipid prior to MB formation. Not only does this 
shorten the process of MB synthesis, but also allows for tighter control of drug 
loading on the MB. There may also be scope to further enhance the stability of 
the MB conjugate through the addition of various other lipids such as 
phosphatidylcholines. This study had several limitations worth discussing. 
Firstly, there remains the question of scalability and regulatory alignment of the 
synthetic approach adopted in the chapter, given the bacterial source of 
phospholipase D. Future work will endeavour to rationally design and develop 
a classical synthetic approach to a Gem-phospholipid conjugate. Secondly, there 
remains uncertainty regarding the precise mechanism of intracellular activation 
of LipidGem. This could be addressed by attaching Gem to the phospholipid 
using enzymatically labile ester or amide bonds as this would result in a more 
predictable activation pathway. The utility of the approach used in this chapter 
could also be extended to a wide variety of other drug candidates and/or 
targeting ligands for a wide variety of solid malignancies. 
While the use of MBs for the targeted drug delivery has been shown to be 
highly effective in many cancers as well as numerous other diseases, there still 
remains the challenge of clinical translation. One of the main challenges is the 
shelf life and long-term storage of MB preparations. Lessons can certainly be 
learned from current clinically approved contrast agents such as SonoVue and 
Definity. SonoVue MBs are prepared at the bedside by reconstituting a 
lyophilised liposomal suspension under a headspace of SF6 while Definity MBs 
are also prepared at the bedside and require activation of a stable liposomal 
suspension with a PFB headspace using a high-speed vial shaking device. 
Compound 15, which was designed and synthesised in chapter 6, along with 
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other similar phospholipid-drug conjugates would be ideally suited to 
formulation into MBs produced by either of these two methods which could help 
to address one of the main barriers to clinical translation of therapeutic MBs. A 
further avenue for future research could involve the development of nanoscale 
particles which could enable improved tumour penetration and drug delivery.  
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8.0. Appendices 
 
Figure A1. ESI-MS spectrum of 10. Recorded in methanol. 
 
 
 
Figure A2. 1H NMR spectrum of 10. Recorded in DMSO-d6. 
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Figure A3. 13C NMR spectrum of 10. Recorded in DMSO-d6.
Figure A4. ESI-MS spectrum of 11. Recorded in methanol. 
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Figure A5. 1H NMR spectrum of 11. Recorded in DMSO-d6. 
 
Figure A6. 13C NMR spectrum of 11. Recorded in DMSO-d6 
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Figure A7. Plot of tumour oxygen partial pressure over time of ectopic BxPC-3 tumour bearing 
mice following a 100 uL I.V injection of O2MB (1 x109 MB/mL) or N2MB (1 x 109 MB) in the 
presence and absence of US. Arrow indicates the point of I.V injection. Error bars indicate 
SEM (n=3). 
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